WO2011044157A1 - Heterocyclic compounds useful as pdk1 inhibitors - Google Patents
Heterocyclic compounds useful as pdk1 inhibitors Download PDFInfo
- Publication number
- WO2011044157A1 WO2011044157A1 PCT/US2010/051517 US2010051517W WO2011044157A1 WO 2011044157 A1 WO2011044157 A1 WO 2011044157A1 US 2010051517 W US2010051517 W US 2010051517W WO 2011044157 A1 WO2011044157 A1 WO 2011044157A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- ring
- nitrogen
- sulfur
- oxygen
- membered
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title abstract description 13
- 150000002391 heterocyclic compounds Chemical class 0.000 title description 2
- 101100351314 Caenorhabditis elegans pdk-1 gene Proteins 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims abstract description 154
- 238000000034 method Methods 0.000 claims abstract description 101
- 239000000203 mixture Substances 0.000 claims abstract description 69
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 408
- 229910052757 nitrogen Inorganic materials 0.000 claims description 327
- 125000005842 heteroatom Chemical group 0.000 claims description 260
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 258
- 229910052760 oxygen Inorganic materials 0.000 claims description 258
- 239000001301 oxygen Chemical group 0.000 claims description 258
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 256
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 255
- 229910052717 sulfur Chemical group 0.000 claims description 255
- 239000011593 sulfur Chemical group 0.000 claims description 255
- 229920006395 saturated elastomer Polymers 0.000 claims description 118
- -1 -CI Chemical group 0.000 claims description 88
- 125000000217 alkyl group Chemical group 0.000 claims description 58
- 229910052739 hydrogen Inorganic materials 0.000 claims description 58
- 239000001257 hydrogen Substances 0.000 claims description 58
- 125000003118 aryl group Chemical group 0.000 claims description 55
- 125000000623 heterocyclic group Chemical group 0.000 claims description 49
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 47
- 125000004429 atom Chemical group 0.000 claims description 45
- 125000002950 monocyclic group Chemical group 0.000 claims description 44
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims description 43
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 42
- 125000002947 alkylene group Chemical group 0.000 claims description 38
- 125000002619 bicyclic group Chemical group 0.000 claims description 37
- 125000001931 aliphatic group Chemical group 0.000 claims description 35
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 claims description 31
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 30
- 125000001424 substituent group Chemical group 0.000 claims description 26
- 150000003839 salts Chemical class 0.000 claims description 24
- 125000006163 5-membered heteroaryl group Chemical group 0.000 claims description 22
- 125000002837 carbocyclic group Chemical group 0.000 claims description 19
- 125000002618 bicyclic heterocycle group Chemical group 0.000 claims description 18
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 17
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 16
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 15
- 239000008194 pharmaceutical composition Substances 0.000 claims description 15
- 206010028980 Neoplasm Diseases 0.000 claims description 14
- 201000011510 cancer Diseases 0.000 claims description 13
- 125000000843 phenylene group Chemical group C1(=C(C=CC=C1)*)* 0.000 claims description 12
- 125000004419 alkynylene group Chemical group 0.000 claims description 11
- 229910052799 carbon Inorganic materials 0.000 claims description 11
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 11
- 125000001475 halogen functional group Chemical group 0.000 claims description 10
- 125000005549 heteroarylene group Chemical group 0.000 claims description 10
- 125000002527 bicyclic carbocyclic group Chemical group 0.000 claims description 9
- 125000005843 halogen group Chemical group 0.000 claims description 9
- 125000004076 pyridyl group Chemical group 0.000 claims description 9
- 125000004450 alkenylene group Chemical group 0.000 claims description 8
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 7
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 claims description 7
- 150000002431 hydrogen Chemical group 0.000 claims description 6
- 229910052731 fluorine Inorganic materials 0.000 claims description 5
- 239000011737 fluorine Substances 0.000 claims description 5
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 5
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims description 4
- 125000002393 azetidinyl group Chemical group 0.000 claims description 4
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 4
- 125000003566 oxetanyl group Chemical group 0.000 claims description 2
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 1
- 230000001404 mediated effect Effects 0.000 abstract description 19
- 101000600756 Homo sapiens 3-phosphoinositide-dependent protein kinase 1 Proteins 0.000 abstract description 17
- 101001117146 Homo sapiens [Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 1, mitochondrial Proteins 0.000 abstract description 17
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 13
- 201000010099 disease Diseases 0.000 abstract description 9
- 102100024148 [Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 1, mitochondrial Human genes 0.000 abstract 2
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 296
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 221
- 238000006243 chemical reaction Methods 0.000 description 132
- 230000015572 biosynthetic process Effects 0.000 description 124
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 121
- 238000003786 synthesis reaction Methods 0.000 description 119
- 235000019439 ethyl acetate Nutrition 0.000 description 115
- 238000005160 1H NMR spectroscopy Methods 0.000 description 93
- 239000000243 solution Substances 0.000 description 84
- 229910001868 water Inorganic materials 0.000 description 84
- 239000000047 product Substances 0.000 description 80
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 78
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 76
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 70
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 69
- 229940093499 ethyl acetate Drugs 0.000 description 67
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 64
- 239000007787 solid Substances 0.000 description 63
- 125000001072 heteroaryl group Chemical group 0.000 description 60
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 60
- 239000002904 solvent Substances 0.000 description 55
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 52
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 50
- 239000011541 reaction mixture Substances 0.000 description 48
- 239000000843 powder Substances 0.000 description 47
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 43
- 239000012267 brine Substances 0.000 description 41
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 41
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 39
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 37
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 34
- OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 32
- 235000019341 magnesium sulphate Nutrition 0.000 description 32
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 31
- 238000003818 flash chromatography Methods 0.000 description 29
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 28
- 238000000746 purification Methods 0.000 description 28
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 27
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 26
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 26
- 238000004128 high performance liquid chromatography Methods 0.000 description 26
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 25
- 230000002378 acidificating effect Effects 0.000 description 25
- 239000012074 organic phase Substances 0.000 description 24
- PIBWKRNGBLPSSY-UHFFFAOYSA-L palladium(II) chloride Chemical compound Cl[Pd]Cl PIBWKRNGBLPSSY-UHFFFAOYSA-L 0.000 description 24
- 239000000741 silica gel Substances 0.000 description 24
- 229910002027 silica gel Inorganic materials 0.000 description 24
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 22
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical class OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 22
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 22
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 21
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 20
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 19
- 239000012044 organic layer Substances 0.000 description 19
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 18
- 125000004432 carbon atom Chemical group C* 0.000 description 17
- 235000017557 sodium bicarbonate Nutrition 0.000 description 17
- 102100037263 3-phosphoinositide-dependent protein kinase 1 Human genes 0.000 description 16
- 108091008611 Protein Kinase B Proteins 0.000 description 16
- 125000004093 cyano group Chemical group *C#N 0.000 description 16
- 230000026731 phosphorylation Effects 0.000 description 16
- 238000006366 phosphorylation reaction Methods 0.000 description 16
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 16
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 15
- KDLHZDBZIXYQEI-UHFFFAOYSA-N palladium Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 15
- 238000002360 preparation method Methods 0.000 description 15
- 229910000029 sodium carbonate Inorganic materials 0.000 description 15
- RGRVLGOGDATJGS-UHFFFAOYSA-N 6-[5-(aminomethyl)thiophen-2-yl]quinazolin-4-amine Chemical compound S1C(CN)=CC=C1C1=CC=C(N=CN=C2N)C2=C1 RGRVLGOGDATJGS-UHFFFAOYSA-N 0.000 description 14
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 14
- 230000000694 effects Effects 0.000 description 14
- 239000000543 intermediate Substances 0.000 description 14
- 239000000377 silicon dioxide Substances 0.000 description 14
- 235000005152 nicotinamide Nutrition 0.000 description 13
- 239000011570 nicotinamide Substances 0.000 description 13
- 238000010992 reflux Methods 0.000 description 13
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 12
- 230000003197 catalytic effect Effects 0.000 description 12
- 239000012043 crude product Substances 0.000 description 12
- 229910000027 potassium carbonate Inorganic materials 0.000 description 12
- DRYRBWIFRVMRPV-UHFFFAOYSA-N quinazolin-4-amine Chemical compound C1=CC=C2C(N)=NC=NC2=C1 DRYRBWIFRVMRPV-UHFFFAOYSA-N 0.000 description 12
- 238000003756 stirring Methods 0.000 description 12
- 239000000725 suspension Substances 0.000 description 12
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 12
- 239000004698 Polyethylene Substances 0.000 description 11
- 239000012298 atmosphere Substances 0.000 description 11
- 210000004027 cell Anatomy 0.000 description 11
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 10
- 125000003342 alkenyl group Chemical group 0.000 description 10
- IPWKHHSGDUIRAH-UHFFFAOYSA-N bis(pinacolato)diboron Chemical compound O1C(C)(C)C(C)(C)OB1B1OC(C)(C)C(C)(C)O1 IPWKHHSGDUIRAH-UHFFFAOYSA-N 0.000 description 10
- 238000004440 column chromatography Methods 0.000 description 10
- 229960003966 nicotinamide Drugs 0.000 description 10
- 102000003923 Protein Kinase C Human genes 0.000 description 9
- 108090000315 Protein Kinase C Proteins 0.000 description 9
- 125000000304 alkynyl group Chemical group 0.000 description 9
- 229910052736 halogen Inorganic materials 0.000 description 9
- 150000002367 halogens Chemical class 0.000 description 9
- 238000000589 high-performance liquid chromatography-mass spectrometry Methods 0.000 description 9
- 230000002829 reductive effect Effects 0.000 description 9
- 239000013058 crude material Substances 0.000 description 8
- 235000019441 ethanol Nutrition 0.000 description 8
- 239000000706 filtrate Substances 0.000 description 8
- 239000003921 oil Substances 0.000 description 8
- 235000019198 oils Nutrition 0.000 description 8
- 235000011056 potassium acetate Nutrition 0.000 description 8
- 239000012321 sodium triacetoxyborohydride Substances 0.000 description 8
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 8
- PHLZUDXEBCQHKM-UHFFFAOYSA-N (3,4-difluorophenyl)methanamine Chemical compound NCC1=CC=C(F)C(F)=C1 PHLZUDXEBCQHKM-UHFFFAOYSA-N 0.000 description 7
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 7
- 239000003937 drug carrier Substances 0.000 description 7
- 208000024891 symptom Diseases 0.000 description 7
- 239000003826 tablet Substances 0.000 description 7
- 125000000175 2-thienyl group Chemical group S1C([*])=C([H])C([H])=C1[H] 0.000 description 6
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 6
- GFBVUFQNHLUCPX-UHFFFAOYSA-N 5-bromothiophene-2-carbaldehyde Chemical compound BrC1=CC=C(C=O)S1 GFBVUFQNHLUCPX-UHFFFAOYSA-N 0.000 description 6
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 6
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 6
- KWYHDKDOAIKMQN-UHFFFAOYSA-N N,N,N',N'-tetramethylethylenediamine Chemical compound CN(C)CCN(C)C KWYHDKDOAIKMQN-UHFFFAOYSA-N 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 6
- 238000003556 assay Methods 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 6
- 125000000753 cycloalkyl group Chemical group 0.000 description 6
- NXQGGXCHGDYOHB-UHFFFAOYSA-L cyclopenta-1,4-dien-1-yl(diphenyl)phosphane;dichloropalladium;iron(2+) Chemical compound [Fe+2].Cl[Pd]Cl.[CH-]1C=CC(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1.[CH-]1C=CC(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1 NXQGGXCHGDYOHB-UHFFFAOYSA-L 0.000 description 6
- 230000003247 decreasing effect Effects 0.000 description 6
- 239000000284 extract Substances 0.000 description 6
- 125000000524 functional group Chemical group 0.000 description 6
- 238000001556 precipitation Methods 0.000 description 6
- 125000003226 pyrazolyl group Chemical group 0.000 description 6
- 238000004007 reversed phase HPLC Methods 0.000 description 6
- 125000005500 uronium group Chemical group 0.000 description 6
- KZPYGQFFRCFCPP-UHFFFAOYSA-N 1,1'-bis(diphenylphosphino)ferrocene Chemical compound [Fe+2].C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1 KZPYGQFFRCFCPP-UHFFFAOYSA-N 0.000 description 5
- WJGFRNFSYJKZEE-UHFFFAOYSA-N 2-[(5-bromothiophen-2-yl)methylamino]-n-[(3,4-difluorophenyl)methyl]pyridine-3-carboxamide Chemical compound C1=C(F)C(F)=CC=C1CNC(=O)C1=CC=CN=C1NCC1=CC=C(Br)S1 WJGFRNFSYJKZEE-UHFFFAOYSA-N 0.000 description 5
- HPFDYPIWZMVHOY-UHFFFAOYSA-N 3-amino-6-bromo-n-[(3,4-difluorophenyl)methyl]pyrazine-2-carboxamide Chemical compound NC1=NC=C(Br)N=C1C(=O)NCC1=CC=C(F)C(F)=C1 HPFDYPIWZMVHOY-UHFFFAOYSA-N 0.000 description 5
- BDAIUOPDSRAOKI-UHFFFAOYSA-N 4-chloro-6-iodoquinazoline Chemical compound C1=C(I)C=C2C(Cl)=NC=NC2=C1 BDAIUOPDSRAOKI-UHFFFAOYSA-N 0.000 description 5
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 5
- AMQJEAYHLZJPGS-UHFFFAOYSA-N N-Pentanol Chemical compound CCCCCO AMQJEAYHLZJPGS-UHFFFAOYSA-N 0.000 description 5
- 108091000080 Phosphotransferase Proteins 0.000 description 5
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 5
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 5
- 229910000024 caesium carbonate Inorganic materials 0.000 description 5
- 239000003054 catalyst Substances 0.000 description 5
- CJYQQUPRURWLOW-YDLUHMIOSA-M dmsc Chemical compound [Na+].OP(=O)=O.OP(=O)=O.OP(=O)=O.[O-]P(=O)=O.O=C1C2=C(O)C=CC=C2[C@H](C)[C@@H]2C1=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@@H]1[C@H]2O CJYQQUPRURWLOW-YDLUHMIOSA-M 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 238000010828 elution Methods 0.000 description 5
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 5
- 230000002401 inhibitory effect Effects 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- INCSQLZZXBPATR-UHFFFAOYSA-N methyl 3-aminopyrazine-2-carboxylate Chemical compound COC(=O)C1=NC=CN=C1N INCSQLZZXBPATR-UHFFFAOYSA-N 0.000 description 5
- 239000003960 organic solvent Substances 0.000 description 5
- 125000002971 oxazolyl group Chemical group 0.000 description 5
- 102000020233 phosphotransferase Human genes 0.000 description 5
- 239000002244 precipitate Substances 0.000 description 5
- 238000002953 preparative HPLC Methods 0.000 description 5
- NIPZZXUFJPQHNH-UHFFFAOYSA-M pyrazine-2-carboxylate Chemical compound [O-]C(=O)C1=CN=CC=N1 NIPZZXUFJPQHNH-UHFFFAOYSA-M 0.000 description 5
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 5
- 125000006413 ring segment Chemical group 0.000 description 5
- 238000010898 silica gel chromatography Methods 0.000 description 5
- 125000000335 thiazolyl group Chemical group 0.000 description 5
- PEUXYULUDSFMNW-UHFFFAOYSA-N 2-[(6-iodoquinazolin-4-yl)amino]ethanol Chemical compound C1=C(I)C=C2C(NCCO)=NC=NC2=C1 PEUXYULUDSFMNW-UHFFFAOYSA-N 0.000 description 4
- CLVAOBDLBIEBHU-UHFFFAOYSA-N 5-chloro-3-[(3,4-difluorophenyl)methyl]pyrido[4,3-d]pyrimidin-4-one Chemical compound C1=C(F)C(F)=CC=C1CN1C(=O)C2=C(Cl)N=CC=C2N=C1 CLVAOBDLBIEBHU-UHFFFAOYSA-N 0.000 description 4
- CDJBDMNUBKPNQF-UHFFFAOYSA-N 7-(benzenesulfonyl)-4-chloro-5-iodopyrrolo[2,3-d]pyrimidine Chemical compound C1=C(I)C=2C(Cl)=NC=NC=2N1S(=O)(=O)C1=CC=CC=C1 CDJBDMNUBKPNQF-UHFFFAOYSA-N 0.000 description 4
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 4
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 4
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 4
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 4
- 238000010171 animal model Methods 0.000 description 4
- 239000007864 aqueous solution Substances 0.000 description 4
- MVXVYAKCVDQRLW-UHFFFAOYSA-N azain Natural products C1=CN=C2NC=CC2=C1 MVXVYAKCVDQRLW-UHFFFAOYSA-N 0.000 description 4
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 150000001721 carbon Chemical group 0.000 description 4
- 125000002993 cycloalkylene group Chemical group 0.000 description 4
- 208000035475 disorder Diseases 0.000 description 4
- 239000002552 dosage form Substances 0.000 description 4
- 239000000839 emulsion Substances 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 125000002883 imidazolyl group Chemical group 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 125000001786 isothiazolyl group Chemical group 0.000 description 4
- 125000000842 isoxazolyl group Chemical group 0.000 description 4
- 239000011664 nicotinic acid Substances 0.000 description 4
- 125000005880 oxathiolanyl group Chemical group 0.000 description 4
- 239000003208 petroleum Substances 0.000 description 4
- IVDFJHOHABJVEH-UHFFFAOYSA-N pinacol Chemical compound CC(C)(O)C(C)(C)O IVDFJHOHABJVEH-UHFFFAOYSA-N 0.000 description 4
- 125000003373 pyrazinyl group Chemical group 0.000 description 4
- 125000002098 pyridazinyl group Chemical group 0.000 description 4
- 125000000714 pyrimidinyl group Chemical group 0.000 description 4
- 125000000168 pyrrolyl group Chemical group 0.000 description 4
- LPXPTNMVRIOKMN-UHFFFAOYSA-M sodium nitrite Chemical compound [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 description 4
- 229910052938 sodium sulfate Inorganic materials 0.000 description 4
- 235000011152 sodium sulphate Nutrition 0.000 description 4
- 239000007858 starting material Substances 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 125000003831 tetrazolyl group Chemical group 0.000 description 4
- 229940124597 therapeutic agent Drugs 0.000 description 4
- 125000001113 thiadiazolyl group Chemical group 0.000 description 4
- 125000001425 triazolyl group Chemical group 0.000 description 4
- ULQRMMDOMAGWFH-UHFFFAOYSA-N 2-[(3-bromophenyl)methylamino]-n-[(3,4-difluorophenyl)methyl]pyridine-3-carboxamide Chemical compound C1=C(F)C(F)=CC=C1CNC(=O)C1=CC=CN=C1NCC1=CC=CC(Br)=C1 ULQRMMDOMAGWFH-UHFFFAOYSA-N 0.000 description 3
- XNHKANPYLWAKLC-UHFFFAOYSA-N 2-[[3-(1h-pyrrolo[2,3-b]pyridin-3-yl)phenyl]methylamino]pyridine-3-carboxylic acid Chemical compound OC(=O)C1=CC=CN=C1NCC1=CC=CC(C=2C3=CC=CN=C3NC=2)=C1 XNHKANPYLWAKLC-UHFFFAOYSA-N 0.000 description 3
- MRAGRHDMTZWWLM-UHFFFAOYSA-N 2-[[5-(4-aminoquinazolin-6-yl)thiophen-2-yl]methylamino]-n-[(3,4-difluorophenyl)methyl]-5-iodopyridine-3-carboxamide Chemical compound C1=C2C(N)=NC=NC2=CC=C1C(S1)=CC=C1CNC1=NC=C(I)C=C1C(=O)NCC1=CC=C(F)C(F)=C1 MRAGRHDMTZWWLM-UHFFFAOYSA-N 0.000 description 3
- KPIVDNYJNOPGBE-UHFFFAOYSA-N 2-aminonicotinic acid Chemical compound NC1=NC=CC=C1C(O)=O KPIVDNYJNOPGBE-UHFFFAOYSA-N 0.000 description 3
- MNQVIZWWCRPZOK-UHFFFAOYSA-N 2-bromo-1,3-thiazole-4-carbaldehyde Chemical compound BrC1=NC(C=O)=CS1 MNQVIZWWCRPZOK-UHFFFAOYSA-N 0.000 description 3
- WPUCCBSJDBFLHR-UHFFFAOYSA-N 2-chloro-n-[(3,4-difluorophenyl)methyl]-4-iodopyridine-3-carboxamide Chemical compound C1=C(F)C(F)=CC=C1CNC(=O)C1=C(I)C=CN=C1Cl WPUCCBSJDBFLHR-UHFFFAOYSA-N 0.000 description 3
- OZNILZYEWSQZOH-UHFFFAOYSA-N 2-chloro-n-[(3,4-difluorophenyl)methyl]-4-methoxypyridine-3-carboxamide Chemical compound COC1=CC=NC(Cl)=C1C(=O)NCC1=CC=C(F)C(F)=C1 OZNILZYEWSQZOH-UHFFFAOYSA-N 0.000 description 3
- 125000001494 2-propynyl group Chemical group [H]C#CC([H])([H])* 0.000 description 3
- JVHVKOKPTLYYQY-UHFFFAOYSA-N 3-amino-n-[(3,4-difluorophenyl)methyl]-6-prop-1-en-2-ylpyrazine-2-carboxamide Chemical compound CC(=C)C1=CN=C(N)C(C(=O)NCC=2C=C(F)C(F)=CC=2)=N1 JVHVKOKPTLYYQY-UHFFFAOYSA-N 0.000 description 3
- OIVFZZNYAIIESO-UHFFFAOYSA-N 5-bromo-n-methylthiophen-2-amine Chemical compound CNC1=CC=C(Br)S1 OIVFZZNYAIIESO-UHFFFAOYSA-N 0.000 description 3
- OVXQYRJTGOMWBY-UHFFFAOYSA-N 6-[2-(aminomethyl)-1,3-thiazol-5-yl]quinazolin-4-amine Chemical compound S1C(CN)=NC=C1C1=CC=C(N=CN=C2N)C2=C1 OVXQYRJTGOMWBY-UHFFFAOYSA-N 0.000 description 3
- QVNIGOMKEYQJHO-UHFFFAOYSA-N 6-bromo-4-n-methylquinoline-3,4-diamine Chemical compound C1=C(Br)C=C2C(NC)=C(N)C=NC2=C1 QVNIGOMKEYQJHO-UHFFFAOYSA-N 0.000 description 3
- DUHOLBFHYZQWEO-UHFFFAOYSA-N 7-(benzenesulfonyl)-5-bromopyrrolo[2,3-d]pyrimidine Chemical compound C12=NC=NC=C2C(Br)=CN1S(=O)(=O)C1=CC=CC=C1 DUHOLBFHYZQWEO-UHFFFAOYSA-N 0.000 description 3
- UGFAIRIUMAVXCW-UHFFFAOYSA-N Carbon monoxide Chemical compound [O+]#[C-] UGFAIRIUMAVXCW-UHFFFAOYSA-N 0.000 description 3
- 229910021595 Copper(I) iodide Inorganic materials 0.000 description 3
- ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 3
- 241000282326 Felis catus Species 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 239000007821 HATU Substances 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 3
- 102000003993 Phosphatidylinositol 3-kinases Human genes 0.000 description 3
- 108090000430 Phosphatidylinositol 3-kinases Proteins 0.000 description 3
- 102000001708 Protein Isoforms Human genes 0.000 description 3
- 108010029485 Protein Isoforms Proteins 0.000 description 3
- 102000001253 Protein Kinase Human genes 0.000 description 3
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 3
- 102100033810 RAC-alpha serine/threonine-protein kinase Human genes 0.000 description 3
- 229910006124 SOCl2 Inorganic materials 0.000 description 3
- 229910021529 ammonia Inorganic materials 0.000 description 3
- 239000008346 aqueous phase Substances 0.000 description 3
- 125000000732 arylene group Chemical group 0.000 description 3
- 125000000440 benzylamino group Chemical group [H]N(*)C([H])([H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 3
- ZADPBFCGQRWHPN-UHFFFAOYSA-N boronic acid Chemical compound OBO ZADPBFCGQRWHPN-UHFFFAOYSA-N 0.000 description 3
- 125000001246 bromo group Chemical group Br* 0.000 description 3
- 229910002091 carbon monoxide Inorganic materials 0.000 description 3
- 239000001768 carboxy methyl cellulose Substances 0.000 description 3
- 239000000460 chlorine Substances 0.000 description 3
- 238000004587 chromatography analysis Methods 0.000 description 3
- LSXDOTMGLUJQCM-UHFFFAOYSA-M copper(i) iodide Chemical compound I[Cu] LSXDOTMGLUJQCM-UHFFFAOYSA-M 0.000 description 3
- 125000000532 dioxanyl group Chemical group 0.000 description 3
- KIAGEDYOPMHRRB-UHFFFAOYSA-N ethyl 2-aminopyridine-3-carboxylate Chemical compound CCOC(=O)C1=CC=CN=C1N KIAGEDYOPMHRRB-UHFFFAOYSA-N 0.000 description 3
- 238000001704 evaporation Methods 0.000 description 3
- 239000000796 flavoring agent Substances 0.000 description 3
- 125000002541 furyl group Chemical group 0.000 description 3
- 239000007789 gas Substances 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 3
- 239000007937 lozenge Substances 0.000 description 3
- NZZDEODTCXHCRS-UHFFFAOYSA-N methyl 2-aminopyridine-3-carboxylate Chemical compound COC(=O)C1=CC=CN=C1N NZZDEODTCXHCRS-UHFFFAOYSA-N 0.000 description 3
- 229920000609 methyl cellulose Polymers 0.000 description 3
- 239000001923 methylcellulose Substances 0.000 description 3
- 235000010981 methylcellulose Nutrition 0.000 description 3
- 125000002757 morpholinyl group Chemical group 0.000 description 3
- 235000001968 nicotinic acid Nutrition 0.000 description 3
- 125000004433 nitrogen atom Chemical group N* 0.000 description 3
- 125000000160 oxazolidinyl group Chemical group 0.000 description 3
- 239000012071 phase Substances 0.000 description 3
- 125000004193 piperazinyl group Chemical group 0.000 description 3
- 125000003386 piperidinyl group Chemical group 0.000 description 3
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 3
- 108060006633 protein kinase Proteins 0.000 description 3
- NIPZZXUFJPQHNH-UHFFFAOYSA-N pyrazine-2-carboxylic acid Chemical compound OC(=O)C1=CN=CC=N1 NIPZZXUFJPQHNH-UHFFFAOYSA-N 0.000 description 3
- 230000011664 signaling Effects 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 239000003381 stabilizer Substances 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 239000000829 suppository Substances 0.000 description 3
- LPVMUQICXQOGRE-UHFFFAOYSA-N tert-butyl n-(1,3-thiazol-2-ylmethyl)carbamate Chemical compound CC(C)(C)OC(=O)NCC1=NC=CS1 LPVMUQICXQOGRE-UHFFFAOYSA-N 0.000 description 3
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 3
- 125000003039 tetrahydroisoquinolinyl group Chemical group C1(NCCC2=CC=CC=C12)* 0.000 description 3
- 125000000147 tetrahydroquinolinyl group Chemical group N1(CCCC2=CC=CC=C12)* 0.000 description 3
- 125000005247 tetrazinyl group Chemical group N1=NN=NC(=C1)* 0.000 description 3
- 125000001544 thienyl group Chemical group 0.000 description 3
- 125000004306 triazinyl group Chemical group 0.000 description 3
- CWMFRHBXRUITQE-UHFFFAOYSA-N trimethylsilylacetylene Chemical compound C[Si](C)(C)C#C CWMFRHBXRUITQE-UHFFFAOYSA-N 0.000 description 3
- QOWBXWFYRXSBAS-UHFFFAOYSA-N (2,4-dimethoxyphenyl)methanamine Chemical compound COC1=CC=C(CN)C(OC)=C1 QOWBXWFYRXSBAS-UHFFFAOYSA-N 0.000 description 2
- GETTZEONDQJALK-UHFFFAOYSA-N (trifluoromethyl)benzene Chemical compound FC(F)(F)C1=CC=CC=C1 GETTZEONDQJALK-UHFFFAOYSA-N 0.000 description 2
- IDPURXSQCKYKIJ-UHFFFAOYSA-N 1-(4-methoxyphenyl)methanamine Chemical compound COC1=CC=C(CN)C=C1 IDPURXSQCKYKIJ-UHFFFAOYSA-N 0.000 description 2
- BAXOFTOLAUCFNW-UHFFFAOYSA-N 1H-indazole Chemical class C1=CC=C2C=NNC2=C1 BAXOFTOLAUCFNW-UHFFFAOYSA-N 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- WHYPYCWLXXLMQV-UHFFFAOYSA-N 2-[(5-bromothiophen-2-yl)methylamino]-5-(methylsulfamoyl)pyridine-3-carboxylic acid Chemical compound OC(=O)C1=CC(S(=O)(=O)NC)=CN=C1NCC1=CC=C(Br)S1 WHYPYCWLXXLMQV-UHFFFAOYSA-N 0.000 description 2
- YGFSVVVBNFDBEH-LBPRGKRZSA-N 2-[(5-bromothiophen-2-yl)methylamino]-n-[(1s)-1-(4-fluorophenyl)ethyl]pyridine-3-carboxamide Chemical compound N([C@@H](C)C=1C=CC(F)=CC=1)C(=O)C1=CC=CN=C1NCC1=CC=C(Br)S1 YGFSVVVBNFDBEH-LBPRGKRZSA-N 0.000 description 2
- SWRPKVOTCXPWKA-UHFFFAOYSA-N 2-[(5-bromothiophen-2-yl)methylamino]-n-[(3,4-difluorophenyl)methyl]-5-(methylsulfamoyl)pyridine-3-carboxamide Chemical compound C=1C=C(F)C(F)=CC=1CNC(=O)C1=CC(S(=O)(=O)NC)=CN=C1NCC1=CC=C(Br)S1 SWRPKVOTCXPWKA-UHFFFAOYSA-N 0.000 description 2
- RGBRTPVNRVVRHJ-UHFFFAOYSA-N 2-[(5-bromothiophen-2-yl)methylamino]-n-[(3,4-difluorophenyl)methyl]-6,7-dihydro-5h-cyclopenta[b]pyridine-3-carboxamide Chemical compound C1=C(F)C(F)=CC=C1CNC(=O)C(C(=N1)NCC=2SC(Br)=CC=2)=CC2=C1CCC2 RGBRTPVNRVVRHJ-UHFFFAOYSA-N 0.000 description 2
- ZOMUEPLZCVBCRH-UHFFFAOYSA-N 2-[(5-bromothiophen-2-yl)methylamino]-n-[(3,4-difluorophenyl)methyl]quinoline-3-carboxamide Chemical compound C1=C(F)C(F)=CC=C1CNC(=O)C1=CC2=CC=CC=C2N=C1NCC1=CC=C(Br)S1 ZOMUEPLZCVBCRH-UHFFFAOYSA-N 0.000 description 2
- NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 2
- IDKIUIKQXPLZAG-UHFFFAOYSA-N 2-[[3-(4-aminoquinazolin-6-yl)phenyl]methylamino]-n-[(3,4-difluorophenyl)methyl]pyridine-3-carboxamide Chemical compound C1=C2C(N)=NC=NC2=CC=C1C(C=1)=CC=CC=1CNC1=NC=CC=C1C(=O)NCC1=CC=C(F)C(F)=C1 IDKIUIKQXPLZAG-UHFFFAOYSA-N 0.000 description 2
- VXVZBASLWUJFLL-UHFFFAOYSA-N 2-[[3-[1-(benzenesulfonyl)pyrrolo[2,3-b]pyridin-3-yl]phenyl]methylamino]pyridine-3-carboxylic acid Chemical compound OC(=O)C1=CC=CN=C1NCC1=CC=CC(C=2C3=CC=CN=C3N(C=2)S(=O)(=O)C=2C=CC=CC=2)=C1 VXVZBASLWUJFLL-UHFFFAOYSA-N 0.000 description 2
- BGVRJVOMIBRHFT-UHFFFAOYSA-N 2-[[3-[5-(cyclopropylcarbamoyl)-1h-pyrrolo[2,3-b]pyridin-3-yl]-5-propan-2-yloxyphenyl]methylamino]pyridine-3-carbonyl chloride Chemical compound C=1C(C=2C3=CC(=CN=C3NC=2)C(=O)NC2CC2)=CC(OC(C)C)=CC=1CNC1=NC=CC=C1C(Cl)=O BGVRJVOMIBRHFT-UHFFFAOYSA-N 0.000 description 2
- RRGIGBKCXLEXMH-UHFFFAOYSA-N 2-[[5-(4-amino-7h-pyrrolo[2,3-d]pyrimidin-5-yl)thiophen-2-yl]methylamino]-n-[(3,4-difluorophenyl)methyl]pyridine-3-carboxamide Chemical compound C1=2C(N)=NC=NC=2NC=C1C(S1)=CC=C1CNC1=NC=CC=C1C(=O)NCC1=CC=C(F)C(F)=C1 RRGIGBKCXLEXMH-UHFFFAOYSA-N 0.000 description 2
- FPWKNTJJSQMKLU-UHFFFAOYSA-N 2-[[5-(4-aminoquinazolin-6-yl)thiophen-2-yl]-methylamino]-n-[(3,4-difluorophenyl)methyl]-5-(oxetan-3-yl)pyridine-3-carboxamide Chemical compound C=1C=C(C=2C=C3C(N)=NC=NC3=CC=2)SC=1N(C)C1=NC=C(C2COC2)C=C1C(=O)NCC1=CC=C(F)C(F)=C1 FPWKNTJJSQMKLU-UHFFFAOYSA-N 0.000 description 2
- WRLQKZOQBIUECA-UHFFFAOYSA-N 2-[[5-(4-aminoquinazolin-6-yl)thiophen-2-yl]methylamino]-n-[(3,4-difluorophenyl)methyl]-5-(2-trimethylsilylethynyl)pyridine-3-carboxamide Chemical compound C=1C(C#C[Si](C)(C)C)=CN=C(NCC=2SC(=CC=2)C=2C=C3C(N)=NC=NC3=CC=2)C=1C(=O)NCC1=CC=C(F)C(F)=C1 WRLQKZOQBIUECA-UHFFFAOYSA-N 0.000 description 2
- HUELUZAHWQJKHC-UHFFFAOYSA-N 2-[[5-(4-aminoquinazolin-6-yl)thiophen-2-yl]methylamino]-n-[(3,4-difluorophenyl)methyl]-5-ethynylpyridine-3-carboxamide Chemical compound C1=C2C(N)=NC=NC2=CC=C1C(S1)=CC=C1CNC1=NC=C(C#C)C=C1C(=O)NCC1=CC=C(F)C(F)=C1 HUELUZAHWQJKHC-UHFFFAOYSA-N 0.000 description 2
- OGLZHDDPDOIJMH-UHFFFAOYSA-N 2-[[5-(4-aminoquinazolin-6-yl)thiophen-2-yl]methylamino]pyridine-3-carboxylic acid Chemical compound C1=C2C(N)=NC=NC2=CC=C1C(S1)=CC=C1CNC1=NC=CC=C1C(O)=O OGLZHDDPDOIJMH-UHFFFAOYSA-N 0.000 description 2
- GKKVCQNNRBWHBL-UHFFFAOYSA-N 2-[[5-(4-chloroquinazolin-6-yl)thiophen-2-yl]methylamino]-n-[(3,4-difluorophenyl)methyl]pyridine-3-carboxamide Chemical compound C1=C(F)C(F)=CC=C1CNC(=O)C1=CC=CN=C1NCC1=CC=C(C=2C=C3C(Cl)=NC=NC3=CC=2)S1 GKKVCQNNRBWHBL-UHFFFAOYSA-N 0.000 description 2
- VUUQSABMWGAAGH-UHFFFAOYSA-N 2-[[5-[7-(benzenesulfonyl)-4-[(2,4,6-trimethoxyphenyl)methylamino]pyrrolo[2,3-d]pyrimidin-5-yl]thiophen-2-yl]methylamino]-n-[(3,4-difluorophenyl)methyl]pyridine-3-carboxamide Chemical compound COC1=CC(OC)=CC(OC)=C1CNC1=NC=NC2=C1C(C=1SC(CNC=3C(=CC=CN=3)C(=O)NCC=3C=C(F)C(F)=CC=3)=CC=1)=CN2S(=O)(=O)C1=CC=CC=C1 VUUQSABMWGAAGH-UHFFFAOYSA-N 0.000 description 2
- DKLPTTIZQLGTIW-VIFPVBQESA-N 2-amino-n-[(1s)-1-(4-fluorophenyl)ethyl]pyridine-3-carboxamide Chemical compound N([C@@H](C)C=1C=CC(F)=CC=1)C(=O)C1=CC=CN=C1N DKLPTTIZQLGTIW-VIFPVBQESA-N 0.000 description 2
- BPZDFZUVMMQBQO-UHFFFAOYSA-N 2-amino-n-[(3,4-difluorophenyl)methyl]pyridine-3-carboxamide Chemical compound NC1=NC=CC=C1C(=O)NCC1=CC=C(F)C(F)=C1 BPZDFZUVMMQBQO-UHFFFAOYSA-N 0.000 description 2
- DJUWIZUEHXRECB-UHFFFAOYSA-N 2-bromo-1,3-thiazole-5-carbaldehyde Chemical compound BrC1=NC=C(C=O)S1 DJUWIZUEHXRECB-UHFFFAOYSA-N 0.000 description 2
- DVJXGNPUDMVFRQ-UHFFFAOYSA-N 2-bromo-n-methyl-5-nitropyridin-4-amine Chemical compound CNC1=CC(Br)=NC=C1[N+]([O-])=O DVJXGNPUDMVFRQ-UHFFFAOYSA-N 0.000 description 2
- NDOPHXWIAZIXPR-UHFFFAOYSA-N 2-bromobenzaldehyde Chemical compound BrC1=CC=CC=C1C=O NDOPHXWIAZIXPR-UHFFFAOYSA-N 0.000 description 2
- DIUKXTASUMSYBZ-UHFFFAOYSA-N 2-chloro-n-[(3,4-difluorophenyl)methyl]-4-(2-trimethylsilylethynyl)pyridine-3-carboxamide Chemical compound C[Si](C)(C)C#CC1=CC=NC(Cl)=C1C(=O)NCC1=CC=C(F)C(F)=C1 DIUKXTASUMSYBZ-UHFFFAOYSA-N 0.000 description 2
- QOJLWASKXFJTSL-UHFFFAOYSA-N 2-chloro-n-[(3,4-difluorophenyl)methyl]-4-ethoxypyridine-3-carboxamide Chemical compound CCOC1=CC=NC(Cl)=C1C(=O)NCC1=CC=C(F)C(F)=C1 QOJLWASKXFJTSL-UHFFFAOYSA-N 0.000 description 2
- ZVHQTDWUVNPGAY-UHFFFAOYSA-N 2-chloro-n-[(3,4-difluorophenyl)methyl]pyridine-3-carboxamide Chemical compound C1=C(F)C(F)=CC=C1CNC(=O)C1=CC=CN=C1Cl ZVHQTDWUVNPGAY-UHFFFAOYSA-N 0.000 description 2
- XWLRUWGWQJADBD-UHFFFAOYSA-N 2-chloro-n-[(3,4-difluorophenyl)methyl]quinoline-3-carboxamide Chemical compound C1=C(F)C(F)=CC=C1CNC(=O)C1=CC2=CC=CC=C2N=C1Cl XWLRUWGWQJADBD-UHFFFAOYSA-N 0.000 description 2
- QGKGASXQTBQINX-UHFFFAOYSA-N 3,4-dihydro-1h-pyrimidin-2-one Chemical compound O=C1NCC=CN1 QGKGASXQTBQINX-UHFFFAOYSA-N 0.000 description 2
- ZOPPFCJCTDXJCB-LBPRGKRZSA-N 3-[(1s)-1-(3,4-difluorophenyl)ethyl]-4-oxo-5-(thiophen-2-ylmethylamino)pyrido[4,3-d]pyrimidine-8-carbonitrile Chemical compound C1([C@H](C)N2C(C3=C(NCC=4SC=CC=4)N=CC(=C3N=C2)C#N)=O)=CC=C(F)C(F)=C1 ZOPPFCJCTDXJCB-LBPRGKRZSA-N 0.000 description 2
- OLOWDBAQIBVPKI-UHFFFAOYSA-N 3-[1-(benzenesulfonyl)pyrrolo[2,3-b]pyridin-3-yl]benzaldehyde Chemical compound O=CC1=CC=CC(C=2C3=CC=CN=C3N(C=2)S(=O)(=O)C=2C=CC=CC=2)=C1 OLOWDBAQIBVPKI-UHFFFAOYSA-N 0.000 description 2
- JWHZSQNLWNUGOL-UHFFFAOYSA-N 3-amino-n-[(3,4-difluorophenyl)methyl]-6-phenylpyrazine-2-carboxamide Chemical compound NC1=NC=C(C=2C=CC=CC=2)N=C1C(=O)NCC1=CC=C(F)C(F)=C1 JWHZSQNLWNUGOL-UHFFFAOYSA-N 0.000 description 2
- SUAIJCGYWIQHSG-UHFFFAOYSA-N 3-amino-n-[(3,4-difluorophenyl)methyl]-6-propan-2-ylpyrazine-2-carboxamide Chemical compound CC(C)C1=CN=C(N)C(C(=O)NCC=2C=C(F)C(F)=CC=2)=N1 SUAIJCGYWIQHSG-UHFFFAOYSA-N 0.000 description 2
- SUISZCALMBHJQX-UHFFFAOYSA-N 3-bromobenzaldehyde Chemical compound BrC1=CC=CC(C=O)=C1 SUISZCALMBHJQX-UHFFFAOYSA-N 0.000 description 2
- SVSUYEJKNSMKKW-UHFFFAOYSA-N 4,4,5,5-tetramethyl-2-prop-1-en-2-yl-1,3,2-dioxaborolane Chemical compound CC(=C)B1OC(C)(C)C(C)(C)O1 SVSUYEJKNSMKKW-UHFFFAOYSA-N 0.000 description 2
- LVHWWQSKFDSHHQ-UHFFFAOYSA-N 4-(azetidin-1-yl)-6-iodoquinazoline Chemical compound C12=CC(I)=CC=C2N=CN=C1N1CCC1 LVHWWQSKFDSHHQ-UHFFFAOYSA-N 0.000 description 2
- JBGFDORKUOEPFB-UHFFFAOYSA-N 4-amino-2-chloro-n-[(3,4-difluorophenyl)methyl]pyridine-3-carboxamide Chemical compound NC1=CC=NC(Cl)=C1C(=O)NCC1=CC=C(F)C(F)=C1 JBGFDORKUOEPFB-UHFFFAOYSA-N 0.000 description 2
- IERSCBNLXPSXDT-LURJTMIESA-N 4-amino-5-bromo-2-chloro-n-[(1s)-1-(3,4-difluorophenyl)ethyl]pyridine-3-carboxamide Chemical compound N([C@@H](C)C=1C=C(F)C(F)=CC=1)C(=O)C1=C(Cl)N=CC(Br)=C1N IERSCBNLXPSXDT-LURJTMIESA-N 0.000 description 2
- JDUXMFGFGCJNGO-UHFFFAOYSA-N 4-bromo-1,3-thiazole-2-carbaldehyde Chemical compound BrC1=CSC(C=O)=N1 JDUXMFGFGCJNGO-UHFFFAOYSA-N 0.000 description 2
- PDONIKHDXYHTLS-UHFFFAOYSA-N 4-bromothiophene-2-carbaldehyde Chemical compound BrC1=CSC(C=O)=C1 PDONIKHDXYHTLS-UHFFFAOYSA-N 0.000 description 2
- PUBQJTLBNNDRSI-UHFFFAOYSA-N 4-chloro-2-[(3,4-difluorophenyl)methyl]-1h-pyrrolo[3,4-c]pyridin-3-one Chemical compound C1=C(F)C(F)=CC=C1CN1C(=O)C2=C(Cl)N=CC=C2C1 PUBQJTLBNNDRSI-UHFFFAOYSA-N 0.000 description 2
- CBWBJFJMNBPWAL-UHFFFAOYSA-N 4-chloro-5-iodo-7h-pyrrolo[2,3-d]pyrimidine Chemical compound ClC1=NC=NC2=C1C(I)=CN2 CBWBJFJMNBPWAL-UHFFFAOYSA-N 0.000 description 2
- DEUGJCZMTOUZJA-UHFFFAOYSA-N 4-n-[(2,4-dimethoxyphenyl)methyl]quinazoline-4,6-diamine Chemical compound COC1=CC(OC)=CC=C1CNC1=NC=NC2=CC=C(N)C=C12 DEUGJCZMTOUZJA-UHFFFAOYSA-N 0.000 description 2
- PNWRFEGJSXYDNM-UHFFFAOYSA-N 5,7-dichloro-3-[(3,4-difluorophenyl)methyl]pyrido[4,3-d]pyrimidin-4-one Chemical compound C1=C(F)C(F)=CC=C1CN1C(=O)C2=C(Cl)N=C(Cl)C=C2N=C1 PNWRFEGJSXYDNM-UHFFFAOYSA-N 0.000 description 2
- XGRKDMCBZRDXIQ-UHFFFAOYSA-N 5-amino-2-[[5-(4-aminoquinazolin-6-yl)thiophen-2-yl]methylamino]-n-[(3,4-difluorophenyl)methyl]pyridine-3-carboxamide Chemical compound C=1C(N)=CN=C(NCC=2SC(=CC=2)C=2C=C3C(N)=NC=NC3=CC=2)C=1C(=O)NCC1=CC=C(F)C(F)=C1 XGRKDMCBZRDXIQ-UHFFFAOYSA-N 0.000 description 2
- AEOOBSRJRTUCOJ-UHFFFAOYSA-N 6-azido-n-[(2,4-dimethoxyphenyl)methyl]quinazolin-4-amine Chemical compound COC1=CC(OC)=CC=C1CNC1=NC=NC2=CC=C(N=[N+]=[N-])C=C12 AEOOBSRJRTUCOJ-UHFFFAOYSA-N 0.000 description 2
- MNAFCHNZEMIAPI-UHFFFAOYSA-N 6-bromo-4-n-methylpyridine-3,4-diamine Chemical compound CNC1=CC(Br)=NC=C1N MNAFCHNZEMIAPI-UHFFFAOYSA-N 0.000 description 2
- PRRDXULBKQOEQK-UHFFFAOYSA-N 6-bromo-n-[(2,4-dimethoxyphenyl)methyl]quinazolin-4-amine Chemical compound COC1=CC(OC)=CC=C1CNC1=NC=NC2=CC=C(Br)C=C12 PRRDXULBKQOEQK-UHFFFAOYSA-N 0.000 description 2
- DPPOGHQFCCEUHL-UHFFFAOYSA-N 6-bromo-n-[(3,4-difluorophenyl)methyl]-3-fluoropyrazine-2-carboxamide Chemical compound C1=C(F)C(F)=CC=C1CNC(=O)C1=NC(Br)=CN=C1F DPPOGHQFCCEUHL-UHFFFAOYSA-N 0.000 description 2
- CVKSJBKEXLNKLZ-UHFFFAOYSA-N 6-bromo-n-methyl-3-nitroquinolin-4-amine Chemical compound C1=C(Br)C=C2C(NC)=C([N+]([O-])=O)C=NC2=C1 CVKSJBKEXLNKLZ-UHFFFAOYSA-N 0.000 description 2
- BBPUOYYUBFLNML-UHFFFAOYSA-N 6-chloro-1h-pyrido[3,4-d]pyrimidin-4-one Chemical compound N1=CNC(=O)C2=C1C=NC(Cl)=C2 BBPUOYYUBFLNML-UHFFFAOYSA-N 0.000 description 2
- QHJNXFUNGGUIDH-UHFFFAOYSA-N 6-chloropyrido[3,4-d]pyrimidin-4-amine Chemical compound N1=C(Cl)C=C2C(N)=NC=NC2=C1 QHJNXFUNGGUIDH-UHFFFAOYSA-N 0.000 description 2
- RUUKOXAEAMGUEV-UHFFFAOYSA-N 7-(benzenesulfonyl)-5-iodo-n-[(2,4,6-trimethoxyphenyl)methyl]pyrrolo[2,3-d]pyrimidin-4-amine Chemical compound COC1=CC(OC)=CC(OC)=C1CNC1=NC=NC2=C1C(I)=CN2S(=O)(=O)C1=CC=CC=C1 RUUKOXAEAMGUEV-UHFFFAOYSA-N 0.000 description 2
- QYAGSIWXFSBXSX-UHFFFAOYSA-N 7-(benzenesulfonyl)-5-iodo-n-[(4-methoxyphenyl)methyl]pyrrolo[2,3-d]pyrimidin-4-amine Chemical compound C1=CC(OC)=CC=C1CNC1=NC=NC2=C1C(I)=CN2S(=O)(=O)C1=CC=CC=C1 QYAGSIWXFSBXSX-UHFFFAOYSA-N 0.000 description 2
- KMOIYTCVSOVRDC-UHFFFAOYSA-N 7-(benzenesulfonyl)-5-iodopyrrolo[2,3-d]pyrimidin-4-amine Chemical compound C1=C(I)C=2C(N)=NC=NC=2N1S(=O)(=O)C1=CC=CC=C1 KMOIYTCVSOVRDC-UHFFFAOYSA-N 0.000 description 2
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 2
- WQJCBGBMQBKVGX-UHFFFAOYSA-N 8-bromo-1-methyl-3h-imidazo[4,5-c]quinolin-2-one Chemical compound C1=C(Br)C=C2C(N(C(N3)=O)C)=C3C=NC2=C1 WQJCBGBMQBKVGX-UHFFFAOYSA-N 0.000 description 2
- YCIPQJTZJGUXND-UHFFFAOYSA-N Aglaia odorata Alkaloid Natural products C1=CC(OC)=CC=C1C1(C(C=2C(=O)N3CCCC3=NC=22)C=3C=CC=CC=3)C2(O)C2=C(OC)C=C(OC)C=C2O1 YCIPQJTZJGUXND-UHFFFAOYSA-N 0.000 description 2
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 2
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 2
- KAKZBPTYRLMSJV-UHFFFAOYSA-N Butadiene Chemical group C=CC=C KAKZBPTYRLMSJV-UHFFFAOYSA-N 0.000 description 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 2
- 206010009944 Colon cancer Diseases 0.000 description 2
- XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
- 238000005481 NMR spectroscopy Methods 0.000 description 2
- 108091007960 PI3Ks Proteins 0.000 description 2
- YNHIGQDRGKUECZ-UHFFFAOYSA-L PdCl2(PPh3)2 Substances [Cl-].[Cl-].[Pd+2].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 YNHIGQDRGKUECZ-UHFFFAOYSA-L 0.000 description 2
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 2
- 102000009738 Ribosomal Protein S6 Kinases Human genes 0.000 description 2
- 108010034782 Ribosomal Protein S6 Kinases Proteins 0.000 description 2
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 2
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- PXGMROMLISRQAF-UHFFFAOYSA-N [3-[[[3-[(3,4-difluorophenyl)methylcarbamoyl]pyridin-2-yl]amino]methyl]-5-propan-2-yloxyphenyl]boronic acid Chemical compound OB(O)C1=CC(OC(C)C)=CC(CNC=2C(=CC=CN=2)C(=O)NCC=2C=C(F)C(F)=CC=2)=C1 PXGMROMLISRQAF-UHFFFAOYSA-N 0.000 description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 150000001299 aldehydes Chemical class 0.000 description 2
- HONIICLYMWZJFZ-UHFFFAOYSA-N azetidine Chemical compound C1CNC1 HONIICLYMWZJFZ-UHFFFAOYSA-N 0.000 description 2
- CSKNSYBAZOQPLR-UHFFFAOYSA-N benzenesulfonyl chloride Chemical compound ClS(=O)(=O)C1=CC=CC=C1 CSKNSYBAZOQPLR-UHFFFAOYSA-N 0.000 description 2
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 239000012472 biological sample Substances 0.000 description 2
- UORVGPXVDQYIDP-UHFFFAOYSA-N borane Chemical compound B UORVGPXVDQYIDP-UHFFFAOYSA-N 0.000 description 2
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 2
- 229910052794 bromium Inorganic materials 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 125000004452 carbocyclyl group Chemical group 0.000 description 2
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 2
- PFKFTWBEEFSNDU-UHFFFAOYSA-N carbonyldiimidazole Chemical compound C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 229910052801 chlorine Inorganic materials 0.000 description 2
- 229940110456 cocoa butter Drugs 0.000 description 2
- 235000019868 cocoa butter Nutrition 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- DOBRDRYODQBAMW-UHFFFAOYSA-N copper(i) cyanide Chemical compound [Cu+].N#[C-] DOBRDRYODQBAMW-UHFFFAOYSA-N 0.000 description 2
- 125000004122 cyclic group Chemical group 0.000 description 2
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 2
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 2
- 125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 description 2
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 2
- NNBZCPXTIHJBJL-UHFFFAOYSA-N decalin Chemical compound C1CCCC2CCCCC21 NNBZCPXTIHJBJL-UHFFFAOYSA-N 0.000 description 2
- 238000007872 degassing Methods 0.000 description 2
- 238000010511 deprotection reaction Methods 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 2
- 125000005411 dithiolanyl group Chemical group S1SC(CC1)* 0.000 description 2
- ZQQJUPYGSFCOSB-UHFFFAOYSA-N ethyl 2-[(5-bromothiophen-2-yl)methylamino]-5-(methylsulfamoyl)pyridine-3-carboxylate Chemical compound CCOC(=O)C1=CC(S(=O)(=O)NC)=CN=C1NCC1=CC=C(Br)S1 ZQQJUPYGSFCOSB-UHFFFAOYSA-N 0.000 description 2
- YGQFRXLGCBUYQF-UHFFFAOYSA-N ethyl 2-[(5-bromothiophen-2-yl)methylamino]pyridine-3-carboxylate Chemical compound CCOC(=O)C1=CC=CN=C1NCC1=CC=C(Br)S1 YGQFRXLGCBUYQF-UHFFFAOYSA-N 0.000 description 2
- NCISISXLYPFMTN-UHFFFAOYSA-N ethyl 2-[[3-[1-(benzenesulfonyl)-5-(cyclopropylcarbamoyl)pyrrolo[2,3-b]pyridin-3-yl]-5-propan-2-yloxyphenyl]methylamino]pyridine-3-carboxylate Chemical compound CCOC(=O)C1=CC=CN=C1NCC1=CC(OC(C)C)=CC(C=2C3=CC(=CN=C3N(C=2)S(=O)(=O)C=2C=CC=CC=2)C(=O)NC2CC2)=C1 NCISISXLYPFMTN-UHFFFAOYSA-N 0.000 description 2
- PCJVBEOWGUIXNI-UHFFFAOYSA-N ethyl 2-[[5-(4-aminoquinazolin-6-yl)thiophen-2-yl]methylamino]pyridine-3-carboxylate Chemical compound CCOC(=O)C1=CC=CN=C1NCC1=CC=C(C=2C=C3C(N)=NC=NC3=CC=2)S1 PCJVBEOWGUIXNI-UHFFFAOYSA-N 0.000 description 2
- RCOXYAHOPGQTJV-UHFFFAOYSA-N ethyl 2-[[5-[4-[(2,4-dimethoxyphenyl)methylamino]quinazolin-6-yl]thiophen-2-yl]methylamino]pyridine-3-carboxylate Chemical compound CCOC(=O)C1=CC=CN=C1NCC1=CC=C(C=2C=C3C(NCC=4C(=CC(OC)=CC=4)OC)=NC=NC3=CC=2)S1 RCOXYAHOPGQTJV-UHFFFAOYSA-N 0.000 description 2
- SMWKMIXABPJPOL-UHFFFAOYSA-N ethyl 2-chloro-5-(methylsulfamoyl)pyridine-3-carboxylate Chemical compound CCOC(=O)C1=CC(S(=O)(=O)NC)=CN=C1Cl SMWKMIXABPJPOL-UHFFFAOYSA-N 0.000 description 2
- KEXGUJMBPOYKBG-UHFFFAOYSA-N ethyl 2-chloro-5-chlorosulfonylpyridine-3-carboxylate Chemical compound CCOC(=O)C1=CC(S(Cl)(=O)=O)=CN=C1Cl KEXGUJMBPOYKBG-UHFFFAOYSA-N 0.000 description 2
- 230000008020 evaporation Effects 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 239000012467 final product Substances 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 125000001153 fluoro group Chemical group F* 0.000 description 2
- 239000012458 free base Substances 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 125000004475 heteroaralkyl group Chemical group 0.000 description 2
- 125000002632 imidazolidinyl group Chemical group 0.000 description 2
- 239000012535 impurity Substances 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 125000003387 indolinyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- BMBMBFPFGQSISS-UHFFFAOYSA-N methyl 2-chloro-4-(cyanomethyl)pyridine-3-carboxylate Chemical compound COC(=O)C1=C(Cl)N=CC=C1CC#N BMBMBFPFGQSISS-UHFFFAOYSA-N 0.000 description 2
- YIIWDZRYILEHMZ-UHFFFAOYSA-N methyl 2-chloro-4-[1-cyano-2-[(2-methylpropan-2-yl)oxy]-2-oxoethyl]pyridine-3-carboxylate Chemical compound COC(=O)C1=C(Cl)N=CC=C1C(C#N)C(=O)OC(C)(C)C YIIWDZRYILEHMZ-UHFFFAOYSA-N 0.000 description 2
- YWUAGVCOZHLJTG-UHFFFAOYSA-N methyl 2-chloro-4-cyanopyridine-3-carboxylate Chemical compound COC(=O)C1=C(Cl)N=CC=C1C#N YWUAGVCOZHLJTG-UHFFFAOYSA-N 0.000 description 2
- FXGPTKSMXUWJGO-UHFFFAOYSA-N methyl 2-chloro-4-iodopyridine-3-carboxylate Chemical compound COC(=O)C1=C(I)C=CN=C1Cl FXGPTKSMXUWJGO-UHFFFAOYSA-N 0.000 description 2
- XBAJHALJJGVXBM-UHFFFAOYSA-N methyl 4-(aminomethyl)-2-chloropyridine-3-carboxylate Chemical compound COC(=O)C1=C(Cl)N=CC=C1CN XBAJHALJJGVXBM-UHFFFAOYSA-N 0.000 description 2
- 125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- UUBVIXWRKIGRFV-JTQLQIEISA-N n-[(1s)-1-(3,4-difluorophenyl)ethyl]-3-fluoro-6-(3-methoxyprop-1-ynyl)pyrazine-2-carboxamide Chemical compound COCC#CC1=CN=C(F)C(C(=O)N[C@@H](C)C=2C=C(F)C(F)=CC=2)=N1 UUBVIXWRKIGRFV-JTQLQIEISA-N 0.000 description 2
- QNSHSFVFNPBLHO-UHFFFAOYSA-N n-[(2,4-dimethoxyphenyl)methyl]-6-nitroquinazolin-4-amine Chemical compound COC1=CC(OC)=CC=C1CNC1=NC=NC2=CC=C([N+]([O-])=O)C=C12 QNSHSFVFNPBLHO-UHFFFAOYSA-N 0.000 description 2
- QLZLNGHQNQSXFQ-UHFFFAOYSA-N n-[(3,4-difluorophenyl)methyl]-2-[[5-[4-(propan-2-ylamino)quinazolin-6-yl]thiophen-2-yl]methylamino]pyridine-3-carboxamide Chemical compound C1=C2C(NC(C)C)=NC=NC2=CC=C1C(S1)=CC=C1CNC1=NC=CC=C1C(=O)NCC1=CC=C(F)C(F)=C1 QLZLNGHQNQSXFQ-UHFFFAOYSA-N 0.000 description 2
- PTRUFFFJFXVDPM-NSCUHMNNSA-N n-[(3,4-difluorophenyl)methyl]-3-fluoro-6-[(e)-prop-1-enyl]pyrazine-2-carboxamide Chemical compound C\C=C\C1=CN=C(F)C(C(=O)NCC=2C=C(F)C(F)=CC=2)=N1 PTRUFFFJFXVDPM-NSCUHMNNSA-N 0.000 description 2
- BANLEUQEKVFDFV-UHFFFAOYSA-N n-cyclopropyl-6-iodoquinazolin-4-amine Chemical compound C12=CC(I)=CC=C2N=CN=C1NC1CC1 BANLEUQEKVFDFV-UHFFFAOYSA-N 0.000 description 2
- 125000006574 non-aromatic ring group Chemical group 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 2
- KJIFKLIQANRMOU-UHFFFAOYSA-N oxidanium;4-methylbenzenesulfonate Chemical compound O.CC1=CC=C(S(O)(=O)=O)C=C1 KJIFKLIQANRMOU-UHFFFAOYSA-N 0.000 description 2
- NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 2
- DPBLXKKOBLCELK-UHFFFAOYSA-N pentan-1-amine Chemical compound CCCCCN DPBLXKKOBLCELK-UHFFFAOYSA-N 0.000 description 2
- HXITXNWTGFUOAU-UHFFFAOYSA-N phenylboronic acid Chemical compound OB(O)C1=CC=CC=C1 HXITXNWTGFUOAU-UHFFFAOYSA-N 0.000 description 2
- 125000003170 phenylsulfonyl group Chemical group C1(=CC=CC=C1)S(=O)(=O)* 0.000 description 2
- 229910052698 phosphorus Inorganic materials 0.000 description 2
- 239000011574 phosphorus Substances 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- IPEHBUMCGVEMRF-UHFFFAOYSA-N pyrazinecarboxamide Chemical compound NC(=O)C1=CN=CC=N1 IPEHBUMCGVEMRF-UHFFFAOYSA-N 0.000 description 2
- VTGOHKSTWXHQJK-UHFFFAOYSA-N pyrimidin-2-ol Chemical compound OC1=NC=CC=N1 VTGOHKSTWXHQJK-UHFFFAOYSA-N 0.000 description 2
- VIXWGKYSYIBATJ-UHFFFAOYSA-N pyrrol-2-one Chemical compound O=C1C=CC=N1 VIXWGKYSYIBATJ-UHFFFAOYSA-N 0.000 description 2
- BLTDCIWCFCUQCB-UHFFFAOYSA-N quinoline-3-carboxamide Chemical compound C1=CC=CC2=CC(C(=O)N)=CN=C21 BLTDCIWCFCUQCB-UHFFFAOYSA-N 0.000 description 2
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 2
- XSCHRSMBECNVNS-UHFFFAOYSA-N quinoxaline Chemical compound N1=CC=NC2=CC=CC=C21 XSCHRSMBECNVNS-UHFFFAOYSA-N 0.000 description 2
- 102000027426 receptor tyrosine kinases Human genes 0.000 description 2
- 108091008598 receptor tyrosine kinases Proteins 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000002390 rotary evaporation Methods 0.000 description 2
- 229910052710 silicon Inorganic materials 0.000 description 2
- 239000010703 silicon Substances 0.000 description 2
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 2
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 2
- 235000010288 sodium nitrite Nutrition 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- FFDLIWZDLKDDNB-UHFFFAOYSA-N tert-butyl n-[(2-methylpropan-2-yl)oxycarbonyl]-n-[6-[2-[[(2-methylpropan-2-yl)oxycarbonylamino]methyl]-1,3-thiazol-5-yl]quinazolin-4-yl]carbamate Chemical compound S1C(CNC(=O)OC(C)(C)C)=NC=C1C1=CC=C(N=CN=C2N(C(=O)OC(C)(C)C)C(=O)OC(C)(C)C)C2=C1 FFDLIWZDLKDDNB-UHFFFAOYSA-N 0.000 description 2
- KZWLYPGSSJIELD-UHFFFAOYSA-N tert-butyl n-[(5-bromo-1,3-thiazol-2-yl)methyl]carbamate Chemical compound CC(C)(C)OC(=O)NCC1=NC=C(Br)S1 KZWLYPGSSJIELD-UHFFFAOYSA-N 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 125000001712 tetrahydronaphthyl group Chemical group C1(CCCC2=CC=CC=C12)* 0.000 description 2
- 125000001412 tetrahydropyranyl group Chemical group 0.000 description 2
- 125000005710 tetrahydropyranylene group Chemical group 0.000 description 2
- 125000004853 tetrahydropyridinyl group Chemical group N1(CCCC=C1)* 0.000 description 2
- 125000003507 tetrahydrothiofenyl group Chemical group 0.000 description 2
- 125000004632 tetrahydrothiopyranyl group Chemical group S1C(CCCC1)* 0.000 description 2
- 125000001984 thiazolidinyl group Chemical group 0.000 description 2
- 239000002562 thickening agent Substances 0.000 description 2
- 125000005503 thioxanyl group Chemical group 0.000 description 2
- BLFRMOOGAICNSZ-UHFFFAOYSA-N (2,4,6-trimethoxyphenyl)methanamine;hydrochloride Chemical compound Cl.COC1=CC(OC)=C(CN)C(OC)=C1 BLFRMOOGAICNSZ-UHFFFAOYSA-N 0.000 description 1
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- TYKYVLDAFDKFHV-UHFFFAOYSA-N (3-formyl-5-propan-2-yloxyphenyl)boronic acid Chemical compound CC(C)OC1=CC(C=O)=CC(B(O)O)=C1 TYKYVLDAFDKFHV-UHFFFAOYSA-N 0.000 description 1
- XUHRVZXFBWDCFB-QRTDKPMLSA-N (3R)-4-[[(3S,6S,9S,12R,15S,18R,21R,24R,27R,28R)-12-(3-amino-3-oxopropyl)-6-[(2S)-butan-2-yl]-3-(2-carboxyethyl)-18-(hydroxymethyl)-28-methyl-9,15,21,24-tetrakis(2-methylpropyl)-2,5,8,11,14,17,20,23,26-nonaoxo-1-oxa-4,7,10,13,16,19,22,25-octazacyclooctacos-27-yl]amino]-3-[[(2R)-2-[[(3S)-3-hydroxydecanoyl]amino]-4-methylpentanoyl]amino]-4-oxobutanoic acid Chemical compound CCCCCCC[C@H](O)CC(=O)N[C@H](CC(C)C)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H]1[C@@H](C)OC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CO)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC1=O)[C@@H](C)CC XUHRVZXFBWDCFB-QRTDKPMLSA-N 0.000 description 1
- 125000006587 (C5-C10) heteroarylene group Chemical group 0.000 description 1
- NDQXKKFRNOPRDW-UHFFFAOYSA-N 1,1,1-triethoxyethane Chemical compound CCOC(C)(OCC)OCC NDQXKKFRNOPRDW-UHFFFAOYSA-N 0.000 description 1
- BCMCBBGGLRIHSE-UHFFFAOYSA-N 1,3-benzoxazole Chemical compound C1=CC=C2OC=NC2=C1 BCMCBBGGLRIHSE-UHFFFAOYSA-N 0.000 description 1
- JOZSYOPADROCMP-UHFFFAOYSA-N 1,3-thiazol-2-ylmethanamine Chemical compound NCC1=NC=CS1 JOZSYOPADROCMP-UHFFFAOYSA-N 0.000 description 1
- TZTSMNAZKFSLIC-UHFFFAOYSA-N 1-(benzenesulfonyl)-3-bromopyrrolo[2,3-b]pyridine Chemical compound C12=NC=CC=C2C(Br)=CN1S(=O)(=O)C1=CC=CC=C1 TZTSMNAZKFSLIC-UHFFFAOYSA-N 0.000 description 1
- ZYGPVHZEYCZWNX-UHFFFAOYSA-N 1-(benzenesulfonyl)-3-iodopyrrolo[2,3-b]pyridine Chemical compound C12=NC=CC=C2C(I)=CN1S(=O)(=O)C1=CC=CC=C1 ZYGPVHZEYCZWNX-UHFFFAOYSA-N 0.000 description 1
- AALMAEYUJRRMRU-UHFFFAOYSA-N 1-(benzenesulfonyl)-n-cyclopropyl-3-iodopyrrolo[2,3-b]pyridine-5-carboxamide Chemical compound C1=C2C(I)=CN(S(=O)(=O)C=3C=CC=CC=3)C2=NC=C1C(=O)NC1CC1 AALMAEYUJRRMRU-UHFFFAOYSA-N 0.000 description 1
- 125000000530 1-propynyl group Chemical group [H]C([H])([H])C#C* 0.000 description 1
- 238000004293 19F NMR spectroscopy Methods 0.000 description 1
- HYZJCKYKOHLVJF-UHFFFAOYSA-N 1H-benzimidazole Chemical compound C1=CC=C2NC=NC2=C1 HYZJCKYKOHLVJF-UHFFFAOYSA-N 0.000 description 1
- RADMRAMXLLLVGG-UHFFFAOYSA-N 1h-pyrido[4,3-d]pyrimidin-4-one Chemical compound C1=NC=C2C(=O)N=CNC2=C1 RADMRAMXLLLVGG-UHFFFAOYSA-N 0.000 description 1
- KIPSRYDSZQRPEA-UHFFFAOYSA-N 2,2,2-trifluoroethanamine Chemical compound NCC(F)(F)F KIPSRYDSZQRPEA-UHFFFAOYSA-N 0.000 description 1
- RZZGFCFQBVRQSX-UHFFFAOYSA-N 2,4-dibromo-5-nitropyridine Chemical compound [O-][N+](=O)C1=CN=C(Br)C=C1Br RZZGFCFQBVRQSX-UHFFFAOYSA-N 0.000 description 1
- MZLGUVLXWIQDHY-UHFFFAOYSA-N 2-(prop-2-ynylamino)pyridine-3-carboxamide Chemical compound NC(=O)C1=CC=CN=C1NCC#C MZLGUVLXWIQDHY-UHFFFAOYSA-N 0.000 description 1
- CTFOUAXNBKQJRK-UHFFFAOYSA-N 2-[(2-bromo-1,3-thiazol-4-yl)methylamino]-n-[(3,4-difluorophenyl)methyl]pyridine-3-carboxamide Chemical compound C1=C(F)C(F)=CC=C1CNC(=O)C1=CC=CN=C1NCC1=CSC(Br)=N1 CTFOUAXNBKQJRK-UHFFFAOYSA-N 0.000 description 1
- BRATZJPBISTYLK-UHFFFAOYSA-N 2-[(5-bromothiophen-2-yl)methylamino]-n-[(3,4-difluorophenyl)methyl]-5-(trifluoromethyl)pyridine-3-carboxamide Chemical compound C1=C(F)C(F)=CC=C1CNC(=O)C1=CC(C(F)(F)F)=CN=C1NCC1=CC=C(Br)S1 BRATZJPBISTYLK-UHFFFAOYSA-N 0.000 description 1
- UJNNAACTSNKNCB-UHFFFAOYSA-N 2-[(5-bromothiophen-2-yl)methylamino]-n-[(3,4-difluorophenyl)methyl]-5-iodopyridine-3-carboxamide Chemical compound C1=C(F)C(F)=CC=C1CNC(=O)C1=CC(I)=CN=C1NCC1=CC=C(Br)S1 UJNNAACTSNKNCB-UHFFFAOYSA-N 0.000 description 1
- CONDKXDAKLSBPV-UHFFFAOYSA-N 2-[(5-bromothiophen-2-yl)methylamino]-n-[(3,4-difluorophenyl)methyl]pyridine-3-carboxamide Chemical compound C1=C(F)C(F)=CC=C1CNC(=O)C1=CC=CN=C1NCC1=CC=C(Br)S1.C1=C(F)C(F)=CC=C1CNC(=O)C1=CC=CN=C1NCC1=CC=C(Br)S1 CONDKXDAKLSBPV-UHFFFAOYSA-N 0.000 description 1
- IPICLMBWFVISJA-UHFFFAOYSA-N 2-[1-(4-fluorophenyl)ethyl]pyridine-3-carboxamide Chemical compound N=1C=CC=C(C(N)=O)C=1C(C)C1=CC=C(F)C=C1 IPICLMBWFVISJA-UHFFFAOYSA-N 0.000 description 1
- OZNVRFZUCREQKQ-AWEZNQCLSA-N 2-[[5-(4-amino-7h-pyrrolo[2,3-d]pyrimidin-5-yl)thiophen-2-yl]methylamino]-n-[(1s)-1-(4-fluorophenyl)ethyl]pyridine-3-carboxamide Chemical compound C1([C@@H](NC(=O)C=2C(=NC=CC=2)NCC=2SC(=CC=2)C=2C3=C(N)N=CN=C3NC=2)C)=CC=C(F)C=C1 OZNVRFZUCREQKQ-AWEZNQCLSA-N 0.000 description 1
- NMZSXNYDOPHWCJ-UHFFFAOYSA-N 2-[[5-(4-aminoquinazolin-6-yl)thiophen-2-yl]methylamino]-5-bromo-n-[(3,4-difluorophenyl)methyl]pyridine-3-carboxamide Chemical compound C1=C2C(N)=NC=NC2=CC=C1C(S1)=CC=C1CNC1=NC=C(Br)C=C1C(=O)NCC1=CC=C(F)C(F)=C1 NMZSXNYDOPHWCJ-UHFFFAOYSA-N 0.000 description 1
- ZFWUCMUSBJNFTA-UHFFFAOYSA-N 2-[[5-(4-aminoquinazolin-6-yl)thiophen-2-yl]methylamino]-5-cyano-n-[(3,4-difluorophenyl)methyl]pyridine-3-carboxamide Chemical compound C1=C2C(N)=NC=NC2=CC=C1C(S1)=CC=C1CNC1=NC=C(C#N)C=C1C(=O)NCC1=CC=C(F)C(F)=C1 ZFWUCMUSBJNFTA-UHFFFAOYSA-N 0.000 description 1
- MJWOKPXVXMCXIY-AWEZNQCLSA-N 2-[[5-(4-aminoquinazolin-6-yl)thiophen-2-yl]methylamino]-n-[(1s)-1-(3,4-difluorophenyl)ethyl]-5-iodopyridine-3-carboxamide Chemical compound C1([C@@H](NC(=O)C=2C(=NC=C(I)C=2)NCC=2SC(=CC=2)C=2C=C3C(N)=NC=NC3=CC=2)C)=CC=C(F)C(F)=C1 MJWOKPXVXMCXIY-AWEZNQCLSA-N 0.000 description 1
- PTQWNMZTINPFFA-INIZCTEOSA-N 2-[[5-(4-aminoquinazolin-6-yl)thiophen-2-yl]methylamino]-n-[(1s)-1-(4-fluorophenyl)ethyl]-5-methylsulfonylpyridine-3-carboxamide Chemical compound C1([C@@H](NC(=O)C=2C(=NC=C(C=2)S(C)(=O)=O)NCC=2SC(=CC=2)C=2C=C3C(N)=NC=NC3=CC=2)C)=CC=C(F)C=C1 PTQWNMZTINPFFA-INIZCTEOSA-N 0.000 description 1
- QSNMDWMGEPUUBZ-UHFFFAOYSA-N 2-[[5-(4-aminoquinazolin-6-yl)thiophen-2-yl]methylamino]-n-[(2,5-difluorophenyl)methyl]pyridine-3-carboxamide Chemical compound C1=C2C(N)=NC=NC2=CC=C1C(S1)=CC=C1CNC1=NC=CC=C1C(=O)NCC1=CC(F)=CC=C1F QSNMDWMGEPUUBZ-UHFFFAOYSA-N 0.000 description 1
- JAFLPOYNKFAJRZ-UHFFFAOYSA-N 2-[[5-(4-aminoquinazolin-6-yl)thiophen-2-yl]methylamino]-n-[(3,4-difluorophenyl)methyl]-5-(methanesulfonamido)pyridine-3-carboxamide Chemical compound C=1C(NS(=O)(=O)C)=CN=C(NCC=2SC(=CC=2)C=2C=C3C(N)=NC=NC3=CC=2)C=1C(=O)NCC1=CC=C(F)C(F)=C1 JAFLPOYNKFAJRZ-UHFFFAOYSA-N 0.000 description 1
- CGGCUABTKQIMHE-UHFFFAOYSA-N 2-[[5-(4-aminoquinazolin-6-yl)thiophen-2-yl]methylamino]-n-[(3,4-difluorophenyl)methyl]-5-(methylsulfamoyl)pyridine-3-carboxamide Chemical compound C=1C(S(=O)(=O)NC)=CN=C(NCC=2SC(=CC=2)C=2C=C3C(N)=NC=NC3=CC=2)C=1C(=O)NCC1=CC=C(F)C(F)=C1 CGGCUABTKQIMHE-UHFFFAOYSA-N 0.000 description 1
- VMMAPOUVZVYQLY-UHFFFAOYSA-N 2-[[5-(4-aminoquinazolin-6-yl)thiophen-2-yl]methylamino]-n-[(3,4-difluorophenyl)methyl]-5-(trifluoromethyl)pyridine-3-carboxamide Chemical compound C1=C2C(N)=NC=NC2=CC=C1C(S1)=CC=C1CNC1=NC=C(C(F)(F)F)C=C1C(=O)NCC1=CC=C(F)C(F)=C1 VMMAPOUVZVYQLY-UHFFFAOYSA-N 0.000 description 1
- OSZMTBWXKMBDIN-UHFFFAOYSA-N 2-[[5-(4-aminoquinazolin-6-yl)thiophen-2-yl]methylamino]-n-[(3,4-difluorophenyl)methyl]-5-ethylpyridine-3-carboxamide Chemical compound C=1C(CC)=CN=C(NCC=2SC(=CC=2)C=2C=C3C(N)=NC=NC3=CC=2)C=1C(=O)NCC1=CC=C(F)C(F)=C1 OSZMTBWXKMBDIN-UHFFFAOYSA-N 0.000 description 1
- PNBNYSOHGWYILL-UHFFFAOYSA-N 2-[[5-(4-aminoquinazolin-6-yl)thiophen-2-yl]methylamino]-n-[(3,4-difluorophenyl)methyl]-5-prop-1-en-2-ylpyridine-3-carboxamide Chemical compound C=1C(C(=C)C)=CN=C(NCC=2SC(=CC=2)C=2C=C3C(N)=NC=NC3=CC=2)C=1C(=O)NCC1=CC=C(F)C(F)=C1 PNBNYSOHGWYILL-UHFFFAOYSA-N 0.000 description 1
- PZAYHKAXSBZUGW-UHFFFAOYSA-N 2-[[5-(4-aminoquinazolin-6-yl)thiophen-2-yl]methylamino]-n-[(3,4-difluorophenyl)methyl]pyridine-3-carboxamide Chemical compound C1=C2C(N)=NC=NC2=CC=C1C(S1)=CC=C1CNC1=NC=CC=C1C(=O)NCC1=CC=C(F)C(F)=C1 PZAYHKAXSBZUGW-UHFFFAOYSA-N 0.000 description 1
- CZLHSHJVSFGTAH-INIZCTEOSA-N 2-[[5-(4-chloroquinazolin-6-yl)thiophen-2-yl]methylamino]-n-[(1s)-1-(4-fluorophenyl)ethyl]pyridine-3-carboxamide Chemical compound C1([C@@H](NC(=O)C=2C(=NC=CC=2)NCC=2SC(=CC=2)C=2C=C3C(Cl)=NC=NC3=CC=2)C)=CC=C(F)C=C1 CZLHSHJVSFGTAH-INIZCTEOSA-N 0.000 description 1
- IEIPHNQIYWVSOF-SFHVURJKSA-N 2-[[5-[4-(2-aminoethylamino)quinazolin-6-yl]thiophen-2-yl]methylamino]-n-[(1s)-1-(4-fluorophenyl)ethyl]pyridine-3-carboxamide Chemical compound C1([C@@H](NC(=O)C=2C(=NC=CC=2)NCC=2SC(=CC=2)C=2C=C3C(NCCN)=NC=NC3=CC=2)C)=CC=C(F)C=C1 IEIPHNQIYWVSOF-SFHVURJKSA-N 0.000 description 1
- QBKUPVJQVYNBOR-UHFFFAOYSA-N 2-[[5-[4-(azetidin-1-yl)quinazolin-6-yl]thiophen-2-yl]methylamino]-n-[(3,4-difluorophenyl)methyl]pyridine-3-carboxamide Chemical compound C1=C(F)C(F)=CC=C1CNC(=O)C1=CC=CN=C1NCC1=CC=C(C=2C=C3C(N4CCC4)=NC=NC3=CC=2)S1 QBKUPVJQVYNBOR-UHFFFAOYSA-N 0.000 description 1
- JBRIUIIDIYCXHS-UHFFFAOYSA-N 2-[[5-[4-(cyclopropylamino)quinazolin-6-yl]thiophen-2-yl]methylamino]-n-[(3,4-difluorophenyl)methyl]pyridine-3-carboxamide Chemical compound C1=C(F)C(F)=CC=C1CNC(=O)C1=CC=CN=C1NCC1=CC=C(C=2C=C3C(NC4CC4)=NC=NC3=CC=2)S1 JBRIUIIDIYCXHS-UHFFFAOYSA-N 0.000 description 1
- XLABWUPAPVVDRL-IBGZPJMESA-N 2-[[5-[4-amino-7-(benzenesulfonyl)pyrrolo[2,3-d]pyrimidin-5-yl]thiophen-2-yl]methylamino]-n-[(1s)-1-(4-fluorophenyl)ethyl]pyridine-3-carboxamide Chemical compound N([C@@H](C)C=1C=CC(F)=CC=1)C(=O)C1=CC=CN=C1NCC(S1)=CC=C1C(C1=C(N)N=CN=C11)=CN1S(=O)(=O)C1=CC=CC=C1 XLABWUPAPVVDRL-IBGZPJMESA-N 0.000 description 1
- KTYDRFWLNANPIH-UHFFFAOYSA-N 2-amino-5-(trifluoromethyl)pyridine-3-carboxylic acid Chemical compound NC1=NC=C(C(F)(F)F)C=C1C(O)=O KTYDRFWLNANPIH-UHFFFAOYSA-N 0.000 description 1
- GNHYVDHQCGCUKG-UHFFFAOYSA-N 2-amino-n-[(3,4-difluorophenyl)methyl]-5-(trifluoromethyl)pyridine-3-carboxamide Chemical compound NC1=NC=C(C(F)(F)F)C=C1C(=O)NCC1=CC=C(F)C(F)=C1 GNHYVDHQCGCUKG-UHFFFAOYSA-N 0.000 description 1
- OECAOMHGRQHCGG-UHFFFAOYSA-N 2-bromo-5-(bromomethyl)thiophene Chemical compound BrCC1=CC=C(Br)S1 OECAOMHGRQHCGG-UHFFFAOYSA-N 0.000 description 1
- OLEQMBHSYSDGRD-JTQLQIEISA-N 2-chloro-4-ethoxy-n-[(1s)-1-(4-fluorophenyl)ethyl]pyridine-3-carboxamide Chemical compound CCOC1=CC=NC(Cl)=C1C(=O)N[C@@H](C)C1=CC=C(F)C=C1 OLEQMBHSYSDGRD-JTQLQIEISA-N 0.000 description 1
- QDUZEGLVAGFGRA-UHFFFAOYSA-N 2-chloro-5-iodopyridine-3-carboxylic acid Chemical compound OC(=O)C1=CC(I)=CN=C1Cl QDUZEGLVAGFGRA-UHFFFAOYSA-N 0.000 description 1
- LVWCGWVHPFGYOR-ZETCQYMHSA-N 2-chloro-n-[(1s)-1-(3,4-difluorophenyl)ethyl]-5-iodopyridine-3-carboxamide Chemical compound N([C@@H](C)C=1C=C(F)C(F)=CC=1)C(=O)C1=CC(I)=CN=C1Cl LVWCGWVHPFGYOR-ZETCQYMHSA-N 0.000 description 1
- FENZHVDLVRDRRL-VIFPVBQESA-N 2-chloro-n-[(1s)-1-(4-fluorophenyl)ethyl]-4-methoxypyridine-3-carboxamide Chemical compound COC1=CC=NC(Cl)=C1C(=O)N[C@@H](C)C1=CC=C(F)C=C1 FENZHVDLVRDRRL-VIFPVBQESA-N 0.000 description 1
- DQBPVCBQUAHQOK-UHFFFAOYSA-N 2-chloro-n-[(3,4-difluorophenyl)methyl]-4-[(4-methoxyphenyl)methylamino]pyridine-3-carboxamide Chemical compound C1=CC(OC)=CC=C1CNC1=CC=NC(Cl)=C1C(=O)NCC1=CC=C(F)C(F)=C1 DQBPVCBQUAHQOK-UHFFFAOYSA-N 0.000 description 1
- GTOOAOUREQLPEP-UHFFFAOYSA-N 2-chloro-n-[(3,4-difluorophenyl)methyl]-5-fluoropyridine-3-carboxamide Chemical compound FC1=CN=C(Cl)C(C(=O)NCC=2C=C(F)C(F)=CC=2)=C1 GTOOAOUREQLPEP-UHFFFAOYSA-N 0.000 description 1
- USVZFKPCRHXYOQ-UHFFFAOYSA-N 2-chloro-n-[(3,4-difluorophenyl)methyl]-6,7-dihydro-5h-cyclopenta[b]pyridine-3-carboxamide Chemical compound C1=C(F)C(F)=CC=C1CNC(=O)C(C(=N1)Cl)=CC2=C1CCC2 USVZFKPCRHXYOQ-UHFFFAOYSA-N 0.000 description 1
- XFSORZYTTCOBFN-UHFFFAOYSA-N 2-chloroquinoline-3-carboxylic acid Chemical compound C1=CC=C2N=C(Cl)C(C(=O)O)=CC2=C1 XFSORZYTTCOBFN-UHFFFAOYSA-N 0.000 description 1
- WRXNJTBODVGDRY-UHFFFAOYSA-N 2-pyrrolidin-1-ylethanamine Chemical compound NCCN1CCCC1 WRXNJTBODVGDRY-UHFFFAOYSA-N 0.000 description 1
- AXNUZKSSQHTNPZ-UHFFFAOYSA-N 3,4-difluoroaniline Chemical compound NC1=CC=C(F)C(F)=C1 AXNUZKSSQHTNPZ-UHFFFAOYSA-N 0.000 description 1
- 108010082078 3-Phosphoinositide-Dependent Protein Kinases Proteins 0.000 description 1
- CGWOEOXQHIMZEQ-UHFFFAOYSA-N 3-[1-[[4-(2-phenylquinolin-3-yl)phenyl]methyl]piperidin-4-yl]-1h-benzimidazol-2-one Chemical compound OC1=NC2=CC=CC=C2N1C(CC1)CCN1CC(C=C1)=CC=C1C1=CC2=CC=CC=C2N=C1C1=CC=CC=C1 CGWOEOXQHIMZEQ-UHFFFAOYSA-N 0.000 description 1
- WILIJDNKHPDBER-UHFFFAOYSA-N 3-[[5-(4-aminoquinazolin-6-yl)thiophen-2-yl]methylamino]-6-bromo-n-[(3,4-difluorophenyl)methyl]pyrazine-2-carboxamide Chemical compound C1=C2C(N)=NC=NC2=CC=C1C(S1)=CC=C1CNC1=NC=C(Br)N=C1C(=O)NCC1=CC=C(F)C(F)=C1 WILIJDNKHPDBER-UHFFFAOYSA-N 0.000 description 1
- XGVBHSHNSLJZNE-UHFFFAOYSA-N 3-[[5-(4-aminoquinazolin-6-yl)thiophen-2-yl]methylamino]-n-[(3,4-difluorophenyl)methyl]-6-propylpyrazine-2-carboxamide Chemical compound N=1C(CCC)=CN=C(NCC=2SC(=CC=2)C=2C=C3C(N)=NC=NC3=CC=2)C=1C(=O)NCC1=CC=C(F)C(F)=C1 XGVBHSHNSLJZNE-UHFFFAOYSA-N 0.000 description 1
- VYSGEYYGXFBZEG-UHFFFAOYSA-N 3-[[5-(4-aminoquinazolin-6-yl)thiophen-2-yl]methylamino]-n-[(3,4-difluorophenyl)methyl]pyrazine-2-carboxamide Chemical compound C1=C2C(N)=NC=NC2=CC=C1C(S1)=CC=C1CNC1=NC=CN=C1C(=O)NCC1=CC=C(F)C(F)=C1 VYSGEYYGXFBZEG-UHFFFAOYSA-N 0.000 description 1
- MTNAQEKMSVDTAQ-UHFFFAOYSA-N 3-amino-6-bromopyrazine-2-carboxylic acid Chemical compound NC1=NC=C(Br)N=C1C(O)=O MTNAQEKMSVDTAQ-UHFFFAOYSA-N 0.000 description 1
- KBEIFKMKVCDETC-UHFFFAOYSA-N 3-iodooxetane Chemical compound IC1COC1 KBEIFKMKVCDETC-UHFFFAOYSA-N 0.000 description 1
- YACFFSVYSPMSGS-UHFFFAOYSA-N 3-methoxyprop-1-yne Chemical compound COCC#C YACFFSVYSPMSGS-UHFFFAOYSA-N 0.000 description 1
- VOVZKEQDQUXIDG-UHFFFAOYSA-N 4-amino-2,6-dichloropyridine-3-carboxylic acid Chemical compound NC1=CC(Cl)=NC(Cl)=C1C(O)=O VOVZKEQDQUXIDG-UHFFFAOYSA-N 0.000 description 1
- VNELHBBHHKNZMW-ZETCQYMHSA-N 4-amino-2-chloro-n-[(1s)-1-(3,4-difluorophenyl)ethyl]pyridine-3-carboxamide Chemical compound N([C@@H](C)C=1C=C(F)C(F)=CC=1)C(=O)C1=C(N)C=CN=C1Cl VNELHBBHHKNZMW-ZETCQYMHSA-N 0.000 description 1
- SYYDIDJHSOXIDB-JTQLQIEISA-N 4-amino-5-bromo-n-[(1s)-1-(3,4-difluorophenyl)ethyl]-2-(thiophen-2-ylmethylamino)pyridine-3-carboxamide Chemical compound N([C@@H](C)C=1C=C(F)C(F)=CC=1)C(=O)C1=C(N)C(Br)=CN=C1NCC1=CC=CS1 SYYDIDJHSOXIDB-JTQLQIEISA-N 0.000 description 1
- 125000002471 4H-quinolizinyl group Chemical group C=1(C=CCN2C=CC=CC12)* 0.000 description 1
- UHPYZYPQBMWBOU-HNNXBMFYSA-N 5-[[5-(4-aminoquinazolin-6-yl)thiophen-2-yl]methylamino]-3-[(1s)-1-(3,4-difluorophenyl)ethyl]-4-oxopyrido[4,3-d]pyrimidine-8-carbonitrile Chemical compound C1([C@H](C)N2C(C3=C(NCC=4SC(=CC=4)C=4C=C5C(N)=NC=NC5=CC=4)N=CC(=C3N=C2)C#N)=O)=CC=C(F)C(F)=C1 UHPYZYPQBMWBOU-HNNXBMFYSA-N 0.000 description 1
- WCZUTMZMEAPPIX-UHFFFAOYSA-N 5-amino-2-chloropyridine-4-carboxylic acid Chemical compound NC1=CN=C(Cl)C=C1C(O)=O WCZUTMZMEAPPIX-UHFFFAOYSA-N 0.000 description 1
- SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 description 1
- PVKMIUSPUFUIDW-UHFFFAOYSA-N 5-bromo-2-[(5-bromothiophen-2-yl)methylamino]-n-[(3,4-difluorophenyl)methyl]pyridine-3-carboxamide Chemical compound C1=C(F)C(F)=CC=C1CNC(=O)C1=CC(Br)=CN=C1NCC1=CC=C(Br)S1 PVKMIUSPUFUIDW-UHFFFAOYSA-N 0.000 description 1
- KVPGXMPCUNFFKE-VIFPVBQESA-N 5-chloro-3-[(1s)-1-(4-fluorophenyl)ethyl]pyrido[4,3-d]pyrimidin-4-one Chemical compound C1([C@H](C)N2C(C3=C(Cl)N=CC=C3N=C2)=O)=CC=C(F)C=C1 KVPGXMPCUNFFKE-VIFPVBQESA-N 0.000 description 1
- IFJGMLHJYXZLED-UHFFFAOYSA-N 6-[[5-(4-aminoquinazolin-6-yl)thiophen-2-yl]methylamino]-5-[(3,4-difluorophenyl)methylcarbamoyl]pyridine-3-carboxylic acid Chemical compound C1=C2C(N)=NC=NC2=CC=C1C(S1)=CC=C1CNC1=NC=C(C(O)=O)C=C1C(=O)NCC1=CC=C(F)C(F)=C1 IFJGMLHJYXZLED-UHFFFAOYSA-N 0.000 description 1
- GLJAGTBLPZOAQG-AWEZNQCLSA-N 6-[[5-(4-aminoquinazolin-6-yl)thiophen-2-yl]methylamino]-5-[[(1S)-1-(3,4-difluorophenyl)ethyl]carbamoyl]pyridine-3-carboxylic acid Chemical compound C[C@H](NC(=O)C1=C(NCC2=CC=C(S2)C2=CC=C3N=CN=C(N)C3=C2)N=CC(=C1)C(O)=O)C1=CC=C(F)C(F)=C1 GLJAGTBLPZOAQG-AWEZNQCLSA-N 0.000 description 1
- ZUHMQIRTPRLLCF-UHFFFAOYSA-N 6-amino-2-[[5-(4-aminoquinazolin-6-yl)thiophen-2-yl]methylamino]-n-[(3,4-difluorophenyl)methyl]pyridine-3-carboxamide Chemical compound C=1C=C(C=2C=C3C(N)=NC=NC3=CC=2)SC=1CNC1=NC(N)=CC=C1C(=O)NCC1=CC=C(F)C(F)=C1 ZUHMQIRTPRLLCF-UHFFFAOYSA-N 0.000 description 1
- VELPFIJKEQNCIK-UHFFFAOYSA-N 6-bromo-1-methylimidazo[4,5-c]pyridin-2-amine Chemical compound N1=C(Br)C=C2N(C)C(N)=NC2=C1 VELPFIJKEQNCIK-UHFFFAOYSA-N 0.000 description 1
- OVEISJPVPHWEHR-UHFFFAOYSA-N 6-bromo-1h-quinazolin-4-one Chemical compound N1C=NC(=O)C2=CC(Br)=CC=C21 OVEISJPVPHWEHR-UHFFFAOYSA-N 0.000 description 1
- KHKPVEMMXJCWGP-UHFFFAOYSA-N 6-bromo-4-chloro-3-nitroquinoline Chemical compound C1=CC(Br)=CC2=C(Cl)C([N+](=O)[O-])=CN=C21 KHKPVEMMXJCWGP-UHFFFAOYSA-N 0.000 description 1
- ZERJIVBOUHIXQC-LURJTMIESA-N 6-bromo-n-[(1s)-1-(3,4-difluorophenyl)ethyl]-3-fluoropyrazine-2-carboxamide Chemical compound N([C@@H](C)C=1C=C(F)C(F)=CC=1)C(=O)C1=NC(Br)=CN=C1F ZERJIVBOUHIXQC-LURJTMIESA-N 0.000 description 1
- CHWNPCZNARJTEK-UHFFFAOYSA-N 6-bromo-n-cyclopropylquinazolin-4-amine Chemical compound C12=CC(Br)=CC=C2N=CN=C1NC1CC1 CHWNPCZNARJTEK-UHFFFAOYSA-N 0.000 description 1
- IFIHYLCUKYCKRH-UHFFFAOYSA-N 6-bromoquinoline Chemical compound N1=CC=CC2=CC(Br)=CC=C21 IFIHYLCUKYCKRH-UHFFFAOYSA-N 0.000 description 1
- BLJDQJLSUDXUGL-UHFFFAOYSA-N 6-iodoquinazoline Chemical compound N1=CN=CC2=CC(I)=CC=C21 BLJDQJLSUDXUGL-UHFFFAOYSA-N 0.000 description 1
- 125000004939 6-pyridyl group Chemical group N1=CC=CC=C1* 0.000 description 1
- AHDBGGPTLJKPCA-UHFFFAOYSA-N 7-(benzenesulfonyl)-5-iodopyrrolo[2,3-d]pyrimidine Chemical compound C12=NC=NC=C2C(I)=CN1S(=O)(=O)C1=CC=CC=C1 AHDBGGPTLJKPCA-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- LCEHBALYFWBCCR-UHFFFAOYSA-N 8-bromo-1-methylimidazo[4,5-c]quinoline Chemical compound C1=CC(Br)=CC2=C3N(C)C=NC3=CN=C21 LCEHBALYFWBCCR-UHFFFAOYSA-N 0.000 description 1
- ANARLMMHDRYFNW-NSHDSACASA-N 8-bromo-3-[(1s)-1-(3,4-difluorophenyl)ethyl]-5-(thiophen-2-ylmethylamino)pyrido[4,3-d]pyrimidin-4-one Chemical compound C1([C@H](C)N2C(C3=C(NCC=4SC=CC=4)N=CC(Br)=C3N=C2)=O)=CC=C(F)C(F)=C1 ANARLMMHDRYFNW-NSHDSACASA-N 0.000 description 1
- 102000019050 90-kDa Ribosomal Protein S6 Kinases Human genes 0.000 description 1
- 108010012196 90-kDa Ribosomal Protein S6 Kinases Proteins 0.000 description 1
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 1
- 229920000856 Amylose Polymers 0.000 description 1
- 206010073478 Anaplastic large-cell lymphoma Diseases 0.000 description 1
- 108020000948 Antisense Oligonucleotides Proteins 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 1
- 206010004593 Bile duct cancer Diseases 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 229920001287 Chondroitin sulfate Polymers 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- HTJDQJBWANPRPF-UHFFFAOYSA-N Cyclopropylamine Chemical compound NC1CC1 HTJDQJBWANPRPF-UHFFFAOYSA-N 0.000 description 1
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- SNRUBQQJIBEYMU-UHFFFAOYSA-N Dodecane Natural products CCCCCCCCCCCC SNRUBQQJIBEYMU-UHFFFAOYSA-N 0.000 description 1
- 102100025027 E3 ubiquitin-protein ligase TRIM69 Human genes 0.000 description 1
- 206010014733 Endometrial cancer Diseases 0.000 description 1
- 206010014759 Endometrial neoplasm Diseases 0.000 description 1
- PNKUSGQVOMIXLU-UHFFFAOYSA-N Formamidine Chemical compound NC=N PNKUSGQVOMIXLU-UHFFFAOYSA-N 0.000 description 1
- 206010051066 Gastrointestinal stromal tumour Diseases 0.000 description 1
- 208000032612 Glial tumor Diseases 0.000 description 1
- 206010018338 Glioma Diseases 0.000 description 1
- 101000830203 Homo sapiens E3 ubiquitin-protein ligase TRIM69 Proteins 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 208000032004 Large-Cell Anaplastic Lymphoma Diseases 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 description 1
- 239000012359 Methanesulfonyl chloride Substances 0.000 description 1
- 208000032818 Microsatellite Instability Diseases 0.000 description 1
- 208000034578 Multiple myelomas Diseases 0.000 description 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 1
- HSHXDCVZWHOWCS-UHFFFAOYSA-N N'-hexadecylthiophene-2-carbohydrazide Chemical compound CCCCCCCCCCCCCCCCNNC(=O)c1cccs1 HSHXDCVZWHOWCS-UHFFFAOYSA-N 0.000 description 1
- ZSXGLVDWWRXATF-UHFFFAOYSA-N N,N-dimethylformamide dimethyl acetal Chemical compound COC(OC)N(C)C ZSXGLVDWWRXATF-UHFFFAOYSA-N 0.000 description 1
- 229910020889 NaBH3 Inorganic materials 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 102000010995 Pleckstrin homology domains Human genes 0.000 description 1
- 108050001185 Pleckstrin homology domains Proteins 0.000 description 1
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229920002685 Polyoxyl 35CastorOil Polymers 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 229920001214 Polysorbate 60 Polymers 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- NPXOKRUENSOPAO-UHFFFAOYSA-N Raney nickel Chemical compound [Al].[Ni] NPXOKRUENSOPAO-UHFFFAOYSA-N 0.000 description 1
- 208000006265 Renal cell carcinoma Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 1
- 208000000389 T-cell leukemia Diseases 0.000 description 1
- 208000028530 T-cell lymphoblastic leukemia/lymphoma Diseases 0.000 description 1
- 102100024547 Tensin-1 Human genes 0.000 description 1
- 108010088950 Tensins Proteins 0.000 description 1
- 208000033781 Thyroid carcinoma Diseases 0.000 description 1
- 208000024770 Thyroid neoplasm Diseases 0.000 description 1
- 229910021626 Tin(II) chloride Inorganic materials 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- OKJPEAGHQZHRQV-UHFFFAOYSA-N Triiodomethane Natural products IC(I)I OKJPEAGHQZHRQV-UHFFFAOYSA-N 0.000 description 1
- YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 1
- 102000001742 Tumor Suppressor Proteins Human genes 0.000 description 1
- 108010040002 Tumor Suppressor Proteins Proteins 0.000 description 1
- CBMCZKMIOZYAHS-NSCUHMNNSA-N [(e)-prop-1-enyl]boronic acid Chemical compound C\C=C\B(O)O CBMCZKMIOZYAHS-NSCUHMNNSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- WETWJCDKMRHUPV-UHFFFAOYSA-N acetyl chloride Chemical compound CC(Cl)=O WETWJCDKMRHUPV-UHFFFAOYSA-N 0.000 description 1
- 239000012346 acetyl chloride Substances 0.000 description 1
- 125000000641 acridinyl group Chemical group C1(=CC=CC2=NC3=CC=CC=C3C=C12)* 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- 239000000908 ammonium hydroxide Substances 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 239000000074 antisense oligonucleotide Substances 0.000 description 1
- 238000012230 antisense oligonucleotides Methods 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 235000021311 artificial sweeteners Nutrition 0.000 description 1
- 125000003710 aryl alkyl group Chemical group 0.000 description 1
- 125000005160 aryl oxy alkyl group Chemical group 0.000 description 1
- 239000012752 auxiliary agent Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
- SIKJAQJRHWYJAI-UHFFFAOYSA-N benzopyrrole Natural products C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 1
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 125000000649 benzylidene group Chemical group [H]C(=[*])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- GPRLTFBKWDERLU-UHFFFAOYSA-N bicyclo[2.2.2]octane Chemical compound C1CC2CCC1CC2 GPRLTFBKWDERLU-UHFFFAOYSA-N 0.000 description 1
- 201000007180 bile duct carcinoma Diseases 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 238000004166 bioassay Methods 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 235000010290 biphenyl Nutrition 0.000 description 1
- 239000004305 biphenyl Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 229910000085 borane Inorganic materials 0.000 description 1
- 229910052796 boron Inorganic materials 0.000 description 1
- 201000008275 breast carcinoma Diseases 0.000 description 1
- 125000004369 butenyl group Chemical group C(=CCC)* 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 125000000609 carbazolyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3NC12)* 0.000 description 1
- 125000005566 carbazolylene group Chemical group 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 150000001722 carbon compounds Chemical class 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 229940105329 carboxymethylcellulose Drugs 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000006364 cellular survival Effects 0.000 description 1
- 239000003610 charcoal Substances 0.000 description 1
- 229910052729 chemical element Inorganic materials 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- 229940059329 chondroitin sulfate Drugs 0.000 description 1
- 125000003016 chromanyl group Chemical group O1C(CCC2=CC=CC=C12)* 0.000 description 1
- 125000005747 chromanylene group Chemical group 0.000 description 1
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 description 1
- 125000000259 cinnolinyl group Chemical group N1=NC(=CC2=CC=CC=C12)* 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 239000000306 component Substances 0.000 description 1
- ARUVKPQLZAKDPS-UHFFFAOYSA-L copper(II) sulfate Chemical compound [Cu+2].[O-][S+2]([O-])([O-])[O-] ARUVKPQLZAKDPS-UHFFFAOYSA-L 0.000 description 1
- 229910000366 copper(II) sulfate Inorganic materials 0.000 description 1
- 239000006184 cosolvent Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 description 1
- ATDGTVJJHBUTRL-UHFFFAOYSA-N cyanogen bromide Chemical compound BrC#N ATDGTVJJHBUTRL-UHFFFAOYSA-N 0.000 description 1
- 125000000392 cycloalkenyl group Chemical group 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001162 cycloheptenyl group Chemical group C1(=CCCCCC1)* 0.000 description 1
- 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 description 1
- 125000004956 cyclohexylene group Chemical group 0.000 description 1
- 125000000522 cyclooctenyl group Chemical group C1(=CCCCCCC1)* 0.000 description 1
- 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- GCUVBACNBHGZRS-UHFFFAOYSA-N cyclopenta-1,3-diene cyclopenta-2,4-dien-1-yl(diphenyl)phosphane iron(2+) Chemical compound [Fe++].c1cc[cH-]c1.c1cc[c-](c1)P(c1ccccc1)c1ccccc1 GCUVBACNBHGZRS-UHFFFAOYSA-N 0.000 description 1
- SNRCKKQHDUIRIY-UHFFFAOYSA-L cyclopenta-1,4-dien-1-yl(diphenyl)phosphane;dichloromethane;dichloropalladium;iron(2+) Chemical compound [Fe+2].ClCCl.Cl[Pd]Cl.C1=C[CH-]C(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1.C1=C[CH-]C(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1 SNRCKKQHDUIRIY-UHFFFAOYSA-L 0.000 description 1
- SVPZJHKVRMRREG-UHFFFAOYSA-N cyclopentanecarbonitrile Chemical compound N#CC1CCCC1 SVPZJHKVRMRREG-UHFFFAOYSA-N 0.000 description 1
- 125000004979 cyclopentylene group Chemical group 0.000 description 1
- UBLYEVLMRSPMOG-UHFFFAOYSA-N cyclopentylmethanamine Chemical compound NCC1CCCC1 UBLYEVLMRSPMOG-UHFFFAOYSA-N 0.000 description 1
- MSXJLEPWWWZERM-UHFFFAOYSA-N cyclopentylmethanamine;hydrochloride Chemical compound Cl.NCC1CCCC1 MSXJLEPWWWZERM-UHFFFAOYSA-N 0.000 description 1
- 125000004856 decahydroquinolinyl group Chemical group N1(CCCC2CCCCC12)* 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 229910052805 deuterium Inorganic materials 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 150000001982 diacylglycerols Chemical class 0.000 description 1
- 125000002576 diazepinyl group Chemical group N1N=C(C=CC=C1)* 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- 125000006287 difluorobenzyl group Chemical group 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 229910001873 dinitrogen Inorganic materials 0.000 description 1
- 125000005716 dioxanylene group Chemical group 0.000 description 1
- 125000005879 dioxolanyl group Chemical group 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 201000003914 endometrial carcinoma Diseases 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- YOJVEUAQIMBZSL-UHFFFAOYSA-N ethyl 2-chloro-4-iodopyridine-3-carboxylate Chemical compound CCOC(=O)C1=C(I)C=CN=C1Cl YOJVEUAQIMBZSL-UHFFFAOYSA-N 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- 208000021045 exocrine pancreatic carcinoma Diseases 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 108010023700 galanin-(1-13)-bradykinin-(2-9)-amide Proteins 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 208000010749 gastric carcinoma Diseases 0.000 description 1
- 201000011243 gastrointestinal stromal tumor Diseases 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 102000034356 gene-regulatory proteins Human genes 0.000 description 1
- 108091006104 gene-regulatory proteins Proteins 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 125000004415 heterocyclylalkyl group Chemical group 0.000 description 1
- 239000008240 homogeneous mixture Substances 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical group 0.000 description 1
- XNXVOSBNFZWHBV-UHFFFAOYSA-N hydron;o-methylhydroxylamine;chloride Chemical compound Cl.CON XNXVOSBNFZWHBV-UHFFFAOYSA-N 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 229940071826 hydroxyethyl cellulose Drugs 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- 229940071676 hydroxypropylcellulose Drugs 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 238000000099 in vitro assay Methods 0.000 description 1
- 238000005462 in vivo assay Methods 0.000 description 1
- 125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 description 1
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 1
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 1
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 1
- 150000002475 indoles Chemical class 0.000 description 1
- 125000003406 indolizinyl group Chemical group C=1(C=CN2C=CC=CC12)* 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 102000006495 integrins Human genes 0.000 description 1
- 108010044426 integrins Proteins 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 125000002346 iodo group Chemical group I* 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- JJWLVOIRVHMVIS-UHFFFAOYSA-N isopropylamine Chemical compound CC(C)N JJWLVOIRVHMVIS-UHFFFAOYSA-N 0.000 description 1
- 125000005956 isoquinolyl group Chemical group 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 235000014380 magnesium carbonate Nutrition 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 208000006178 malignant mesothelioma Diseases 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 1
- GRWIABMEEKERFV-UHFFFAOYSA-N methanol;oxolane Chemical compound OC.C1CCOC1 GRWIABMEEKERFV-UHFFFAOYSA-N 0.000 description 1
- 125000001434 methanylylidene group Chemical group [H]C#[*] 0.000 description 1
- POVLPWJRRCGVMM-UHFFFAOYSA-N methyl 2-[[3-[1-(benzenesulfonyl)pyrrolo[2,3-b]pyridin-3-yl]phenyl]methylamino]pyridine-3-carboxylate Chemical compound COC(=O)C1=CC=CN=C1NCC1=CC=CC(C=2C3=CC=CN=C3N(C=2)S(=O)(=O)C=2C=CC=CC=2)=C1 POVLPWJRRCGVMM-UHFFFAOYSA-N 0.000 description 1
- VGGZQZVAWYLQHH-UHFFFAOYSA-N methyl 6-[[5-(4-aminoquinazolin-6-yl)thiophen-2-yl]methylamino]-5-[(3,4-difluorophenyl)methylcarbamoyl]pyridine-3-carboxylate Chemical compound C=1C(C(=O)OC)=CN=C(NCC=2SC(=CC=2)C=2C=C3C(N)=NC=NC3=CC=2)C=1C(=O)NCC1=CC=C(F)C(F)=C1 VGGZQZVAWYLQHH-UHFFFAOYSA-N 0.000 description 1
- 239000012046 mixed solvent Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 239000002808 molecular sieve Substances 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- RLSZPRPVHOOMBN-UHFFFAOYSA-N n'-(2-cyano-4-nitrophenyl)-n,n-dimethylmethanimidamide Chemical compound CN(C)C=NC1=CC=C([N+]([O-])=O)C=C1C#N RLSZPRPVHOOMBN-UHFFFAOYSA-N 0.000 description 1
- HRMXGVOKGHGZQL-INIZCTEOSA-N n-[(1s)-1-(4-fluorophenyl)ethyl]-2-[[5-([1,2,4]triazolo[1,5-a]pyridin-6-yl)thiophen-2-yl]methylamino]pyridine-3-carboxamide Chemical compound C1([C@@H](NC(=O)C=2C(=NC=CC=2)NCC=2SC(=CC=2)C2=CN3N=CN=C3C=C2)C)=CC=C(F)C=C1 HRMXGVOKGHGZQL-INIZCTEOSA-N 0.000 description 1
- WANJFUFDYTYQDB-UHFFFAOYSA-N n-[(3,4-difluorophenyl)methyl]-2-(prop-2-ynylamino)pyridine-3-carboxamide Chemical compound C1=C(F)C(F)=CC=C1CNC(=O)C1=CC=CN=C1NCC#C WANJFUFDYTYQDB-UHFFFAOYSA-N 0.000 description 1
- QPFGGBRCRRTGQG-UHFFFAOYSA-N n-[(3,4-difluorophenyl)methyl]-2-[(5-quinolin-6-ylthiophen-2-yl)methylamino]pyridine-3-carboxamide Chemical compound C1=C(F)C(F)=CC=C1CNC(=O)C1=CC=CN=C1NCC1=CC=C(C=2C=C3C=CC=NC3=CC=2)S1 QPFGGBRCRRTGQG-UHFFFAOYSA-N 0.000 description 1
- OLKXFWLTPIKSIR-UHFFFAOYSA-N n-[(3,4-difluorophenyl)methyl]-2-[[1-[4-[(2,4-dimethoxyphenyl)methylamino]quinazolin-6-yl]triazol-4-yl]methylamino]pyridine-3-carboxamide Chemical compound COC1=CC(OC)=CC=C1CNC1=NC=NC2=CC=C(N3N=NC(CNC=4C(=CC=CN=4)C(=O)NCC=4C=C(F)C(F)=CC=4)=C3)C=C12 OLKXFWLTPIKSIR-UHFFFAOYSA-N 0.000 description 1
- RWNJXYOCTILEAZ-UHFFFAOYSA-N n-[(3,4-difluorophenyl)methyl]-2-[[3-(1h-pyrrolo[2,3-b]pyridin-3-yl)phenyl]methylamino]pyridine-3-carboxamide Chemical compound C1=C(F)C(F)=CC=C1CNC(=O)C1=CC=CN=C1NCC1=CC=CC(C=2C3=CC=CN=C3NC=2)=C1 RWNJXYOCTILEAZ-UHFFFAOYSA-N 0.000 description 1
- KYZOOWIFDFHVIZ-UHFFFAOYSA-N n-[(3,4-difluorophenyl)methyl]-2-[[3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]methylamino]pyridine-3-carboxamide Chemical compound O1C(C)(C)C(C)(C)OB1C1=CC=CC(CNC=2C(=CC=CN=2)C(=O)NCC=2C=C(F)C(F)=CC=2)=C1 KYZOOWIFDFHVIZ-UHFFFAOYSA-N 0.000 description 1
- BLIRFRFNGPJNMJ-UHFFFAOYSA-N n-[(3,4-difluorophenyl)methyl]-2-[[3-(7h-pyrrolo[2,3-d]pyrimidin-5-yl)phenyl]methylamino]pyridine-3-carboxamide Chemical compound C1=C(F)C(F)=CC=C1CNC(=O)C1=CC=CN=C1NCC1=CC=CC(C=2C3=CN=CN=C3NC=2)=C1 BLIRFRFNGPJNMJ-UHFFFAOYSA-N 0.000 description 1
- IBRIUYWFKKEBCQ-UHFFFAOYSA-N n-[(3,4-difluorophenyl)methyl]-2-[[3-[4-[(2,4-dimethoxyphenyl)methylamino]quinazolin-6-yl]-5-propan-2-yloxyphenyl]methylamino]pyridine-3-carboxamide Chemical compound COC1=CC(OC)=CC=C1CNC1=NC=NC2=CC=C(C=3C=C(OC(C)C)C=C(CNC=4C(=CC=CN=4)C(=O)NCC=4C=C(F)C(F)=CC=4)C=3)C=C12 IBRIUYWFKKEBCQ-UHFFFAOYSA-N 0.000 description 1
- SPDQAIYQUYNJDD-UHFFFAOYSA-N n-[(3,4-difluorophenyl)methyl]-2-[[3-[4-[(2,4-dimethoxyphenyl)methylamino]quinazolin-6-yl]phenyl]methylamino]pyridine-3-carboxamide Chemical compound COC1=CC(OC)=CC=C1CNC1=NC=NC2=CC=C(C=3C=C(CNC=4C(=CC=CN=4)C(=O)NCC=4C=C(F)C(F)=CC=4)C=CC=3)C=C12 SPDQAIYQUYNJDD-UHFFFAOYSA-N 0.000 description 1
- XGJGHNSLZVITCA-UHFFFAOYSA-N n-[(3,4-difluorophenyl)methyl]-2-[[5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)thiophen-2-yl]methylamino]pyridine-3-carboxamide Chemical compound O1C(C)(C)C(C)(C)OB1C(S1)=CC=C1CNC1=NC=CC=C1C(=O)NCC1=CC=C(F)C(F)=C1 XGJGHNSLZVITCA-UHFFFAOYSA-N 0.000 description 1
- SGRIEOHUGXFTQP-UHFFFAOYSA-N n-[(3,4-difluorophenyl)methyl]-2-[[5-(4-morpholin-4-ylquinazolin-6-yl)thiophen-2-yl]methylamino]pyridine-3-carboxamide Chemical compound C1=C(F)C(F)=CC=C1CNC(=O)C1=CC=CN=C1NCC1=CC=C(C=2C=C3C(N4CCOCC4)=NC=NC3=CC=2)S1 SGRIEOHUGXFTQP-UHFFFAOYSA-N 0.000 description 1
- DKNLEEDLFWPGPK-UHFFFAOYSA-N n-[(3,4-difluorophenyl)methyl]-2-[[5-(7h-pyrrolo[2,3-d]pyrimidin-5-yl)thiophen-2-yl]methylamino]pyridine-3-carboxamide Chemical compound C1=C(F)C(F)=CC=C1CNC(=O)C1=CC=CN=C1NCC1=CC=C(C=2C3=CN=CN=C3NC=2)S1 DKNLEEDLFWPGPK-UHFFFAOYSA-N 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- OHLNHCVCADNWFX-UHFFFAOYSA-N n-cyclopropyl-3-[3-[[[3-[(3,4-difluorophenyl)carbamoyl]pyridin-2-yl]amino]methyl]-5-propan-2-yloxyphenyl]-1h-pyrrolo[2,3-b]pyridine-5-carboxamide Chemical compound C=1C(C=2C3=CC(=CN=C3NC=2)C(=O)NC2CC2)=CC(OC(C)C)=CC=1CNC1=NC=CC=C1C(=O)NC1=CC=C(F)C(F)=C1 OHLNHCVCADNWFX-UHFFFAOYSA-N 0.000 description 1
- 125000003136 n-heptyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 125000004593 naphthyridinyl group Chemical group N1=C(C=CC2=CC=CN=C12)* 0.000 description 1
- 235000021096 natural sweeteners Nutrition 0.000 description 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 150000002829 nitrogen Chemical class 0.000 description 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 1
- 125000005060 octahydroindolyl group Chemical group N1(CCC2CCCCC12)* 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 125000001715 oxadiazolyl group Chemical group 0.000 description 1
- 125000005565 oxadiazolylene group Chemical group 0.000 description 1
- AICOOMRHRUFYCM-ZRRPKQBOSA-N oxazine, 1 Chemical compound C([C@@H]1[C@H](C(C[C@]2(C)[C@@H]([C@H](C)N(C)C)[C@H](O)C[C@]21C)=O)CC1=CC2)C[C@H]1[C@@]1(C)[C@H]2N=C(C(C)C)OC1 AICOOMRHRUFYCM-ZRRPKQBOSA-N 0.000 description 1
- 125000005564 oxazolylene group Chemical group 0.000 description 1
- AHHWIHXENZJRFG-UHFFFAOYSA-N oxetane Chemical compound C1COC1 AHHWIHXENZJRFG-UHFFFAOYSA-N 0.000 description 1
- 229910052763 palladium Inorganic materials 0.000 description 1
- JGBZTJWQMWZVNX-UHFFFAOYSA-N palladium;tricyclohexylphosphane Chemical compound [Pd].C1CCCCC1P(C1CCCCC1)C1CCCCC1.C1CCCCC1P(C1CCCCC1)C1CCCCC1 JGBZTJWQMWZVNX-UHFFFAOYSA-N 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000006201 parenteral dosage form Substances 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- 125000004934 phenanthridinyl group Chemical group C1(=CC=CC2=NC=C3C=CC=CC3=C12)* 0.000 description 1
- 125000001791 phenazinyl group Chemical group C1(=CC=CC2=NC3=CC=CC=C3N=C12)* 0.000 description 1
- 125000001484 phenothiazinyl group Chemical group C1(=CC=CC=2SC3=CC=CC=C3NC12)* 0.000 description 1
- 125000001644 phenoxazinyl group Chemical group C1(=CC=CC=2OC3=CC=CC=C3NC12)* 0.000 description 1
- 125000004592 phthalazinyl group Chemical group C1(=NN=CC2=CC=CC=C12)* 0.000 description 1
- 125000005545 phthalimidyl group Chemical group 0.000 description 1
- 229920001993 poloxamer 188 Polymers 0.000 description 1
- 125000003367 polycyclic group Chemical group 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 239000001818 polyoxyethylene sorbitan monostearate Substances 0.000 description 1
- 235000010989 polyoxyethylene sorbitan monostearate Nutrition 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229940068977 polysorbate 20 Drugs 0.000 description 1
- 229940113124 polysorbate 60 Drugs 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 229940068968 polysorbate 80 Drugs 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 235000019422 polyvinyl alcohol Nutrition 0.000 description 1
- 229920006316 polyvinylpyrrolidine Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- JKANAVGODYYCQF-UHFFFAOYSA-N prop-2-yn-1-amine Chemical compound NCC#C JKANAVGODYYCQF-UHFFFAOYSA-N 0.000 description 1
- 125000004368 propenyl group Chemical group C(=CC)* 0.000 description 1
- 125000006410 propenylene group Chemical group 0.000 description 1
- WGYKZJWCGVVSQN-UHFFFAOYSA-N propylamine Chemical compound CCCN WGYKZJWCGVVSQN-UHFFFAOYSA-N 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- 201000001514 prostate carcinoma Diseases 0.000 description 1
- 125000001042 pteridinyl group Chemical group N1=C(N=CC2=NC=CN=C12)* 0.000 description 1
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 1
- 125000005550 pyrazinylene group Chemical group 0.000 description 1
- GRJJQCWNZGRKAU-UHFFFAOYSA-N pyridin-1-ium;fluoride Chemical compound F.C1=CC=NC=C1 GRJJQCWNZGRKAU-UHFFFAOYSA-N 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- ANNOWMBWHHKGLN-UHFFFAOYSA-N pyridine-3,5-dicarboxamide Chemical compound NC(=O)C1=CN=CC(C(N)=O)=C1 ANNOWMBWHHKGLN-UHFFFAOYSA-N 0.000 description 1
- 125000005551 pyridylene group Chemical group 0.000 description 1
- 125000005576 pyrimidinylene group Chemical group 0.000 description 1
- 125000004929 pyrrolidonyl group Chemical group N1(C(CCC1)=O)* 0.000 description 1
- 125000001422 pyrrolinyl group Chemical group 0.000 description 1
- JWVCLYRUEFBMGU-UHFFFAOYSA-N quinazoline Chemical compound N1=CN=CC2=CC=CC=C21 JWVCLYRUEFBMGU-UHFFFAOYSA-N 0.000 description 1
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 1
- 125000005493 quinolyl group Chemical group 0.000 description 1
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 1
- 125000004621 quinuclidinyl group Chemical group N12C(CC(CC1)CC2)* 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 210000003705 ribosome Anatomy 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 125000003548 sec-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 208000000587 small cell lung carcinoma Diseases 0.000 description 1
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 1
- PPASLZSBLFJQEF-RKJRWTFHSA-M sodium ascorbate Substances [Na+].OC[C@@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RKJRWTFHSA-M 0.000 description 1
- 235000010378 sodium ascorbate Nutrition 0.000 description 1
- 229960005055 sodium ascorbate Drugs 0.000 description 1
- 239000012279 sodium borohydride Substances 0.000 description 1
- 229910000033 sodium borohydride Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 229910000104 sodium hydride Inorganic materials 0.000 description 1
- PPASLZSBLFJQEF-RXSVEWSESA-M sodium-L-ascorbate Chemical compound [Na+].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RXSVEWSESA-M 0.000 description 1
- CUTQWXGMRNLXQC-WCCKRBBISA-M sodium;(2s)-pyrrolidine-2-carboxylate Chemical compound [Na+].[O-]C(=O)[C@@H]1CCCN1 CUTQWXGMRNLXQC-WCCKRBBISA-M 0.000 description 1
- LYPGDCWPTHTUDO-UHFFFAOYSA-M sodium;methanesulfinate Chemical compound [Na+].CS([O-])=O LYPGDCWPTHTUDO-UHFFFAOYSA-M 0.000 description 1
- 239000007909 solid dosage form Substances 0.000 description 1
- 239000012265 solid product Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 235000011150 stannous chloride Nutrition 0.000 description 1
- 239000008174 sterile solution Substances 0.000 description 1
- 201000000498 stomach carcinoma Diseases 0.000 description 1
- 125000005017 substituted alkenyl group Chemical group 0.000 description 1
- 125000004426 substituted alkynyl group Chemical group 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 description 1
- BFNYNEMRWHFIMR-UHFFFAOYSA-N tert-butyl 2-cyanoacetate Chemical compound CC(C)(C)OC(=O)CC#N BFNYNEMRWHFIMR-UHFFFAOYSA-N 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- YBRBMKDOPFTVDT-UHFFFAOYSA-N tert-butylamine Chemical compound CC(C)(C)N YBRBMKDOPFTVDT-UHFFFAOYSA-N 0.000 description 1
- 125000005958 tetrahydrothienyl group Chemical group 0.000 description 1
- 238000011285 therapeutic regimen Methods 0.000 description 1
- 230000004797 therapeutic response Effects 0.000 description 1
- 125000005308 thiazepinyl group Chemical group S1N=C(C=CC=C1)* 0.000 description 1
- 125000005557 thiazolylene group Chemical group 0.000 description 1
- 125000005556 thienylene group Chemical group 0.000 description 1
- FKKJJPMGAWGYPN-UHFFFAOYSA-N thiophen-2-ylmethanamine Chemical compound NCC1=CC=CS1 FKKJJPMGAWGYPN-UHFFFAOYSA-N 0.000 description 1
- 201000002510 thyroid cancer Diseases 0.000 description 1
- 208000013077 thyroid gland carcinoma Diseases 0.000 description 1
- AXZWODMDQAVCJE-UHFFFAOYSA-L tin(II) chloride (anhydrous) Chemical compound [Cl-].[Cl-].[Sn+2] AXZWODMDQAVCJE-UHFFFAOYSA-L 0.000 description 1
- 239000006208 topical dosage form Substances 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000000844 transformation Methods 0.000 description 1
- 125000005559 triazolylene group Chemical group 0.000 description 1
- GKASDNZWUGIAMG-UHFFFAOYSA-N triethyl orthoformate Chemical compound CCOC(OCC)OCC GKASDNZWUGIAMG-UHFFFAOYSA-N 0.000 description 1
- 229910052722 tritium Inorganic materials 0.000 description 1
- 238000001665 trituration Methods 0.000 description 1
- PXXNTAGJWPJAGM-UHFFFAOYSA-N vertaline Natural products C1C2C=3C=C(OC)C(OC)=CC=3OC(C=C3)=CC=C3CCC(=O)OC1CC1N2CCCC1 PXXNTAGJWPJAGM-UHFFFAOYSA-N 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 239000011345 viscous material Substances 0.000 description 1
- 239000003039 volatile agent Substances 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- GTLDTDOJJJZVBW-UHFFFAOYSA-N zinc cyanide Chemical compound [Zn+2].N#[C-].N#[C-] GTLDTDOJJJZVBW-UHFFFAOYSA-N 0.000 description 1
- DUNKXUFBGCUVQW-UHFFFAOYSA-J zirconium tetrachloride Chemical compound Cl[Zr](Cl)(Cl)Cl DUNKXUFBGCUVQW-UHFFFAOYSA-J 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/452—Piperidinium derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
- C07D213/82—Amides; Imides in position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/84—Nitriles
- C07D213/85—Nitriles in position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D241/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D241/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with nitrogen atoms directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D241/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D241/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with nitrogen atoms directly attached to ring carbon atoms
- C07D241/28—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with nitrogen atoms directly attached to ring carbon atoms in which said hetero-bound carbon atoms have double bonds to oxygen, sulfur or nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
- C07D473/32—Nitrogen atom
- C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/052—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Definitions
- the 3-phosphoinositide-dependent protein kinase-1 includes a 556 amino acid protein, an N-terminal catalytic domain, and a C-terminal pleckstrin homology (PH) domain that activates substrate kinases via activation loop phosphorylation (Belham, C. et al., Curr. Biol, 9, pp. R93-R96, 1999).
- PDKl is involved in regulating the activity of AGC subfamily of protein kinases (Alessi, D. et al, Biochem. Soc.
- PDB protein kinase B
- S6K p70 ribosomal S6 kinase
- PKC protein kinase C
- PDKl mediated signaling increases in response to insulin, growth factors, and extracellular matrix cell binding (integrin signaling) resulting in diverse cellular events such as cell survival, growth, proliferation and glucose regulation [(Lawlor, M. A. et al, J. Cell Sci., 114, pp. 2903-2910, 2001), (Lawlor, M. A. et al, EMBO J., 21, pp.
- Elevated PDKl signaling has been detected in several cancers resulting from distinct genetic events such as PTEN mutations or over-expression of certain key regulatory proteins [(Graff, J. Pv., Expert Opin. Ther. Targets, 6, pp. 103-113, 2002), (Brognard, J., et al, Cancer Res., 61, pp. 3986-3997, 2001)].
- the tumor-suppressor phosphatase with tensin homology is an important negative regulator of the cell-survival signaling pathway initiated by phosphatidylinositol 3- kinase (PI3K).
- PI3K phosphatidylinositol 3- kinase
- the PDKl/Akt pathway is activated in many cancer via mutations in Receptor Tyrosine Kinases (RTKs), Ras, PI-3 kinase or PTEN (Cully et al, Nature Reviews Cancer 6: 184- 192 (2006)).
- RTKs Receptor Tyrosine Kinases
- Ras Ras
- PI-3 kinase PI-3 kinase
- PTEN phosphatidylinositol 3- kinase
- the potential of PDKl inhibitors as anti-cancer compounds was demonstrated by transfection of a PTEN negative human cancer cell line (U87MG) with antisense oligonucleot
- a ls Ring A 2 , Ring A 3 , Ring A 4 , L 1 , L 2 , L 3 , X, and R 1 are as defined and described in classes and subclasses herein.
- Provided compounds are useful as inhibitors of protein kinases (e.g., PDKl), and thus are useful, for example, for the treatment of PDKl -mediated diseases.
- protein kinases e.g., PDKl
- the invention provides pharmaceutical compositions comprising a compound of the invention, wherein the compound is present in an amount effective to inhibit PDKl activity.
- the invention provides pharmaceutical compositions comprising a compound of the invention and optionally further comprising an additional therapeutic agent.
- the additional therapeutic agent is an agent for the treatment of cancer.
- the present invention provides methods for inhibiting kinase
- the present invention provides methods for treating any one of the following conditions: a)-2-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoe.g., PDKl) activity in a patient or a biological sample, comprising administering to said patient, or contacting said biological sample with, an effective inhibitory amount of a compound of the invention.
- the present invention provides methods for treating any one of the following conditions: a compound of the invention.
- the present invention provides a compound of formula I:
- R 1 is hydrogen or optionally substituted Ci_ 6 aliphatic, or:
- R 1 and a substituent on Ring A 4 are taken together with their intervening atoms to form an optionally substituted 5-7 membered partially unsaturated or aromatic fused ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur;
- X is -C(0)- or -S(0) 2 -
- L 1 is a covalent bond or an optionally substituted bivalent group selected from Ci_ 4 alkylene, C 2 _ 4 alkenylene, or C 2 - 4 alkynylene wherein one or more methylene units of L 1 are optionally and independently replaced by -Cy 1 -, -0-, -S-, -N(R 2 )-, -C(O)-, -C(0)N(R 2 )-, -N(R 2 )C(0)N(R 2 )-, -N(R 2 )C(0)-, -N(R 2 )C(0)0- -OC(0)N(R 2 )-, -S(0) 2 - -S(0) 2 N(R 2 )-, -N(R 2 )S(0) 2 - -OC(O)-, or -C(0)0;
- Cy 1 is an optionally substituted bivalent ring selected from phenylene, 3-7 membered saturated or partially unsaturated carbocyclylene, 4-7 membered saturated or partially unsaturated heterocyclylene having 1 -2 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or 5-6 membered heteroarylene having 1 -3 heteroatoms independently selected from nitrogen, oxygen, or sulfur;
- each R 2 is hydrogen or optionally substituted Ci_ 6 aliphatic
- 4741418vl Attorney Docket No. 2009253-0070 Ai is a covalent bond or an optionally substituted bivalent ring selected from 3-7 membered saturated or partially unsaturated monocyclic carbocyclylene, 7-10 membered saturated or partially unsaturated bicyclic carbocyclylene, 4-7 membered saturated or partially unsaturated monocyclic heterocyclylene having 1-2 heteroatoms independently selected from nitrogen, oxygen, or sulfur, 7-10 membered saturated or partially unsaturated bicyclic heterocyclylene having 1-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur, phenylene, 8-10 membered bicyclic arylene, 5-6 membered monocyclic heteroarylene having 1-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or 8-10 membered bicyclic heteroarylene having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur;
- L 2 is a covalent bond, alkylidenylene, or an optionally substituted alkylene chain wherein one or more methylene units of L 2 are optionally and independently replaced by -0-, -S-, -N(R 2 )-, -C(O)-, -C(0)N(R 2 )-, -N(R 2 )C(0)N(R 2 )-, -N(R 2 )C(0)-, -N(R 2 )C(0)0- -OC(0)N(R 2 )-, -S(0) 2 - -S(0) 2 N(R 2 )-, -N(R 2 )S(0) 2 - -OC(O)-, or -C(0)0-;
- Ring A 2 is a 3-7 membered saturated or partially unsaturated monocyclic carbocyclic ring, a 7-10 membered saturated or partially unsaturated bicyclic carbocyclic ring, a 4-7 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, or sulfur, a 7-10 membered saturated or partially unsaturated bicyclic heterocyclic ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur, a phenyl ring, an 8-10 membered bicyclic aryl ring, a 5-6 membered monocyclic heteroaryl ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur, an 8-10 membered bicyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or a 10-16 membered saturated, partially unsaturated, or aromatic tricyclic ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, wherein Ring A 2 is
- each R is independently hydrogen or an optionally substituted group selected from Ci_ 6 aliphatic, a 3-7 membered saturated or partially unsaturated monocyclic carbocyclic ring, a 7-10 membered saturated or partially unsaturated bicyclic carbocyclic ring, a 4-7 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, or sulfur, a 7-10 membered saturated or partially unsaturated bicyclic heterocyclic ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur, a phenyl ring, an 8-10 membered bicyclic aryl ring, a 5-6 membered heteroaryl ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or an 8-10 membered bicyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur;
- each R' is independently -R, or two R' groups on the same nitrogen are taken together with their intervening atoms to form an optionally substituted 5-8 membered saturated, partially unsaturated, or aromatic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur;
- L 3 is a covalent bond or an optionally substituted Ci_ 4 alkylene chain wherein one or more methylene units of L 3 are optionally and independently replaced by -0-, -S-, -N(R 2 )-, -C(O)-, -C(0)N(R 2 )-, -N(R 2 )C(0)N(R 2 )-, -N(R 2 )C(0)-, -N(R 2 )C(0)0- -OC(0)N(R 2 )-, -S(0) 2 - -S(0) 2 N(R 2 )-, -N(R 2 )S(0) 2 - -OC(O)-, or -C(0)0-;
- Ring A 3 is an optionally substituted ring selected from a 3-7 membered saturated or partially unsaturated monocyclic carbocyclic ring, a 7-10 membered saturated or partially unsaturated bicyclic carbocyclic ring, a 4-7 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, or sulfur, a 7-10 membered saturated or partially unsaturated bicyclic heterocyclic ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur, a phenyl ring, an 8- 10 membered bicyclic aryl ring, a 5-6 membered monocyclic heteroaryl ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or an 8-10 membered bicyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur;
- Ring A 4 is a 5-6 membered heteroaryl ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or an 8-10 membered bicyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur; wherein any
- each R 6 is independently -R, -C(0)R, -C0 2 R, -C(0)C(0)R, -C(0)CH 2 C(0)R, -S(0)R,
- R 3 and R 6 are taken together with their intervening atoms to form an optionally substituted fused ring selected from a 5-6 membered saturated or partially unsaturated heterocyclic ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or a 5-6 membered heteroaryl ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur.
- L 2 is not -0-. In certain embodiments, when Ai is a bivalent monocyclic or bicyclic ring, L 1 and L 2 do not occur simultaneously as a covalent bond.
- structures depicted herein are also meant to include all isomeric (e.g., enantiomeric, diastereomeric, and geometric (or conformational)) forms of the structure; for example, the R and S configurations for each asymmetric center, Z and E double bond isomers, and Z and E conformational isomers. Therefore, single stereochemical isomers as well as enantiomeric, diastereomeric, and geometric (or conformational) mixtures of the present compounds are within the scope of the invention. Unless otherwise stated, all tautomeric forms of the compounds of the invention are within the scope of the invention.
- structures depicted herein are also meant to include compounds that differ only in the presence of one or more isotopically enriched atoms.
- compounds having the present structures including the replacement of hydrogen by deuterium or tritium, or the replacement of a carbon by a 13 C- or 14 C-enriched carbon are within the scope of this invention.
- Such compounds are useful, for example, as analytical tools, as probes in biological assays, or as therapeutic agents in accordance with the present invention.
- a particular enantiomer may, in some embodiments be provided substantially free of the corresponding enantiomer, and may also be referred to as "optically enriched.”
- “Optically-enriched,” as used herein, means that the compound is made up of a significantly greater proportion of one enantiomer. In certain embodiments the compound is made up of at least about 90% by weight of a preferred enantiomer. In other embodiments the compound is made up of at least about 95%, 98%>, or 99% by weight of a preferred enantiomer.
- enantiomers may be isolated from racemic mixtures by any method known to those skilled in the art, including chiral high pressure liquid chromatography (HPLC) and the formation and crystallization of chiral salts or prepared by asymmetric syntheses.
- HPLC high pressure liquid chromatography
- Jacques et al. Enantiomers, Racemates and Resolutions (Wiley Interscience, New York, 1981); Wilen, et al, Tetrahedron 33:2725 (1977); Eliel, E.L. Stereochemistry of Carbon Compounds (McGraw-Hill, NY, 1962); Wilen, S.H. Tables of Resolving Agents and Optical Resolutions p. 268 (E.L. Eliel, Ed., Univ. of Notre Dame Press, Notre Dame, IN 1972).
- heteroatom means one or more of oxygen, sulfur, nitrogen, phosphorus, or silicon (including, any oxidized form of nitrogen, sulfur, phosphorus, or silicon; the quaternized form of any basic nitrogen or; a substitutable nitrogen of a heterocyclic ring, for example N (as in 3,4-dihydro-2H-pyrrolyl), NH (as in pyrrolidinyl) or NR + (as in N-substituted pyrrolidinyl)).
- a "direct bond” or “covalent bond” refers to a single, double or triple bond. In certain embodiments, a “direct bond” or “covalent bond” refers to a single bond.
- halo and halogen as used herein refer to an atom selected from fluorine (fluoro, -F), chlorine (chloro, -CI), bromine (bromo, -Br), and iodine (iodo, -I).
- aliphatic or "aliphatic group”, as used herein, denotes a hydrocarbon moiety that may be straight-chain (i.e., unbranched), branched, or cyclic (including fused, bridging, and spiro-fused polycyclic) and may be completely saturated or may contain one or more units of unsaturation, but which is not aromatic. Unless otherwise specified, aliphatic groups contain 1-6 carbon atoms. In some embodiments, aliphatic groups contain 1-4 carbon atoms, and in yet other embodiments aliphatic groups contain 1-3 carbon atoms.
- Suitable aliphatic groups include, but are not limited to, linear or branched, alkyl, alkenyl, and alkynyl groups, and hybrids thereof such as (cycloalkyl)alkyl, (cycloalkenyl)alkyl or (cycloalkyl)alkenyl.
- cycloaliphatic refers to a saturated or partially unsaturated cyclic aliphatic monocyclic or bicyclic ring systems, as described herein, having from 3 to 10 members, wherein the aliphatic ring system is optionally substituted as defined above and described herein.
- Cycloaliphatic groups include, without limitation, cyclopropyl,
- cycloalkyl has 3-6 carbons.
- cycloaliphatic also include aliphatic rings that are fused to one or more aromatic or nonaromatic rings, such as decahydronaphthyl, tetrahydronaphthyl, decalin, or bicyclo[2.2.2]octane, where the radical or point of attachment is on an aliphatic ring.
- cycloalkylene refers to a bivalent cycloalkyl group.
- a cycloalkylene group is a 1,1 - ene group (i.e., a spiro-fused
- Exemplary 1,1 -cycloalkylene groups include In other embodiments, a cycloalkylene group is a 1 ,2-cycloalkylene group or a 1,3-cycloalkylene group. Exemplary 1,2-
- cycloalkylene groups include .
- carbocyclylene refers to a bivalent carbocyclic group.
- alkyl refers to saturated, straight- or branched-chain hydrocarbon radicals derived from an aliphatic moiety containing between one and six carbon atoms by removal of a single hydrogen atom.
- the alkyl group employed in the invention contains 1-5 carbon atoms.
- the alkyl group employed contains 1-4 carbon atoms.
- the alkyl group contains 1-3 carbon atoms.
- the alkyl group contains 1-2 carbons.
- alkyl radicals include, but are not limited to, methyl, ethyl, n-propyl, isopropyl, n-butyl, iso-butyl, sec-butyl, sec-pentyl, iso-pentyl, tert-butyl, n-pentyl, neopentyl, n-hexyl, sec-hexyl, n-heptyl, n-octyl, n-decyl, n-undecyl, dodecyl, and the like.
- alkenyl denotes a monovalent group derived from a straight- or branched-chain aliphatic moiety having at least one carbon-carbon double bond by the removal of a single hydrogen atom.
- the alkenyl group employed in the invention contains 2-6 carbon atoms.
- the alkenyl group employed in the invention contains 2-5 carbon atoms.
- the alkenyl group employed in the invention contains 2-4 carbon atoms.
- Alkenyl groups include, for example, ethenyl, propenyl, butenyl, 1- methyl-2-buten-l-yl, and the like.
- alkynyl refers to a monovalent group derived from a straight- or branched-chain aliphatic moiety having at least one carbon-carbon triple bond by the removal of a single hydrogen atom.
- the alkynyl group employed in the invention contains 2-6 carbon atoms.
- the alkynyl group employed in the invention contains 2-5 carbon atoms.
- the alkynyl group employed in the invention contains 2-4 carbon atoms.
- the alkynyl group employed contains 2-3 carbon atoms.
- Representative alkynyl groups include, but are not limited to, ethynyl, 2-propynyl (propargyl), 1-propynyl, and the like.
- aryl used alone or as part of a larger moiety as in “aralkyl”, “aralkoxy”, or “aryloxyalkyl”, refers to monocyclic and bicyclic ring systems having a total of five to 10 ring members, wherein at least one ring in the system is aromatic and wherein each ring in the system contains three to seven ring members.
- aryl may be used interchangeably with the term “aryl ring”.
- aryl refers to an aromatic ring system which includes, but not limited to, phenyl, biphenyl, naphthyl, anthracyl and the like, which may bear one or more substituents.
- aryl is a group in which an aromatic ring is fused to one or more non-aromatic rings, such as indanyl, phthalimidyl, naphthimidyl, phenantriidinyl, or tetrahydronaphthyl, and the like.
- arylene refers to a bivalent aryl group.
- heteroaryl and “heteroar-”, used alone or as part of a larger moiety refer to groups having 5 to 10 ring atoms, preferably 5, 6, or 9 ring atoms; having 6, 10, or 14 ⁇ electrons shared in a cyclic array; and having, in addition to carbon atoms, from one to five heteroatoms.
- heteroatom refers to nitrogen, oxygen, or sulfur, and includes any oxidized form of nitrogen or sulfur, and any quatemized form of a basic nitrogen.
- Heteroaryl groups include, without limitation, thienyl, furanyl, pyrrolyl, imidazolyl, pyrazolyl, triazolyl, tetrazolyl, oxazolyl, isoxazolyl, oxadiazolyl, thiazolyl, isothiazolyl, thiadiazolyl, pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl, indolizinyl, purinyl, naphthyridinyl, and pteridinyl.
- heteroaryl and “heteroar-”, as used herein, also include groups in which a heteroaromatic ring is fused to one or more aryl, cycloaliphatic, or heterocyclyl rings.
- Nonlimiting examples include indolyl, isoindolyl, benzothienyl,
- heteroaryl group may be mono- or bicyclic.
- heteroaryl may be used interchangeably with the terms “heteroaryl ring", “heteroaryl group”, or “heteroaromatic”, any of which terms include rings that are optionally substituted.
- heteroarylkyl refers to an alkyl group substituted by a heteroaryl, wherein the alkyl and heteroaryl portions independently are optionally substituted.
- heteroarylene refers to a bivalent heteroaryl group.
- heterocycle As used herein, the terms “heterocycle”, “heterocyclyl”, “heterocyclic radical”, and “heterocyclic ring” are used interchangeably and refer to a stable 4- to 7-membered monocyclic or 7-10-membered bicyclic heterocyclic moiety that is either saturated or partially unsaturated, and having, in addition to carbon atoms, one or more, preferably one to four, heteroatoms, as defined above.
- nitrogen includes a substituted nitrogen.
- the nitrogen may be N (as in 3,4-dihydro-2H-pyrrolyl), ⁇ (as in pyrrolidinyl), or ⁇ NR (as in N-substituted pyrrolidinyl).
- a heterocyclic ring can be attached to its pendant group at any heteroatom or carbon atom that results in a stable structure and any of the ring atoms can be optionally substituted.
- saturated or partially unsaturated heterocyclic radicals include, without limitation, tetrahydrofuranyl, tetrahydrothienyl, pyrrolidinyl, pyrrolidonyl, piperidinyl, pyrrolinyl, tetrahydroquinolinyl, tetrahydroisoquinolinyl, decahydroquinolinyl, oxazolidinyl, piperazinyl, dioxanyl, dioxolanyl, diazepinyl, oxazepinyl, thiazepinyl, morpholinyl, and quinuclidinyl.
- heterocycle used interchangeably herein, and also include groups in which a heterocyclyl ring is fused to one or more aryl, heteroaryl, or cycloaliphatic rings, such as indolinyl, 3H-indolyl, chromanyl, phenanthridinyl, 2- azabicyclo[2.2.1]heptanyl, octahydroindolyl, or tetrahydroquinolinyl.
- a heterocyclyl group may be mono- or bicyclic.
- heterocyclylalkyl refers to an alkyl group substituted by a heterocyclyl, wherein the alkyl and heterocyclyl portions independently are optionally substituted.
- heterocyclylene refers to a bivalent heterocyclic group.
- partially unsaturated refers to a ring moiety that includes at least one double or triple bond between ring atoms.
- the term “partially unsaturated” is intended to encompass rings having multiple sites of unsaturation, but is not intended to include aryl or heteroaryl moieties, as herein defined.
- alkylene refers to a bivalent alkyl group.
- An "alkylene chain” is a polymethylene group, i.e., -(CH 2 ) n -, wherein n is a positive integer, preferably from 1 to 6, from 1 to 4, from 1 to 3, from 1 to 2, or from 2 to 3.
- a substituted alkylene chain is a polymethylene group in which one or more methylene hydrogen atoms are replaced with a substituent. Suitable substituents include those described below for a substituted aliphatic group.
- an alkylene chain also can be optionally replaced by a functional group.
- An alkylene chain is "replaced" by a functional group when an internal methylene unit is replaced with the functional group. Examples of suitable "interrupting functional groups" are described in the specification and claims herein.
- a bivalent carbocycle is “carbocyclylene”
- a bivalent aryl ring is “arylene”
- a bivalent benzene ring is “phenylene”
- a bivalent heterocycle is "heterocyclylene”
- a bivalent heteroaryl ring is “heteroarylene”
- a bivalent alkyl chain is “alkylene”
- a bivalent alkenyl chain is “alkenylene”
- a bivalent alkynyl chain is “alkynylene”
- compounds of the invention may contain "optionally substituted” moieties.
- substituted whether preceded by the term “optionally” or not, means that one or more hydrogens of the designated moiety are replaced with a suitable substituent.
- an “optionally substituted” group may have a suitable substituent at each substitutable position of the group, and when more than one position in any given structure may be substituted with more than one substituent selected from a specified group, the substituent may be either the same or different at every position.
- Combinations of substituents envisioned under this invention are preferably those that result in the formation of stable or chemically feasible compounds.
- stable refers to compounds that are not substantially altered when subjected to conditions to allow for their production, detection, and, in certain embodiments, their recovery, purification, and use for one or more of the purposes disclosed herein.
- Suitable monovalent substituents on R° are independently halogen, -(CH 2 ) 0 2 R*, -(haloR*), -(CH 2 ) 0 2 OH, -(CH 2 ) 0 2 OR*, -(CH 2 ) 0 2 CH(OR*) 2 ; -O(haloR'), -CN, -N 3 , -(CH 2 )o 2 C(0)R*, -(CH 2 )o 2 C(0)OH, -(CH 2 ) 0 2 C(0)OR*, -(CH 2 ) 0 _ 2 SR*, -(CH 2 ) 0 _ 2 SH, -(CH 2 )o 2 NH 2 , -(CH 2 )o_ 2 NHR*, -(CH 2 ) 0 2 NR* 2 , -N0 2 , -S
- Suitable divalent substituents that are bound to vicinal substitutable carbons of an "optionally substituted” group include: -0(CR 2 ) 2 3 0-, wherein each independent occurrence of R is selected from hydrogen, Ci_6 aliphatic which may be substituted as defined below, or an unsubstituted 5-6-membered saturated, partially unsaturated, or aryl ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur.
- Suitable substituents on the aliphatic group of R * include halogen, -R*, -(haloR*), -OH, -OR*, -O(haloR'), -CN, -C(0)OH, -C(0)OR*, -NH 2 , -NHR*, -NR* 2 , or -N0 2 , wherein each R* is unsubstituted or where preceded by "halo" is substituted only with one or more halogens, and is independently Ci_ 4 aliphatic, -CH 2 Ph, -O(CH 2 ) 0 -iPh, or a 5-6-membered saturated, partially unsaturated, or aryl ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur.
- Suitable substituents on a substitutable nitrogen of an "optionally substituted" group include -R ⁇ , -NR ⁇ 2 , -C(0)R ⁇ , -C(0)OR ⁇ , -C(0)C(0)R ⁇ , -C(0)CH 2 C(0)R ⁇ , -S(0) 2 R ⁇ , -S(0) 2 NR ⁇ 2 , -C(S)NR ⁇ 2 , -C(NH)NR ⁇ 2 , or -N(R ⁇ )S(0) 2 R ⁇ ; wherein each R ⁇ is independently hydrogen, Ci_6 aliphatic which may be substituted as defined below, unsubstituted -OPh, or an unsubstituted 5-6-membered saturated, partially unsaturated, or aryl ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or, notwithstanding the definition above, two independent occurrences of R ⁇ , taken together with their intervening atom(s
- Suitable substituents on the aliphatic group of R ⁇ are independently halogen, -R*, -(haloR*), -OH, -OR*, -O(haloR'), -CN, -C(0)OH, -C(0)OR*, -NH 2 , -NHR*, -NR* 2 , or -N0 2 , wherein each R* is unsubstituted or where preceded by "halo" is substituted only with one or more halogens, and is independently Ci_ 4 aliphatic, -CH 2 Ph, -O(CH 2 ) 0 iPh, or a 5-6-membered
- L 1 is a covalent bond or an optionally substituted bivalent group selected from Ci_ 4 alkylene, C 2 _ 4 alkenylene, or C 2 _ 4 alkynylene wherein one or more methylene units of L 1 are optionally and independently replaced by -Cy 1 -, -0-, -S-, -N(R 2 )-, -C(O)-, -C(0)N(R 2 )-, -N(R 2 )C(0)N(R 2 )-, -N(R 2 )C(0)-, -N(R 2 )C(0)0- -OC(0)N(R 2 )-, -S(0) 2 - -S(0) 2 N(R 2 )-, -N(R 2 )S(0) 2 -, -OC(O)-, or -C(0)0, wherein R 2 is as defined and described herein.
- L 1 is a covalent bond. In certain embodiments, L 1 is a single bond. In some embodiments, L 1 is an optionally substituted Ci_ 4 alkylene group wherein one or more methylene units of L 1 are optionally and independently replaced by -0-, -S-, -N(R 2 )-, -C(O)-, -C(0)N(R 2 )-, -N(R 2 )C(0)N(R 2 )-, -N(R 2 )C(0)-, -N(R 2 )C(0)0- -OC(0)N(R 2 )-, -S(0) 2 -, -S(0) 2 N(R 2 )-, -N(R 2 )S(0) 2 -, -OC(O)-, or -C(0)0.
- L 1 is an optionally substituted C 2 _ 4 alkyenylene group. In yet other embodiments, L 1 is an optionally substituted C 2 _ 4 alkynylene group. In certain embodiments, L 1 is optionally substituted Ci_ 3 alkylene, optionally substituted C 2 _ 3 alkylene, or optionally substituted C 2 _ 3 alkynylene. In certain other embodiments, L 1 is optionally substituted -0-Ci_ 3 alkylene. In some embodiments, L 1 is optionally substituted methylene. In certain embodiments, L 1 is unsubstituted methylene. In certain embodiments, L 1 is propenylene or propynylene.
- L 1 is optionally substituted -0-C 2 alkylene, C 3 alkylene, or C 3 alkynylene. In some embodiments, L 1 is substituted with an optionally substituted group selected from alkyl, cycloalkyl, aryl, or heteroaryl.
- L 1 is -0-C 2 alkylene, C 3 alkenylene, or C 3 alkynylene, wherein L 1 is substituted with an optionally substituted group selected from Ci_ 4 alkyl, a 3-7 membered carbocyclic ring, a 4-7 membered heterocyclic ring having 1-2 heteroatoms selected from nitrogen, oxygen, or sulfur, phenyl, or a 5-6 membered heteroaryl ring having 1-3 heteroatoms selected from nitrogen, oxygen, or sulfur.
- L 1 is -0-C 2 alkylene, C 3 alkenylene, or C 3 alkynylene, wherein L 1 is substituted with methyl, cyclopropyl, oxetanyl, azetidinyl, phenyl, or pyridyl.
- L 1 is substituted with -(CH 2 ) 0 _ 4 C0 2 R° or -(CH 2 )o_ 4 CON(R°) 2 .
- a substituent on L 1 is of the R
- L 1 is of the S stereochemistry
- L 1 is one of the following:
- Ring B is a 5-membered heteroaryl ring having 1-3 heteroatoms selected from nitrogen, oxygen, or sulfur
- Ring C is a 6-membered heteroaryl ring having 1-3 nitrogens.
- L 1 is one of the following:
- L 1 comprises -Cy 1 -.
- -Cy 1 - is an optionally substituted bivalent ring selected from phenylene, 3-7 membered saturated or partially unsaturated carbocyclylene, 4-7 membered saturated or partially unsaturated heterocyclylene having 1-2 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or 5-6 membered heteroarylene having 1-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur.
- L 1 comprises phenylene.
- L 1 is phenylene.
- L 1 comprises 3-7 membered saturated or partially unsaturated carbocyclylene.
- L 1 is 3-7 membered saturated or partially unsaturated carbocyclylene. In some embodiments, L 1 comprises 4-7 membered saturated or partially unsaturated heterocyclylene having 1-2 heteroatoms independently selected from nitrogen, oxygen, or sulfur. In certain embodiments, L 1 is 4-7 membered saturated or partially unsaturated heterocyclylene having 1-2 heteroatoms independently selected from nitrogen, oxygen, or sulfur. In some embodiments, L 1 comprises a 5-6 membered heteroarylene having 1-3 heteroatoms
- L 1 comprises a 5-6 membered heteroarylene having 1-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur.
- Ai is a covalent bond or an optionally substituted bivalent ring selected from 3-7 membered saturated or partially unsaturated monocyclic carbocyclylene, 7-10 membered saturated or partially unsaturated bicyclic carbocyclylene, 4-7 membered saturated or partially unsaturated monocyclic heterocyclylene having 1-2 heteroatoms independently selected from nitrogen, oxygen, or sulfur, 7-10 membered saturated or partially unsaturated bicyclic heterocyclylene having 1-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur, phenylene, 8-10 membered bicyclic arylene, 5-6 membered monocyclic heteroarylene having 1-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or 8-10 membered bicyclic heteroarylene having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur.
- Ai is a covalent bond.
- Ai is a single bond.
- Ai is an optionally substituted bivalent ring selected from 3-7 membered saturated or partially unsaturated carbocyclylene, 7-10 membered saturated or partially unsaturated bicyclic carbocyclylene, 4-7 membered saturated or partially unsaturated heterocyclylene having 1-2 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or 7-10 membered saturated or partially unsaturated bicyclic heterocyclylene having 1-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur.
- Ai is optionally substituted 5-10 membered carbocyclylene. In certain embodiments, Ai is cyclopentylene or cyclohexylene. In other embodiments, Ai is optionally substituted 5-10 membered heterocyclylene.
- Ai is oxiranylene, oxetanylene, tetrahydrofuranylene, tetrahydropyranylene, oxepaneylene, aziridineylene, azetidineylene, pyrrolidinylene, piperidinylene, azepanylene, thiiranylene, thietanylene, tetrahydrothiophenylene, tetrahydrothiopyranylene, thiepanylene, dioxolanylene, oxathiolanylene, oxazolidinylene, imidazolidinylene, thiazolidinylene, dithiolanylene, dioxanylene, morpholinylene, oxathianylene, piperazinylene, thiomorpholinylene, dithianylene, dioxepanylene, oxazepanylene, oxathiepanylene, dithiepanylene, di
- Ai is an optionally substituted bivalent ring selected from phenylene, 8-10 membered bicyclic arylene, 5-6 membered heteroarylene having 1-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or 8-10 membered bicyclic heteroarylene having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur.
- Ai is phenylene.
- Ai is 8-10 membered arylene.
- Ai is 5-10 membered heteroarylene.
- Ai is 5-6 membered heteroarylene.
- Ai is thienylene, furanylene, pyrrolylene, imidazolylene, pyrazolylene, triazolylene, tetrazolylene, oxazolylene, isoxazolylene, oxadiazolylene, thiazolylene, isothiazolylene, thiadiazolylene, pyridylene, pyridazinylene, pyrimidinylene, pyrazinylene, indolizinylene, purinylene, naphthyridinylene, pteridinylene, indolylene, isoindolylene, benzothienylene, benzofuranylene, dibenzofuranylene, indazolylene, benzimidazolylene, benzthiazolylene, quinolylene, isoquinolylene, cinnolinylene, phthalazinylene, quinazolinylene, quinoxalinylene, 4H-quinolizinylene,
- Ai is an optionally substituted bivalent ring selected from:
- Ai is an optionally substituted bivalent ring selected
- L 2 is a covalent bond, alkylidenylene, or an optionally substituted alkylene chain wherein one or more methylene units of L 2 are optionally and independently replaced by -0-, -S-, -N(R 2 )-, -C(O)-, -C(0)N(R 2 )-, -N(R 2 )C(0)N(R 2 )-, -N(R 2 )C(0)-, -N(R 2 )C(0)0-, -OC(0)N(R 2 ) -, -S(0) 2 -, -S(0) 2 N(R 2 )-, -N(R 2 )S(0) 2 -, -OC(O)-, or -C(0)0-, wherein R 2 is as defined and described herein.
- L 2 is a covalent bond. In certain embodiments, L 2 is a single bond, a double bond or a triple bond. In certain embodiments, L 2 is alkylidenylene. In certain other embodiments, L 2 is -0-. In other embodiments, L 2 is not a Ci alkylene replaced by a bivalent oxygen. In some embodiments, L 2 is -N(R 2 )-, -S-, -S(O)-, or -S(0) 2 -.
- L 2 is an optionally substituted alkylene chain wherein one or more methylene units of L 2 are optionally and independently replaced by -0-, -S-, -N(R 2 )-, -C(O)-, -C(0)N(R 2 )-, -N(R 2 )C(0)N(R 2 )-, -N(R 2 )C(0)-, -N(R 2 )C(0)0- -OC(0)N(R 2 )-, -S0 2 -, -S0 2 N(R 2 )-, -N(R 2 )S0 2 -, -OC(O)-, or -C(0)0-.
- L 2 is optionally substituted Ci_ 4 alkylene.
- L 2 is methylene.
- Ring A 2 is a 3-7 membered saturated or partially unsaturated monocyclic carbocyclic ring, a 7-10 membered saturated or partially unsaturated bicyclic carbocyclic ring, a 4-7 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, or sulfur, a 7-10 membered saturated or partially unsaturated bicyclic heterocyclic ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur, a phenyl ring, an 8-10 membered bicyclic aryl ring, a 5-6 membered monocyclic heteroaryl ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur, an 8-10 membered bicyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or a 10-16 membered saturated, partially unsaturated, or aromatic tricyclic ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur
- Ring A 2 is optionally substituted with 1 -4 R x groups and is selected from phenyl, an 8-10 membered bicyclic aryl ring, a 5-6 membered heteroaryl ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or an 8-10 membered bicyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur.
- Ring A 2 is an optionally substituted C 8 -io bicyclic aryl ring. In some embodiments, Ring A 2 is an optionally substituted phenyl ring. In certain embodiments, Ring A 2 is a 5-6 membered heteroaryl ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur. In certain embodiments, Ring A 2 is an 8-10 membered bicyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur.
- Ring A 2 is an optionally substituted 4-7 membered saturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, or sulfur. In some embodiments, Ring A 2 is an optionally substituted 5-6 membered saturated monocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, or sulfur. In some embodiments, Ring A 2 is an optionally substituted 7-10 membered saturated bicyclic ring having 1-3 heteroatoms selected from nitrogen, oxygen, or sulfur. In certain embodiments, Ring A 2 is an optionally substituted 5,6- or 6,6-fused saturated bicyclic ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur.
- Ring A 2 is an optionally substituted 5-membered saturated monocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, or sulfur. In some embodiments, Ring A 2 is an optionally substituted 5-membered saturated monocyclic ring having 2 heteroatoms independently selected from nitrogen, oxygen, or sulfur. In other embodiments, Ring A 2 is an optionally substituted 5-membered saturated monocyclic ring having 2 heteroatoms independently selected from nitrogen or oxygen. In certain embodiments, Ring A 2 is an optionally substituted 5-membered saturated monocyclic ring having 1 heteroatom selected from nitrogen, oxygen, or sulfur.
- Ring A 2 is an optionally substituted 6-membered saturated monocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, or sulfur. In some embodiments, Ring A 2 is an optionally substituted 6-membered saturated monocyclic ring having 2 heteroatoms independently selected from nitrogen, oxygen, or sulfur. In other embodiments, Ring A 2 is an optionally substituted 6-membered saturated monocyclic
- Ring A 2 is an optionally substituted 6-membered saturated monocyclic ring having 1 heteroatom selected from nitrogen, oxygen, or sulfur.
- Exemplary Ring A 2 groups include optionally substituted octahydroazocinyl, thiocyclopentanyl, thiocyclohexanyl, pyrrolidinyl, piperidinyl, piperazinyl, tetrahydrothiopyranyl, tetrahydrothiophenyl, dithiolanyl, tetrahydrofuranyl, tetrahydropyranyl, dioxanyl, thioxanyl, morpholinyl, oxathiolanyl, imidazolidinyl, oxathiolanyl, oxazolidinyl, or thiazolidinyl groups.
- Ring A 2 is an optionally substituted 5-membered heteroaryl ring having 1-3 heteroatoms selected from nitrogen, oxygen, or sulfur. In some embodiments, Ring A 2 is an optionally substituted 5-membered heteroaryl ring having 1-2 heteroatoms selected from nitrogen, oxygen, or sulfur. In other embodiments, Ring A 2 is an optionally substituted 5-membered heteroaryl ring having 2 heteroatoms selected from nitrogen, oxygen, or sulfur. In some embodiments, Ring A 2 is an optionally substituted 5-membered heteroaryl ring having 1 heteroatom selected from nitrogen, oxygen, or sulfur.
- Ring A 2 is an optionally substituted 5-membered heteroaryl ring having 1 nitrogen atom, and an additional heteroatom selected from sulfur or oxygen.
- exemplary Ring A 2 groups include optionally substituted pyrrolyl, pyrazolyl, imidazolyl, triazolyl, tetrazolyl, thienyl, furanyl, thiazolyl, isothiazolyl, thiadiazolyl, oxazolyl, isoxazolyl, or oxadiaziolyl.
- Ring A 2 is an optionally substituted 6-membered heteroaryl ring having 1-3 nitrogens. In other embodiments, Ring A 2 is an optionally substituted 6- membered heteroaryl ring having 1-2 nitrogens. In some embodiments, Ring A 2 is an optionally substituted 6-membered heteroaryl ring having 2 nitrogens. In certain embodiments, Ring A 2 is an optionally substituted 6-membered heteroaryl ring having 1 nitrogen. Exemplary Ring A 2 groups include optionally substituted pyridinyl, pyrimidinyl, pyrazinyl, pyridazinyl, triazinyl, or tetrazinyl.
- Ring A 2 is an optionally substituted 5-6 membered partially unsaturated monocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, or sulfur. In certain embodiments, Ring A 2 is an optionally substituted tetrahydropyridinyl group. In some embodiments, Ring A 2 is an optionally substituted 7-10
- Ring A 2 is an optionally substituted 8-10 membered bicyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur. In some embodiments, Ring A 2 is an optionally substituted 5,6-fused heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur. In other embodiments, Ring A 2 is an optionally substituted 5,6-fused heteroaryl ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, or sulfur. In certain embodiments, Ring A 2 is an optionally substituted 5,6-fused heteroaryl ring having 1 heteroatom independently selected from nitrogen, oxygen, or sulfur. In some embodiments, Ring A 2 is an optionally substituted indole.
- Ring A 2 is an optionally substituted 5,6-fused heteroaryl ring having 2 heteroatoms independently selected from nitrogen, oxygen, or sulfur. In some embodiments, Ring A 2 is an optionally substituted azaindole. In some embodiments, Ring A 2 is an indazole. In certain embodiments, Ring A 2 is an optionally substituted 5,6-fused heteroaryl ring having 3 heteroatoms independently selected from nitrogen, oxygen, or sulfur.
- Ring A 2 is an optionally substituted 6,6-fused heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur. In some embodiments, Ring A 2 is an optionally substituted 6,6-fused heteroaryl ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, or sulfur. In other embodiments, Ring A 2 is an optionally substituted 6,6-fused heteroaryl ring having 1 heteroatom independently selected from nitrogen, oxygen, or sulfur. In some embodiments, Ring A 2 is a quinoline. According to one aspect, Ring A 2 is an optionally substituted 6,6-fused heteroaryl ring having 2 heteroatoms independently selected from nitrogen, oxygen, or sulfur. In some embodiments, Ring A 2 is a quinazoline or a quinoxaline.
- Ring A 2 is an optionally substituted 10-16 membered saturated tricyclic ring having 0-4 heteroatoms selected from nitrogen, oxygen, or sulfur. In some embodiments, Ring A 2 is an optionally substituted 10-16 membered partially unsaturated tricyclic ring having 0-4 heteroatoms selected from nitrogen, oxygen, or sulfur. In other embodiments, Ring A 2 is an optionally substituted 10-16 membered aromatic tricyclic ring having 0-4 heteroatoms selected from nitrogen, oxygen, or sulfur.
- each R x on a nitrogen is independently hydrogen or Ci_ 4 alkyl.
- a carbon on one of the rings shown above is substituted with R x .
- a 2 is optionally substituted with 1-4 R x groups and is selected from:
- each R x on a nitrogen is independently hydrogen or Ci_ 4 alkyl and each R' is
- Ci_ 4 alkyl independently hydrogen or Ci_ 4 alkyl, or two R' on the same nitrogen are taken together with the intervening nitrogen to form a 4-7 membered heterocylic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, or sulfur.
- a carbon on one of the rings shown above is substituted with R x .
- a 2 is or In certain embodiments, A 2 is optionally substituted with 1-4 R x groups and is selected from
- each R x on a nitrogen is independently hydrogen or Ci_ 4 alkyl.
- a 2 optionally substituted with 1-4 R x groups and is selected
- R x is -R. In certain embodiments, R x is hydrogen. In certain embodiments, R x is optionally substituted alkylidenyl. In certain embodiments, R x is alkylidenyl substituted with a heteroaryl group. In some embodiments, R x is Ci_ 4 alkyl. In certain embodiments, R x is methyl. In some embodimetns, R x is -N(R') 2 . In certain embodiments, R x is -NH 2 . In certain embodiments, R x is -NH(R'). In some embodiments, R x is -C(0)N(R') 2 . In certain embodiments, R x is -C(0)NH(R').
- R x is -C(0)NH(Ci_ 4 alkyl). In certain embodiments, R x is -C(0)NH(cycloalkyl). In some embodiments, R x is a 4-7 membered heterocyclic group
- R x is a 4-7 membered heterocyclic group having 1 nitrogen.
- R x is azetidinyl.
- R x is oxo.
- R x is -N(R')OR.
- R x is -NHOCH 3 .
- L 3 is a covalent bond or an optionally substituted Ci_ 4 alkylene chain wherein one or more methylene units of L 3 are optionally and independently replaced by
- L 3 is a covalent bond. In certain embodiments, L 3 is a single bond.
- L 3 is optionally substituted Ci_ 4 alkylene. In some embodiments, L 3 is unsubstituted. In some embodiments, L 3 is an optionally substituted methylene. In certain embodiments, L 3 is unsubstituted methylene. In certain other embodiments, L 3 is substituted methylene. In certain embodiments, L 3 is methylene substituted with methyl or ethyl. In certain embodiments, the substituent on L 3 is of the R stereochemistry. In certain embodiments, the substituent on L 3 is of the S stereochemistry. In certain embodiments, L 3 is .
- Ring A 3 is an optionally substituted ring selected from a 3-7 membered saturated or partially unsaturated monocyclic carbocyclic ring, a 7-10 membered saturated or partially unsaturated bicyclic carbocyclic ring, a 4-7 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, or sulfur, a 7-10 membered saturated or partially unsaturated bicyclic heterocyclic ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur, a phenyl ring, an 8-10 membered bicyclic aryl ring, a 5-6 membered monocyclic heteroaryl ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or an 8-10 membered bicyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur.
- Ring A 3 is an optionally substituted 8-10 membered bicyclic aryl ring. In some embodiments, Ring A 3 is an optionally substituted phenyl ring. In some embodiments, Ring A 3 is a cyclopropyl ring. In some embodiments, Ring A 3 is an optionally
- Ring A 3 is an optionally substituted cyclohexyl ring. In some embodiments, Ring A 3 is an optionally substituted cycloheptyl ring.
- Ring A 3 is an optionally substituted 4-7 membered saturated heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, or sulfur. In some embodiments, Ring A 3 is an optionally substituted 4-membered saturated heterocyclic ring having 1 heteroatom independently selected from nitrogen, oxygen or sulfur. In some embodiments, Ring A 3 is an oxetane. In some embodiments, Ring A 3 is an azetidine. In some embodiments, Ring A 3 is an optionally substituted 5-6 membered saturated monocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, or sulfur.
- Ring A 3 is an optionally substituted 7-10 membered saturated bicyclic ring having 1-3 heteroatoms selected from nitrogen, oxygen, or sulfur. In certain embodiments, Ring A 3 is an optionally substituted 5,6- or 6,6-fused saturated bicyclic ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur.
- Ring A 3 is an optionally substituted 5-membered saturated monocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, or sulfur. In some embodiments, Ring A 3 is an optionally substituted 5-membered saturated monocyclic ring having 2 heteroatoms independently selected from nitrogen, oxygen, or sulfur. In other embodiments, Ring A 3 is an optionally substituted 5-membered saturated monocyclic ring having 2 heteroatoms independently selected from nitrogen or oxygen. In certain embodiments, Ring A 3 is an optionally substituted 5-membered saturated monocyclic ring having 1 heteroatom selected from nitrogen, oxygen, or sulfur.
- Ring A 3 is an optionally substituted 6-membered saturated monocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, or sulfur. In some embodiments, Ring A 3 is an optionally substituted 6-membered saturated monocyclic ring having 2 heteroatoms independently selected from nitrogen, oxygen, or sulfur. In other embodiments, Ring A 3 is an optionally substituted 6-membered saturated monocyclic ring having 2 heteroatoms independently selected from nitrogen or oxygen. In certain embodiments, Ring A 3 is an optionally substituted 6-membered saturated monocyclic ring having 1 heteroatom selected from nitrogen, oxygen, or sulfur.
- Exemplary Ring A 3 groups include optionally substituted octahydroazocinyl, thiocyclopentanyl, thiocyclohexanyl, pyrrolidinyl, piperidinyl, piperazinyl,
- Ring A3 is an optionally substituted 5-membered heteroaryl ring having 1-3 heteroatoms selected from nitrogen, oxygen, or sulfur. In some embodiments, Ring A 3 is an optionally substituted 5-membered heteroaryl ring having 1-2 heteroatoms selected from nitrogen, oxygen, or sulfur. In other embodiments, Ring A 3 is an optionally substituted 5-membered heteroaryl ring having 2 heteroatoms selected from nitrogen, oxygen, or sulfur. In some embodiments, Ring A 3 is an optionally substituted 5-membered heteroaryl ring having 1 heteroatom selected from nitrogen, oxygen, or sulfur.
- Ring A 3 is an optionally substituted 5-membered heteroaryl ring having 1 nitrogen atom, and an additional heteroatom selected from sulfur or oxygen.
- exemplary Ring A 3 groups include optionally substituted pyrrolyl, pyrazolyl, imidazolyl, triazolyl, tetrazolyl, thienyl, furanyl, thiazolyl, isothiazolyl, thiadiazolyl, oxazolyl, isoxazolyl, or oxadiaziolyl group.
- Ring A 3 is an optionally substituted 6-membered heteroaryl ring having 1-3 nitrogens. In other embodiments, Ring A 3 is an optionally substituted 6- membered heteroaryl ring having 1-2 nitrogens. In some embodiments, Ring A 3 is an optionally substituted 6-membered heteroaryl ring having 2 nitrogens. In certain embodiments, Ring A 3 is an optionally substituted 6-membered heteroaryl ring having 1 nitrogen. Exemplary Ring A 3 groups include optionally substituted pyridinyl, pyrimidinyl, pyrazolyl, pyrazinyl, pyridazinyl, triazinyl, or tetrazinyl.
- Ring A 3 is an optionally substituted 5-6 membered partially unsaturated monocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, or sulfur. In certain embodiments, Ring A 3 is an optionally substituted tetrahydropyridinyl group. In some embodiments, Ring A 3 is an optionally substituted 7-10 membered partially unsaturated bicyclic ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur.
- Ring A 3 is an optionally substituted 8-10 membered bicyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur. In certain embodiments, Ring A 3 is an optionally substituted 7-10 membered saturated or partially unsaturated bicyclic heterocyclic ring having 1-3 heteroatoms independently selected
- Ring A3 is an indoline ring. In some embodiments, Ring A 3 is a tetrahydroisoquinoline ring. In some embodiments, Ring A 3 is an optionally substituted 5,6-fused heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur. In other embodiments, Ring A 3 is an optionally substituted 5,6-fused heteroaryl ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, or sulfur. In some embodiments, Ring A 3 is a benzoxazole or a benzimidazole. In some embodiments, Ring A 3 is a quinoline ring. In certain embodiments, Ring A 3 is an optionally substituted 5,6-fused heteroaryl ring having 1 heteroatom independently selected from nitrogen, oxygen, or sulfur.
- Ring A 3 is an optionally substituted 6,6-fused heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur. In some embodiments, Ring A 3 is an optionally substituted 6,6-fused heteroaryl ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, or sulfur. In other embodiments, Ring A 3 is an optionally substituted 6,6-fused heteroaryl ring having 1 heteroatom independently selected from nitrogen, oxygen, or sulfur. According to one aspect, Ring A 3 is an optionally substituted 6,6-fused heteroaryl ring having 2 heteroatoms independently selected from nitrogen, oxygen, or sulfur.
- Ring A 3 is phenyl, an 8-10 membered bicyclic aryl ring, a 5- 6 membered heteroaryl ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or an 8-10 membered bicyclic heteroaryl ring having 1-4 heteroatoms selected from nitrogen, oxygen, or sulfur, wherein Ring A 3 is optionally substituted with one or more halo or alkyl groups.
- Ring A 3 is optionally substituted phenyl. In certain embodiments, Ring A 3 is substituted with at least one halogen. In certain embodiments, Ring A 3 is substituted with at least one fluorine. In other embodiments, Ring A 3 is substituted with at least one chlorine. In other embodiments, Ring A 3 is substituted with at least one alkyl group. In some embodiments, Ring A 3 is substituted with at least one trifluoromethyl group. In other embodiments, Ring A 3 is substituted with at least one methoxy group. In some embodiments, Ring A 3 is substituted at the para position. In some embodiments, Ring A 3 is substituted at the meta position. In certain embodiments, Ring A 3 is one of the following:
- X is -C(O)- or -S(0) 2 -. In certain embodiments, X is -C(O)-. In other embodiments, X is -S(0) 2 -.
- Ring A 4 is a 5-6 membered heteroaryl ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or an 8-10 membered bicyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur; wherein any substitutable carbon on Ring A 4 is optionally substituted with R 3 , R 4 , or R 5 , and any substitutable nitrogen on Ring A 4 is optionally substituted with R 6 , wherein R 3 , R 4 , R 5 , and R 6 are as defined and described herein.
- R 3 , R 4 , R 5 , and R 6 are as defined and described herein.
- Ring A 4 is an optionally substituted 5 -membered heteroaryl ring having 1-3 heteroatoms selected from nitrogen, oxygen, or sulfur. In some embodiments, Ring A 4 is an optionally substituted 5 -membered heteroaryl ring having 1-2 heteroatoms selected from nitrogen, oxygen, or sulfur. In other embodiments, Ring A 4 is an optionally substituted 5 -membered heteroaryl ring having 2 heteroatoms selected from nitrogen, oxygen, or sulfur. According to one aspect, Ring A 4 is an optionally substituted 5 -membered heteroaryl ring having 1 heteroatom selected from nitrogen, oxygen, or sulfur.
- Ring A 4 is an optionally substituted 5 -membered heteroaryl ring having 1 nitrogen, and an additional heteroatom selected from sulfur or oxygen.
- exemplary Ring A 4 groups include optionally substituted pyrrolyl, pyrazolyl, imidazolyl, triazolyl, tetrazolyl, thiazolyl, isothiazolyl, thiadiazolyl, oxazolyl, isoxazolyl, or oxadiaziolyl.
- Ring A 4 is an optionally substituted 6-membered heteroaryl ring having 1-3 nitrogens. In other embodiments, Ring A 4 is an optionally substituted 6- membered heteroaryl ring having 1-2 nitrogen atoms. In some embodiments, Ring A 4 is an
- Exemplary A 4 groups include an optionally substituted pyridinyl, pyrimidinyl, pyrazolyl, pyrazinyl, pyridazinyl, triazinyl, or tetrazinyl.
- Ring A 4 is an optionally substituted 8-10 membered aromatic bicyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur. In some embodiments, Ring A 4 is an optionally substituted 5,6-fused heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur. In other embodiments, Ring A 4 is an optionally substituted 5,6-fused heteroaryl ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, or sulfur. In certain embodiments, Ring A 4 is an optionally substituted 5,6-fused heteroaryl ring having 1 nitrogen.
- Ring A 4 is an optionally substituted 6,6-fused heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur. In some embodiments, Ring A 4 is an optionally substituted 6,6-fused heteroaryl ring having 1-2 nitrogens. In other embodiments, Ring A 4 is an optionally substituted 6,6-fused heteroaryl ring having 1 nitrogen. In some embodiments, Rin A 4 is a quinoline ring. In certain embodiments, Ring A 4 is an optionally substituted 6,6-fused heteroaryl ring having 2 nitrogens.
- Ring A 4 is an optionally substituted 5,5-fused heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur. In some embodiments, Ring A 4 is an optionally substituted 5,5-fused heteroaryl ring having 1-2 heteroatoms selected from nitrogen, oxygen, or sulfur. In other embodiments, Ring A 4 is an optionally substituted 5,5-fused heteroaryl ring having 1 nitrogen. In certain embodiments, Ring A 4 is an optionally substituted 5,5-fused heteroaryl ring having 2 nitrogens. In certain embodiments, Ring A 4 is an optionally substituted 5,5-fused heteroaryl ring having 1 nitrogen and 1-2 other heteroatoms selected from nitrogen, oxygen, or sulfur.
- Ring A 4 is selected from:
- Ring A 4 is of formula:
- R 3 and R 4 are taken together with their intervening atoms to form an optionally substituted fused ring selected from a 4-7 membered saturated or partially unsaturated carbocyclic ring, phenyl, a 5-6 membered saturated or partially unsaturated bicyclic heterocyclic ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or a 5-6 membered heteroaryl ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur.
- Ring A 4 is of formula:
- R 4 and R 5 are taken together with their intervening atoms to form an optionally substituted fused ring selected from a 4-7 membered saturated or partially unsaturated
- Ring A 4 is of formula:
- R 4 and R 5 are taken together with their intervening atoms to form an optionally substituted 5 -membered heteroaryl fused ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur.
- Ring A 4 is of formula:
- R 4 and R 5 are taken together with their intervening atoms to form an optionally substituted 5 -membered heteroaryl fused ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur.
- Ring A 4 is of formula:
- R 3 and R 4 are taken together with their intervening atoms to form an optionally substituted 5 -membered heteroaryl fused ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur.
- Ring A 4 is selected from:
- R 3 is hydrogen, -CI, or -CF 3 ;
- R 4 is hydrogen, -F, -CI, -Br, -I, Ci_ 6 alkyl, Ci_ 6 alkenyl, Ci_ 6 alkynyl, -CN, -N0 2 , -NH 2 , -N(R') 2 , -NHC(0)Ci_ 6 alkyl, -C0 2 H, -C0 2 Ci_ 4 alkyl, -C(0)N(R') 2 , -NHS(0)Ci_ 6 alkyl, -NHS(0) 2 Ci_ 6alkyl, -Sd_ 6 alkyl, -S(0)C 1 _ 6 alkyl, -S(0) 2 C 1 _ 6 alkyl, -S(0)N(R') 2 , -S(0) 2 N(R') 2 , -CF 3 , -OCH 3 , -OCH 2 CH 3 , benzyloxy, phenyl; or an optionally substituted 3-5 membered saturated or partially unsatur
- R 5 is hydrogen, -OCH 3 , -OCH 2 CH 3 , -CF 3 or -NH 2 ;
- R 6 is hydrogen or an optionally substituted group selected from Ci_ 4 alkyl, phenyl, or a 5-6
- each R' is independently hydrogen or Ci_ 4 alkyl, or two R' on the same nitrogen are taken together with the intervening nitrogen to form an optionally substituted 5-6 membered saturated, partially unsaturated, or aromatic ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur.
- R 1 is hydrogen or optionally substituted Ci_ 6 aliphatic, or R 1 and a substituent on Ring A 4 are taken together with their intervening atoms to form an optionally substituted 5-7 membered partially unsaturated or aromatic fused ring having 0-3 ring heteroatoms independently selected from nitrogen, oxygen, or sulfur.
- R 1 is hydrogen.
- R 1 is Ci_ 6 aliphatic.
- R 1 is Ci_ 4 alkyl.
- R 1 is methyl.
- R 1 and a substituent on Ring A 4 are taken together with their intervening atoms to form an optionally substituted 5-7 membered partially unsaturated or aromatic fused ring having 0-3 ring heteroatoms independently selected from nitrogen, oxygen, or sulfur.
- R 1 and a substituent on Ring A 4 are taken together with their intervening atoms to form an optionally substituted fused ring selected from a 5-6 membered partially unsaturated heterocyclic ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or a 5-6 membered heteroaryl ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur.
- R 1 and a substituent on ring A 4 are taken together with their intervening atoms to form a fused pyrimidinone, dihydropyrimidinone, dihydropyridinone, or pyrrolone.
- R 2 is hydrogen or optionally substituted Ci_ 6 aliphatic. In certain embodiments, R 2 is hydrogen. In some embodiments, R 2 is optionally substituted Ci_ 6 aliphatic.
- R 2 is Ci_ 4 alkyl. In certain embodiments, R 2 is methyl, ethyl, or propyl.
- R 3 is -R, -halo, -N0 2 , -CN, -OR, -SR, -N(R') 2 , -C(0)R, -C0 2 R,
- R and R' are as defined and described herein, or R 3 and R 4 are taken together with their intervening atoms to form an optionally substituted fused ring selected from a 4-7 membered partially unsaturated carbocyclic ring, phenyl, a 5-6 membered partially unsaturated heterocyclic ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or a 5-6 membered heteroaryl ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or R 3 and R 6 are taken together with their intervening atoms to form an optionally substituted fused ring selected from a 5-6 membered saturated or partially unsaturated heterocyclic ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or a 5-6
- R 3 is -R. In certain embodiments, R 3 is hydrogen. In some embodiments, R 3 is halo. In some embodiments, R 3 is -OR, -SR, or-N(R') 2 . In some embodiments, R 3 is -C(0)R, -C0 2 R, -C(0)C(0)R, or -C(0)CH 2 C(0)R. In some embodiments,
- R 3 is -S(0)R, -S(0) 2 R, -C(0)N(R') 2 , -S(0) 2 N(R') 2 , -OC(0)R, -N(R')C(0)R, -N(R')N(R') 2 ,
- R 3 is -CI. In certain embodiments, R 3 is -CF 3 . In certain embodiments, R 3 is -CN.
- R 4 is -R. In certain embodiments, R 4 is hydrogen. In some embodiments, R 4 is halo. In certain embodiments, R 4 is fluorine. In some embodiments, R 4 is Ci_6 aliphatic. In certain embodiments, R 4 is Ci_ 4 alkyl. In certain embodiments, R 4 is methyl or ethyl. In certain embodiments, R 4 is optionally substituted alkynyl. In certain embodimetns, R 4 is optionally substituted alkenyl.
- R 4 is -CN, -N0 2 , -NH 2 , -NHC(0)Ci_ ealkyl, -C0 2 H, -C0 2 Ci_ 4 alkyl, -C(0)N(R') 2 , -NHS(0)Ci_ 6 alkyl, -NHS(0) 2 Ci_ 6 alkyl, -SCi_ 6 alkyl, -S(0)Ci_ 6 alkyl, -S(0) 2 Ci_ 6 alkyl, -S(0)N(R') 2 , -S(0) 2 N(R') 2 , -CF 3 , -OCH 3 , -OCH 2 CH 3 , or benzyloxy.
- R 4 is halo, -NH 2 , -CN, -N0 2 , -SCi_ 4 alkyl, -S(0)Ci_ 4 alkyl, -S(0) 2 Ci_ 4 alkyl, -S(0)N(R') 2 , -CF 3 , -OCH 3 , -OCH 2 CH 3 , benzyloxy, -C(0)N(R') 2 , or -NHC(0)Ci_ 4 alkyl.
- R 4 is -CN, -N0 2 , -SCi_ 4 alkyl, -S(0)Ci_ 4 alkyl, -S(0) 2 Ci_ 4 alkyl, -S(0)N(R') 2 , -S(0) 2 N(R') 2 , -CF 3 , -OCH 3 , -OCH 2 CH 3 , or benzyloxy.
- R 5 is -R. In certain embodiments, R 5 is hydrogen. In some embodiments, R 5 is halo. In some embodiments, R 5 is -OR, -SR, or -N(R') 2 . In some embodiments, R 5 is -C(0)R, -C0 2 R, -C(0)C(0)R, or -C(0)CH 2 C(0)R.
- R 5 is -OCH 3 or -NH 2 .
- R 5 is -CF 3 .
- each R 6 is independently -R, -C(0)R, -C0 2 R, -C(0)C(0)R, -C(0)CH 2 C(0)R, -S(0)R, -S(0) 2 R, -C(0)N(R') 2 , or -S(0) 2 N(R') 2 .
- R 6 is -R.
- R 6 is hydrogen.
- R 6 is Ci_ 6 aliphatic.
- R 6 is Ci_ 4 alkyl.
- R 6 is methyl.
- R 6 is -C(0)R, -C0 2 R, -C(0)C(0)R, -C(0)CH 2 C(0)R, -S(0)R, -S(0) 2 R, -C(0)N(R') 2 , or -S(0) 2 N(R') 2 .
- R 6 is phenyl.
- R is a 5-6 membered heteroaryl ring having 1-3 heteroatoms selected from nitrogen, oxygen, or sulfur.
- R 6 is pyridyl.
- R 1 and R 5 are taken together with their intervening atoms to form an optionally substituted fused ring selected from a 5-6 membered partially unsaturated heterocyclic ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or a 5-6 membered heteroaryl ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur.
- R 1 and R 5 are taken together with their intervening atoms to form a fused pyrimidinone, dihydropyrimidinone, dihydropyridinone, or pyrrolone.
- R 3 and R 4 are taken together with their intervening atoms to form an optionally substituted fused ring selected from a 4-7 membered partially unsaturated carbocyclic ring, phenyl, a 5-6 membered partially unsaturated bicyclic heterocyclic ring having
- heteroatoms independently selected from nitrogen, oxygen, or sulfur, or a 5-6 membered heteroaryl ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur.
- R 3 and R 4 are taken together with their intervening atoms to form a fused benzene ring. In other embodiments, R 3 and R 4 are taken together with their intervening atoms to form a fused 4-7 membered partially unsaturated carbocyclic ring. In certain embodiments,
- R 3 and R 4 are taken together with their intervening atoms to form a fused cyclopentene ring.
- R 4 and R 5 are taken together with their intervening atoms to form an optionally substituted fused ring selected from a 4-7 membered partially unsaturated carbocyclic ring, phenyl, a 5-6 membered partially unsaturated bicyclic heterocyclic ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or a 5-6 membered heteroaryl ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur.
- R 3 and R 6 are taken together with their intervening atoms to form an optionally substituted fused ring selected from a 5-6 membered partially unsaturated heterocyclic ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or a 5-6 membered heteroaryl ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur.
- each R is independently hydrogen or an optionally substituted group selected from Ci_6 aliphatic, a 3-7 membered saturated or partially unsaturated monocyclic carbocyclic ring, a 7-10 membered saturated or partially unsaturated bicyclic carbocyclic ring, a 4-7 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, or sulfur, a 7-10 membered saturated or partially unsaturated bicyclic heterocyclic ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur, a phenyl ring, an 8-10 membered bicyclic aryl ring, a 5-6 membered heteroaryl ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or an 8-10 membered bicyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur.
- R is hydrogen. In some embodiments, R is an optionally substituted Ci_ 6 aliphatic group. In certain embodiments, R is a Ci_6 alkyl group. In certain embodiments, R is a Ci_ 4 alkyl group. In certain embodiments, R is methyl, ethyl, or propyl. In some embodiments, R is optionally substituted phenyl. In some embodiments, R is an optionally substituted group selected from an 8-10 membered bicyclic aryl ring, a 5-6 membered heteroaryl ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or an 8-10 membered bicyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur.
- each R' is independently R, or two R' groups on the same nitrogen are taken together with the intervening nitrogen to form an optionally substituted 4-8 membered
- R' is hydrogen. In some embodiments, R' is an optionally substituted Ci_ 6 aliphatic group. In certain embodiments, R' is a Ci_6 alkyl group. In certain embodiments, R' is a Ci_ 4 alkyl group. In certain embodiments, R' is methyl, ethyl, or propyl. In some embodiments, R' is optionally substituted phenyl.
- R' is an optionally substituted group selected from an 8-10 membered bicyclic aryl ring, a 5-6 membered heteroaryl ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or an 8-10 membered bicyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur.
- two R' groups on the same nitrogen are taken together with the intervening nitrogen to form an optionally substituted 4-8 membered saturated, partially unsaturated, or aromatic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur.
- -Ai-L 1 - is one of the following:
- -L 2 -Ai-L 1 - is optionally substituted -0-C 2 alkylene, C 3 alkenylene, or
- Ring B is a 5-membered heteroaryl ring having 1-3 heteroatoms selected from nitrogen, oxygen, or sulfur
- Ring C is a 6-membered heteroaryl ring having 1-3 nitrogens.
- -L 2 -Ai-L 1 - is one of the following:
- -L 2 -Ai-L 1 - is optionally substituted with 1-4 R x groups and is selected from:
- Ring A 2 is
- -L -Ring A 3 is optionally substituted benzyl. In certain embodiments, -L 3 -Ring A 3 is one of the following:
- the present invention provides a compound of formula II:
- the present invention provides a compound of formulae II or Il-a:
- R 3 of formula II is hydrogen, -CI, or -CF 3 .
- R 4 is -CN, -N0 2 , -SCi_ 4 alkyl, -S(0)Ci_ 4 alkyl, -S(0) 2 Ci_ 4 alkyl, -S(0)N(R') 2 , -S(0) 2 N(R') 2 , -CF 3 , -OCH 3 , -OCH 2 CH 3 , or benzyloxy, wherein each R' is independently hydrogen or Ci_ 4 alkyl.
- R 5 is hydrogen, -OCH 3 , or -NH 2 .
- R 1 and R 5 are taken together with their intervening atoms to form an optionally substituted ring selected from a 5-6 membered saturated or partially unsaturated heterocyclic ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or a 5-6 membered heteroaryl ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur.
- R 3 and R 4 are taken together with their intervening atoms to form an optionally substituted ring selected from a 4-7 membered saturated or partially unsaturated carbocyclic ring, phenyl, a 5-6 membered
- R 4 and R 5 are taken together with their intervening atoms to form an optionally substituted ring selected from a 4-7 membered saturated or partially unsaturated carbocyclic ring, phenyl, a 5-6 membered saturated or partially unsaturated bicyclic heterocyclic ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or a 5-6 membered heteroaryl ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur.
- L 3 of formula II is optionally substituted methylene. In certain embodiments, L 3 is unsubstituted methylene. In certain other embodiments, L 3 is methylene substituted with methyl. In some embodiments, Ring A 3 is optionally substituted phenyl. In certain embodiments, Ring A 3 is phenyl substituted with at least one fluorine at the para position or meta position. In some embodiments, L 1 is optionally substituted methylene, propylene, propynylene, or -0-C 1-3 alkylene. In certain embodiments, L 1 is optionally substituted -0-C 2 alkylene. In certain embodiments, L 1 is optionally substituted methylene. In certain embodiments, L 1 is -CH 2 -.
- Ai of formula II is an optionally substituted group selected from:
- L 2 of formula II is a covalent bond or methylene.
- Ring A 2 is optionally substituted with 1-4 R x groups and is selected from:
- each R x on a nitrogen is independently hydrogen or Ci_ 4 alkyl
- each R' is independently hydrogen or Ci_ 4 alkyl, or two R' on the same nitrogen are taken together with the intervening nitrogen to form a 4-7 membered heterocylic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, or sulfur.
- L 3 of formula Il-a is a covalent bond.
- R x of formula Il-a is Ci_ 4 alkyl, Ci_ 4 alkenyl, or Ci_ 4 alkynyl.
- R x of formula Il-a is a methyl group.
- R x of formula Il-a is a propargyl group.
- Another aspect of the present invention provides a compound of formula III:
- L 1 , L 2 , L 3 , A l s Ring A 2 , Ring A 3 , R 1 , R 3 , and R 4 are as defined above for formula I and described herein.
- the present invention provides a compound of formula IV:
- the com ound of formula IV is of formula IV-a or IV-b:
- the present invention provides a compound of formula V:
- R 6 of formula V is Ci_ 4 alkyl or a 5-6 membered heteroaryl ring having 1-3 heteroatoms selected from nitrogen, oxygen, or sulfur.
- R 6 is methyl.
- R 6 is pyridyl.
- each of L 1 , L 2 , L 3 , A ls Ring A 2 , Ring A 3 , Ring A 4 , R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R, and R' is selected from those groups depicted in the Schemes and Examples found in the Examples section, infra.
- the present invention provides a compound of formula VI:
- L 1 , L 2 , A ls Ring A 2 , X, R 1 , R 3 , R 4 and R 6 are as defined above for formula I and described herein.
- the present invention provides a compound of formula VII:
- L 1 , L 2 , L 3 , A ls Ring A 2 , Ring A 3 , and Ring A 4 are as defined above for formula I and described herein.
- L 3 of formula VII is a covalent bond.
- Ring A 3 of formula VII is a 4-7 membered saturated heterocyclic ring having 1-2 heteroatoms independently selected from nitorgen, oxygen or sulfur.
- Ring A 3 is a 5-6 membered monocyclic heteroaryl ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or an 8-10 membered bicyclic heteroaryl ring having 1-4
- Ring A 3 groups include optionally substituted azetidinyl, benzoxazolyl, benzimidazolyl, thiazolyl or oxazolyl.
- the present invention provides a compound of formula VIII:
- n is 0 or 1
- L 1 , L 2 , L 3 , A ls Ring A 2 , Ring A 3 , R 3 and R 4 are as defined above for formula I and described herein.
- n is 0.
- n is 1.
- the present invention provides a compound of formula VIII:
- n is 0 or 1
- X, L 1 , L 2 , L 3 , A ls Ring A 2 , Ring A 3 , and R 1 are as defined above for formula I and described herein.
- n is 0.
- n is 1.
- the present invention provides the following compounds:
- the present invention provides a method of decreasing PDKl catalytic activity.
- the method includes contacting a PDKl kinase with an effective amount of a compound of the present invention. Therefore, the present invention further provides a method of inhibiting PDKl catalytic activity by contacting a PDKl kinase with a provided compound.
- PDKl catalytic activity refers to PDKl kinase catalytic activity.
- the phosphorylation of a PDKl substrate e.g. Akt
- the IC 50 of a provided PDKl substrate e.g. Akt
- the IC 50 of a provided compound against PDK1 is less than 1 ⁇ .
- the IC 50 of a provided compound against PDK1 is less than 500 nM.
- the IC 50 of a provided compound against PDK1 is less than 100 nM.
- the IC 50 of a provided compound against PDK1 is less than 10 nM.
- the IC 50 of a provided compound against PDK1 is less than 1 nM.
- the IC 50 of a provided compound against PDK1 is from 0.1 nM to 10 ⁇ .
- the IC 50 of a provided compound against PDK1 is from 0.1 nM to 1 ⁇ . In other embodiments, the IC 50 of a provided compound against PDK1 is from 0.1 nM to 100 nM. In other embodiments, the IC 50 of a provided compound against PDK1 is from 0.1 nM to 10 nM.
- provided compounds are useful for the treatment of one or more diseases, disorders, and/or conditions that may be alleviated by inhibiting (i.e. decreasing) PDK1 catalytic activity.
- treatment refers to reversing, alleviating, delaying the onset of, or inhibiting the progress of a disease or disorder, or one or more symptoms thereof, as described herein.
- treatment may be administered after one or more symptoms have developed.
- treatment may be administered in the absence of symptoms.
- treatment may be administered to a susceptible individual prior to the onset of symptoms (e.g., in light of a history of symptoms and/or in light of genetic or other susceptibility factors). Treatment may also be continued after symptoms have resolved, for example to prevent or delay their recurrence.
- the present invention provides a method of treating cancer in a subject in need thereof.
- provided methods include administering to the subject a therapeutically effective amount of a provided compound.
- cancer includes diseases or disorders involving abnormal cell growth and/or proliferation, such as glioma, thyroid carcinoma, breast carcinoma, lung cancer (e.g. small-cell lung carcinoma, non-small-cell lung carcinoma), gastric carcinoma, gastrointestinal stromal tumors, pancreatic carcinoma, bile duct carcinoma, ovarian carcinoma, endometrial carcinoma, prostate carcinoma, renal cell carcinoma, anaplastic large-cell lymphoma, leukemia (e.g.
- the present invention provides methods for reducing PDK1- mediated phosphorylation of Akt.
- Provided methods include contacting PDK1 with a provided
- PDKl -mediated phosphorylation of Akt is reduced relative to PDKl -mediated phosphorylation of PKC (e.g. PKC iso forms zeta, delta, and/or theta).
- the PDKl -mediated phosphorylation of Akt is inhibited at least 5-, 10-, 50-, 100-, or 1000-fold relative to the PDKl -mediated phosphorylation of PKC.
- Exemplary assays for determining the inhibition of PDKl -mediated phosphorylation of Akt are provided in the Examples below.
- the PDKl -mediated phosphorylation of Akt is reduced in a cell.
- the present invention provides methods for reducing PDK1- mediated phsophorylation of Akt in a cell.
- provided methods include contacting the cell with a compound of the present invention.
- PDK1- mediated phsophorylation of Akt is reduced relative to PDKl -mediated phosphorylation of PKC (e.g. PKC isoforms zeta, delta, and/or theta).
- the PDKl-mediated phosphorylation of Akt is inhibited at least 5-, 10-, 50-, 100-, or 1000-fold relative to the PDKl- mediated phosphorylation of PKC.
- Exemplary assays for determining the inhibition of PDKl- mediated phosphorylation of Akt are provided in the Examples below.
- the cell in which PDKl-mediated phsophorylation of Akt is reduced is a mammalian cell, such as a domestic animal (e.g. cat, dog, hose, cow, etc.) or human.
- candidate inhibitors capable of decreasing PDKl catalytic activity may be identified in vitro.
- the activity of provided compounds can be assayed utilizing methods known in the art and/or those methods presented herein.
- Compounds that decrease PDKl catalytic activity may be identified and tested using biologically active PDKl, either recombinant or naturally occurring.
- PDKl can be found in native cells, isolated in vitro, or co-expressed or expressed in a cell. Measuring the reduction in the PDKl catalytic activity in the presence of an inhibitor relative to the activity in the absence of the inhibitor may be performed using a variety of methods known in the art, such as the assay described in Example 21. Other methods for assaying the activity of PDKl are known in the art. The selection of appropriate assay methods is well within the capabilities of those of skill in the art.
- Compounds may be further tested in cell models or animal models for their ability to cause a detectable changes in phenotype related to PDKl activity.
- animal models may be used to test inhibitors of PDKl for their ability to treat cancer in an animal model.
- the present invention provides pharmaceutical compositions comprising a provided compound optionally in combination with a pharmaceutically acceptable excipient (e.g. carrier).
- a pharmaceutically acceptable excipient e.g. carrier
- compositions include optical isomers, diastereomers, or pharmaceutically acceptable salts of the compounds disclosed herein.
- pharmaceutical compositions include a pharmaceutically acceptable salt.
- a compound included in the pharmaceutical composition may be covalently attached to a pharmaceutically acceptable carrier.
- the inventive compound included in the pharmaceutical composition is not covalently linked to a pharmaceutically acceptable carrier.
- a "pharmaceutically acceptable carrier,” as used herein refers to pharmaceutical excipients, for example, pharmaceutically, physiologically, acceptable organic, or inorganic carrier substances suitable for enteral or parenteral application which do not deleteriously react with the extract.
- suitable pharmaceutically acceptable carriers include water, salt solutions (such as Ringer's solution), alcohols, oils, gelatins and carbohydrates such as lactose, amylose or starch, fatty acid esters, hydroxymethycellulose, and polyvinyl pyrrolidine.
- Such preparations can be sterilized and, if desired, mixed with auxiliary agents such as lubricants, preservatives, stabilizers, wetting agents, emulsifiers, salts for influencing osmotic pressure, buffers, coloring, and/or aromatic substances and the like which do not deleteriously react with the compounds of the invention.
- auxiliary agents such as lubricants, preservatives, stabilizers, wetting agents, emulsifiers, salts for influencing osmotic pressure, buffers, coloring, and/or aromatic substances and the like which do not deleteriously react with the compounds of the invention.
- Provided compounds can be administered alone or can be coadministered to a patient along with one or more other drugs. Coadministration is meant to include simultaneous or
- Compounds of the present invention can be prepared and administered in a wide variety of oral, parenteral and topical dosage forms.
- provided compounds are administered by injection (e.g. intravenously, intramuscularly, intracutaneously, subcutaneously, intraduodenally, or intraperitoneally).
- compounds described herein are administered by inhalation, for example, intranasally.
- provided compounds are administered transdermally. It is also envisioned that multiple routes of administration (e.g., intramuscular, oral, transdermal) can be used to administer the compounds of the invention.
- the present invention also provides pharmaceutical compositions comprising one or more provided compounds and one or more pharmaceutically acceptable carriers or excipients.
- pharmaceutically acceptable carriers can be either solid or liquid.
- Solid form preparations include powders, tablets, pills, capsules, cachets, suppositories, and dispersible granules.
- a solid carrier is one or more substances, which may also act as diluents, flavoring agents, binders, preservatives, tablet disintegrating agents, or an encapsulating material.
- the carrier when the composition is a powder, the carrier is a finely divided solid in a mixture with the finely divided active component. In some embodiments, when the composition is formulated for a tablet, the active component is mixed with the carrier having the necessary binding properties in suitable proportions and compacted in the shape and size desired.
- provided powders and tablets contain from 5% to 70% of the active compound.
- Suitable carriers include magnesium carbonate, magnesium stearate, talc, sugar, lactose, pectin, dextrin, starch, gelatin, tragacanth, methylcellulose, sodium carboxymethylcellulose, a low melting wax, cocoa butter, and the like.
- the composition is formulated for a cachet or lozenge.
- a low melting wax such as a mixture of fatty acid glycerides or cocoa butter
- the active component is dispersed homogeneously therein.
- the molten homogeneous mixture is then poured into convenient sized molds, allowed to cool and solidify.
- Liquid form preparations include solutions, suspensions, and emulsions, for example, water or water/propylene glycol solutions.
- liquid preparations can be formulated in solution in aqueous polyethylene glycol solution.
- suitable admixtures for the compounds of the invention are injectable, sterile solutions, preferably oily or aqueous solutions, as well as suspensions, emulsions, or implants, including suppositories.
- carriers for parenteral administration include aqueous solutions of dextrose, saline, pure water, ethanol, glycerol, propylene glycol, peanut oil, sesame oil, polyoxyethylene-block polymers, and the like.
- Ampules are convenient unit dosages.
- the compounds of the invention can also be incorporated into liposomes or administered via transdermal pumps or patches.
- Pharmaceutical admixtures suitable for use in the present invention include those described, for example, in Pharmaceutical Sciences (17th Ed., Mack Pub. Co., Easton, PA) and WO 96/05309, each of which is hereby incorporated by reference.
- Aqueous solutions suitable for oral use can be prepared by dissolving the active component in water and adding suitable colorants, flavors, stabilizers, and thickening agents as desired.
- Aqueous suspensions suitable for oral use can be made by dispersing the finely divided active component in water with viscous material, such as natural or synthetic gums, resins, methylcellulose, sodium carboxymethylcellulose, and other well-known suspending agents.
- liquid form preparations intended for conversion shortly before use to liquid form preparations for oral administration.
- liquid forms include solutions, suspensions, and emulsions.
- These preparations may contain, in addition to the active component, colorants, flavors, stabilizers, buffers, artificial and natural sweeteners, dispersants, thickeners, solubilizing agents, and the like.
- provided pharmaceutical compositions are in unit dosage form. In such form the composition is subdivided into unit doses containing appropriate
- the unit dosage form can be a packaged preparation, the package containing discrete quantities of a pharmaceutical composition, such as packeted tablets, capsules, and powders in vials or ampoules.
- the unit dosage form is a capsule, tablet, cachet, or lozenge itself, or it is the appropriate number of any of these in packaged form.
- the quantity of active component in a unit dosage form may be varied or adjusted from 0.1 mg to 10000 mg, more typically 1.0 mg to 1000 mg, most typically 10 mg to 500 mg, according to the particular application and the potency of the active component.
- provided compositions contain other compatible therapeutic agents.
- Some compounds may have limited solubility in water and may require a surfactant or other appropriate co-solvent in the composition.
- co-solvents include: Polysorbate 20, 60 and 80, Pluronic F-68, F-84 and P-103, cyclodextrin, and polyoxyl 35 castor oil.
- co-solvents are typically employed at a level between about 0.01 % and about 2% by weight.
- viscosity greater than that of simple aqueous solutions may be desirable to decrease variability in dispensing the formulations, to decrease physical separation of components of a suspension or emulsion of formulation and/or otherwise to improve the formulation.
- viscosity building agents include, for example, polyvinyl alcohol, polyvinyl pyrrolidone, methyl cellulose, hydroxy propyl methylcellulose, hydroxyethyl cellulose, carboxymethyl cellulose, hydroxy propyl cellulose, chondroitin sulfate and salts thereof, hyaluronic acid and salts thereof, combinations of the foregoing.
- Such agents are typically employed at a level between about 0.01% and about 2% by weight.
- compositions may additionally include components to provide sustained release and/or comfort.
- components include high molecular weight, anionic mucomimetic polymers, gelling polysaccharides and finely-divided drug carrier substrates. These components are discussed in greater detail in U.S. Pat. Nos. 4,911,920; 5,403,841; 5,212,162; and 4,861,760. The entire contents of these patents are incorporated herein by reference in their entirety for all purposes.
- compositions include compositions wherein the active ingredient is contained in a therapeutically effective amount, i.e., in an amount effective to
- compositions when administered in methods to treat cancer, provided compositions will contain an amount of active ingredient effective to achieve the desired result (e.g. decreasing the number of cancer cells in a subject).
- the dosage and frequency (single or multiple doses) of administered to a mammal can vary depending upon a variety of factors, including a disease that results in increased activity of PDK1, whether the mammal suffers from another disease, and its route of administration; size, age, sex, health, body weight, body mass index, and diet of the recipient; nature and extent of symptoms of the disease being treated (e.g., cancer), kind of concurrent treatment, complications from the disease being treated or other health-related problems.
- Other therapeutic regimens or agents can be used in conjunction with the methods and compounds of the invention.
- a therapeutically effective amount may be initially determined from cell culture assays.
- Target concentrations will be those concentrations of active compound(s) that are capable of reducing the activity of PDK1 catalytic activity, as measured, for example, using the methods described herein.
- Therapeutically effective amounts for use in humans may be determined from animal models. For example, a dose for humans can be formulated to achieve a concentration that has been found to be effective in animals. The dosage in humans can be adjusted by monitoring PDK1 inhibition and adjusting the dosage upwards or downwards, as described above.
- Dosages may be varied depending upon the requirements of the patient and the compound being employed.
- the dose administered to a patient is sufficient to effect a beneficial therapeutic response in the patient over time.
- the size of the dose also will be determined by the existence, nature, and extent of any adverse side-effects.
- treatment is initiated with smaller dosages that are less than the optimum dose of the compound. Thereafter, the dosage is increased by small increments until the optimum effect under circumstances is reached.
- the dosage range is 0.001% to 10% w/v. In another embodiment, the dosage range is 0.1 % to 5% w/v.
- a compound when reverse phase HPLC is used to purify a compound, a compound may exist as a mono-, di-, or tri- trifluoroacetic acid salt.
- the present invention contemplates individual compounds described herein. Where individual compounds exemplified are isolated and/or characterized as a salt, for example, as a trifluoroacetic acid salt, the present invention contemplates a free base of the salt, as well as other pharmaceutically acceptable salts of the free base.
- Step 1 Synthesis of 3-(l-(phenylsulfonyl)-lH-pyrrolo[2,3-b]pyridin-3- yl)benzaldehyde (Ex. 1.2): A flask charged with 3-bromo-l-(phenylsulfonyl)-lH-pyrrolo[2,3- b]pyridine (1.1, prepared by the method reported in application WO2008005457) (3.0 g, 8.9 mmol), bis(pinacolato)diboron (9.0 g, 35.6 mmol), KOAc (1.8 g, 17.8 mmol), Pd(dppf)Cl 2 CH 2 Ci2 (0.23 g, 0.28 mmol) and DMSO (1 ml) was flushed with nitrogen.
- 3-bromo-l-(phenylsulfonyl)-lH-pyrrolo[2,3- b]pyridine 1.1, prepared by the method reported in application WO20080054
- Step 2 Synthesis of methyl 2-(3-(l-(phenylsulfonyl)-lH-pyrrolo[2,3-b]pyridin-3- yl)benzyl-amino)nicotinate (Ex.
- Step 3 Synthesis of 2-(3-(lH-pyrrolo[2,3-b]pyridin-3-yl)benzylamino)nicotinic acid
- Examples 1.6-1.15 were prepared in a manner analogous to Ex. 1.5.
- Ex. 1.20 was prepared in a manner analogous to Ex. 1.5.
- Step 1 Synthesis of (S)-2-amino-N-(l-(4-fluorophenyl)ethyl)nicotinamide (Ex. 2.1): To a solution of 2-aminonicotinic acid (3g, 21.7 mmol) in DCM (100 ml), was added
- Step 2 Synthesis of (S)-2-(((5-bromothiophen-2-yl)methyl)amino)-N-(l-(4- fluorophenyl)ethyl)-nicotinamide: To a solution of (S)-2-amino-N-(l-(4- fluorophenyl)ethyl)nicotinamide (2.6g 10 mmol) in 5 mL of methanol was added 5- bromothiophene-2-carbaldehyde (2.29g, 12 mmol 1.2eq) at rt. The reaction mixture was heated to refluxing and stirred for 16 h.
- Step 3 (S)-N-(l-(4-fluorophenyl)ethyl)-2-(((5-(4,4,5,5-tetramethyl-l,3,2- dioxaborolan-2-yl)-thiophen-2-yl)methyl)amino)nicotinamide: A flask charged with (S)-2- (((5-bromothiophen-2-yl)methyl)amino)-N-(l-(4-fluorophenyl)ethyl)nicotinamide (0.58g, 1.4 mmol), 4,4,4',4',5,5,5',5'-octamethyl-2,2'-bi(l,3,2-dioxaborolane) (690 mg, 2.8 mmol, 2.0 equiv), KOAc (248 mg, 2.8 mmol, 2.0 equiv) and [l,l-Bis(diphenylphosphino)ferrocene] dichlor
- Examples 2.5 - 2.14 were prepared in a manner analogous to Ex. 2.4.
- Step 1 A solution of 5-amino-2-chloroisonicotinic acid (1.3 g, 7.6 mmol), formimidamide (0.66 g, 15.1 mmol, 2.0 equiv) in AcOH was heated to 120°C for 4 h. and then the solvent was removed, water was added and adjusted pH to 8 with NaHC03, filtered to give 6-chloropyrido[3,4-d]pyrimidin-4(3H)-one (1.1 g, yield 81.5%).
- Step 2 A solution of SOCl 2 (20 ml), 6-chloropyrido[3,4-d]pyrimidin-4(3H)-one (1.81 g, 10 mmol), and DMF (cat amount) was heated to reflux for 2 h. Evaporated off the solvents and the crude product was used for the next step without further purifications.
- ESI-MS M+H + ): 200.0.
- Step 3 The above product (2 g, 10 mmol) was dissolved in ammonia (20 ml), the reaction was stirred at rt for lh, and filtered to give 6-chloropyrido[3,4-d]pyrimidin-4-amine
- Examples 2.16 - 2.39 were prepared in a manner analogous to Ex. 2.4.
- Step 1 Synthesis of 4-chloro-5-iodo-7-(phenylsulfonyl)-7H-pyrrolo[2,3- d]pyrimidine: To a suspension of 4-chloro-5-iodo-7H-pyrrolo[2,3-d]pyrimidine (ref. Young, et al.
- Step 2 Synthesis of 5-iodo-N-(4-methoxybenzyl)-7-(phenylsulfonyl)-7H- pyrrolo[2,3-d]pyrimidin-4-amine: A mixture of 4-chloro-5-iodo-7-(phenylsulfonyl)-7H- pyrrolo[2,3-d]pyrimidine (420 mg, 1 mmol), K 2 CO 3 (280 mg, 2 mmol, 2 equiv), and p- methoxybenzylamine (280 mg, 2 mmol) in dioxane (200 ml) was heated to 90 °C for 1 h. The solvent was removed and the residue was purified on silica gel column to give the desired product (440 mg, 50%). ESI-MS (M+H + ): 521.
- Step 3 Synthesis of 5-iodo-7-(phenylsulfonyl)-7H-pyrrolo[2,3-d]pyrimidin-4- amine: A solution of 5-iodo-N-(4-methoxybenzyl)-7-(phenylsulfonyl)-7H-pyrrolo[2,3- d]pyrimidin-4-amine (520 mg, 1 mmol) in trifluoroacetic acid (10 ml) was heated to reflux for 1 h. Evaporated off the solvent and the residue was neutralized with NaHC0 3 and purified by column chromatography to give the desired product (344 mg, 86%>).
- Step 4 Synthesis of (S)-2-(((5-(4-amino-7-(phenylsulfonyl)-7H-pyrrolo[2,3- d]pyrimidin-5-yl)thiophen-2-yl)methyl)amino)-N-(l-(4-fluorophenyl)ethyl)nicotinamide: A mixture of (S)-N-(l-(4-fluorophenyl)ethyl)-2-(((5-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2- yl)thiophen-2-yl)methyl)amino)nicotinamide (400 mg, 0.83 mmol), 5-iodo-7-(phenylsulfonyl)- 7H-pyrrolo[2,3-d]pyrimidin-4-amine (332 mg, 0.83 mmol), 2M K 2 C0 3 (230 mg, 1.66 mmol), 2M K
- Step 1 A mixture 2,4-dibromo-5-nitropyridine (700 mg, 2.5 mmol), MeNH 2 (155 mg, 5mmol), and K 2 CO 3 (690 mg, 5 mmol) in DCM/H 2 0 was stirred at rt for 6 h. Evaporated off the solvents to give the product, 2-bromo-N-methyl-5-nitropyridin-4-amine, which was used in the next step without further purifications.
- ESI-MS M+H + ):232.0; 1H NMR (400 MHz, CDC1 3 ) ⁇ : 8.97(s, 1H), 6.93(s, 1H), 3.06(s, 3H).
- Step 2 A mixture of 2-bromo-N-methyl-5-nitropyridin-4-amine (519 mg, 2.2 mmol), iron (440 mg, 7.9 mmol), and NH 4 C1 (1.2 g, 22 mmol) in THF/H 2 0 was heated to reflux for 2 h. The reaction mixture was filtered, and THF was removed under vacuo to give the product, 6- bromo-N 4 -methylpyridine-3,4-diamine, which was used in the next step without further purifications.
- ESI-MS M+H + ):202.1; 1H NMR (400 MHz, CD 3 OD) ⁇ : 7.18 (s, 1H), 6.50 (s, 1H), 2.66 (s, 3H).
- Examples 3.7-3.87 were synthesized in an analogous manner to Example 3.6.
- Finely ground sodium triacetoxyborohydride (2.03 g, 9.58 mmol) was added portionwise, and the reaction was allowed to stir at room temperature overnight. The reaction was quenched by vigorously stirring with aqueous sodium bicarbonate (20 mL). Added ethyl acetate (125 mL) and washed twice with aqueous sodium bicarbonate, then with brine. The organic layer was dried over magnesium sulfate and evaporated. The crude boronic acid was isolated as a brown oil (1.18 g).
- the reaction was heated at 100 °C and monitored by LCMS. The reaction was complete after 1.5 hours, but was heated for a total of 2.5 hours.
- the reaction was cooled to room temperature, concentrated, and diluted with water (10 mL).
- the reaction was acidified with 2.35 mL IN hydrochloric acid and a white precipitate crashed out.
- the mixture was stirred overnight, filtered, washed with water, and dried under high-vacuum. Collected 222 mg of the carboxylic acid as a yellow solid (91 >).
- the solid was carried onto the next step by stirring in DCM (9.1 mL), adding thionyl chloride (334 ⁇ ), followed by triethylamine (500 ⁇ ) and stirring at room temperature.
- the reaction was done instantly, and the reaction was evaporated to dryness and the acid chloride was carried on as crude.
- Ex. 4.6 was prepared in a manner similar to Ex. 4.5 using 6-iodoquinazoline.
- Step 1 Synthesis of 4-chloro-5-iodo-7-(phenylsulfonyl)-7H-pyrrolo[2,3- d]pyrimidine: To a suspension of 4-chloro-5-iodo-7H-pyrrolo[2,3-d]pyrimidine (ref. Young, et al.
- Step 2 Synthesis of 5-iodo-7-(phenylsulfonyl)-N-(2,4,6-trimethoxybenzyl)-7H- pyrrolo[2,3-d]pyrimidin-4-amine: A suspension of 4-chloro-5-iodo-7-(phenylsulfonyl)-7H- pyrrolo[2,3-d]pyrimidine (0.5 g, 0.001 mol), 2,4,6-Trimethoxybenzylamine hydrochloride (0.31 g, 0.0013 mol), and Cesium Carbonate (0.78 g, 0.0024 mol) in trifluoromethylbenzene (100 mL, 1 mol) was heated to reflux for overnight.
- Step 3 Synthesis of N-(3,4-difluorobenzyl)-2-(((5-(7-(phenylsulfonyl)-4-(2,4,6- trimethoxybenzylamino)-7H-pyrrolo[2,3-d]pyrimidin-5-yl)thiophen-2- yl)methyl)amino)nicotinamide: A mixture of 2-[(5-Bromo-thiophen-2-ylmethyl)-amino]-N- (3,4-difluoro-benzyl)-nicotinamide 2-[(5-Bromo-thiophen-2-ylmethyl)-amino]-N-(3,4-difluoro- benzyl)-nicotinamide (200 mg, 0.4 mmol), bis(pinacolato)diboron (100 mg, 0.4 mmol), Potassium acetate (170 mg, 1.8 mmol), and [l,l'-B
- the reaction was microwaved on 150 watts, 90°C for 10 minutes and LC-MS showed no more starting materials.
- the above reaction mixture was then added 5-iodo-7-(phenylsulfonyl)-N- (2,4,6-trimethoxybenzyl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine (300 mg, 0.4 mmol) and 1.2 M of Sodium bicarbonate in water(0.7 mL, 0.8 mmol) and was microwaved on 150 watts , 90°C for 10 minutes and LC-MS showed the formation of the desired product (1.66min, ES+/812.3). Worked up with water and DCM, dried over MgS0 4 . Purified on silica gel column with 0-60% EtOAc in hexane to give the desired product (lOOmg, 30%>).
- the reaction was diluted with 60 mL ethyl acetate, filtered through Celite, and washed with 60 mL ethyl acetate.
- the combined organic extracts were washed twice with water, then brine, dried over magnesium sulfate and evaporated. Collected 0.38g of a crude heterogeneous material.
- Ex. 4.11 N-(3,4-difluorobenzyl)-2-(((5-(4-morpholinoquinazolin-6-yl)thiophen-2- yl)methyl)amino)nicotinamide: Ex. 4.11 was prepared in a similar manner as in Examples 4.9 and 4.10 from N-cyclopropyl-6-iodoquinazolin-4-amine (Prepared from 4-chloro-6- iodoquinazoline and morpholine following the same procedure as 2-(6-iodoquinazolin-4- ylamino)ethanol in the synthesis of Ex. 2.14.).
- reaction was microwaved on 300 watts, 110°C for 10 minutes.
- the reaction mixture was filtered, was washed H 2 0 (DI), was extracted EtOAc, dried over sodium sulfate and solvent removed in vacuo. Purification was done by HPLC to yield desired product as a TFA salt. Collected 17.8 mg solid yellow powder (47% yield).
- Ex. 4.13 was prepared in a manner consistent with Ex. 4.12 from 1-Propanamine.
- Ex. 4.14 was prepared in a manner consistent with Ex. 4.12 from methoxylamine hydrochloride.
- Ex. 4.15 was prepared in a manner consistent with Ex. 4.12 from dimethylamine.
- Ex. 4.16 was prepared in a manner consistent with Ex. 4.12 from ethylamine.
- Ex. 4.17 was prepared in a manner consistent with Ex. 4.12 from diethylamine.
- Ex. 4.18 was prepared in a manner consistent with Ex. 4.12 from n-pentylamine.
- Ex. 4.19 was prepared in a manner consistent with Ex. 4.12 from pyrrolidine.
- Ex. 4.20 was prepared in a manner consistent with Ex. 4.12 from 1- Pyrrolidineethanamine .
- Ex. 4.21 was prepared in a manner consistent with Ex. 4.12 from N-methyl- cy clohexanamine .
- Ex. 4.22 was prepared in a manner consistent with Ex. 4.12 from 2,2,2-Trifluoro- ethylamine.
- Ex. 4.23 was prepared in a manner consistent with Ex. 4.12 from tert-Butylamine.
- Ex. 4.24 was prepared in a manner consistent with Ex. 4.12 from methylamine.
- Ex. 5.3 was synthesized in a manner consistent with Ex. 4.5. Purification was done by HPLC to yield desired product as a TFA salt. Collected 38.7 mg solid yellow powder (77% yield). LC-MS (Agilent 460, acidic method): RT: 1.2 min.
- Ex. 5.4 was synthesized in a manner consistent with Ex. 4.5. and Ex. 5.4. Purification was done by HPLC to yield desired product as a TFA salt. Collected 21.4 mg solid off white powder (42% yield). LC-MS (Agilent 460, acidic method): RT: 1.2 min.
- Ex. 5.5 was synthesized in a manner consistent with Ex. 4.5. Purification was done by HPLC to yield desired product as a TFA salt. Collected 35.3 mg solid off white powder (64%> yield). LC-MS (Agilent 460, acidic method): RT: 1.2 min.
- Ex. 5.7 was synthesized in a manner consistent with Ex. 4.5, from 3-iodo-l- (phenylsulfonyl)-lH-pyrrolo[2,3-b]pyridine, followed with phenylsulfonyl deprotection with potassium in methanol to yield desired product as a TFA salt. Collected 30.6 mg solid yellow powder (62% yield). LC-MS (Agilent 460, acidic method): RT: 1.2 min.
- Ex. 5.8 was synthesized in a manner consistent with Ex. 4.5, from 5-iodo-7- (phenylsulfonyl)-7H-pyrrolo[2,3-d]pyrimidine, followed with phenylsulfonyl deprotection with potassium in methanol to yield desired product as a TFA salt. Collected 24.5 mg solid yellow powder (49% yield). LC-MS (Agilent 460, acidic method): RT: 1.1 min.
- Step 1 Synthesis of 2-(3-bromobenzylamino)-N-(3,4- difluorobenzyl)nicotinamide: 2-Amino-N-(3,4-difluoro-benzyl)-nicotinamide (1.00 g, 3.80 mmol) was dissolved in 1 ,2-dichloroethane (19.00 mL, 241.2 mmol). To this was added Acetic acid (cat), 3-Bromobenzaldehyde (664 ⁇ ,, 5.70 mmol), pre-stirred for 60 minutes, and then Sodium triacetoxyborohydride (1.61 g, 7.60 mmol).
- Step 2 Synthesis of N-(3,4-difluorobenzyl)-2-(3-(4-(2,4- dimethoxybenzylamino)quinazolin-6-yl)benzylamino)nicotinamide: Into a vial was added 2- (3-Bromo-benzylamino)-N-(3,4-difluoro-benzyl)-nicotinamide (95.00 mg, 0.2198 mmol) ,(2,4- Dimethoxy-benzyl)-[6-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)-quinazolin-4-yl]-amine (111 mg, 0.264 mmol) and [l, -Bis(diphenylphosphino)ferrocene] dichloropalladium(II),complex with dichloromethane (1 : 1) (22 mg, 0.026 mmol).
- Ex. 6.3 was prepared following the procedure for Ex. 6.1 from (6-Bromo-quinazolin- 4-yl)-cyclopropyl-amine.
- Ex. 6.4 was prepared following the procedure for Ex. 6.2 from 2-bromobenzaldehyde and l-(phenylsulfonyl)-3-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)-lH-pyrrolo[2,3- b]pyridine.
- Ex. 6.5 was prepared following the procedure for Ex. 6.1 from 2-bromobenzaldehyde and N-(2,4-dimethoxybenzyl)-6-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)quinazolin-4- amine.
- Ex. 6.6 was prepared following the procedure for Ex. 6.1 from 2-bromothiazole-5- carbaldehyde and N-(2,4-dimethoxybenzyl)-6-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2- yl)quinazolin-4-amine.
- Ex. 6.7 was prepared following the procedure for Ex. 6.1 from 4-bromothiazole-2- carbaldehyde and N-(2,4-dimethoxybenzyl)-6-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2- yl)quinazolin-4-amine.
- Ex. 6.8 was prepared following the procedure for Ex. 6.1 from 2-bromothiazole-4- carbaldehyde and N-(2,4-dimethoxybenzyl)-6-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2- yl)quinazolin-4-amine.
- Ex. 6.9 was prepared following the procedure for Ex. 6.1 from 2-bromothiazole-4- carbaldehyde and N-cyclopropyl-6-(4,4,5,5-tetramethyl-l ,3,2-dioxaborolan-2-yl)quinazolin-4- amine.
- Ex. 6.10 was prepared following the procedure for Ex. 6.2 from 2-bromothiazole-5- carbaldehyde and l-Benzenesulfonyl-3-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)-lH- pyrrolo[2,3-b]pyridine.
- Ex. 6.11 was prepared following the procedure for Ex. 6.2 from 4-bromothiazole-2- carbaldehyde and l-Benzenesulfonyl-3-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)-lH- pyrrolo[2,3-b]pyridine.
- Ex. 6.12 was prepared following the procedure for Ex. 6.2 from 2-bromothiazole-4- carbaldehyde and l-Benzenesulfonyl-3-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)-lH- pyrrolo[2,3-b]pyridine.
- Ex. 6.13 was prepared following the procedure for Ex. 6.2 from 5-bromo-7- (phenylsulfonyl)-7H-pyrrolo[2,3-d]pyrimidine and 2-[(2-Bromo-thiazol-4-ylmethyl)-amino]-N- (3,4-difluoro-benzyl)-nicotinamide.
- Ex. 6.14 was prepared following the procedure for Ex. 6.1 from 4-bromo-thiophene- 2-carbaldehyde and (2,4-dimethoxy-benzyl)-[6-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)- quinazolin-4-yl]-amine.
- Ex. 6.15 was prepared following the procedure for Ex. 6.2 from 4-bromothiophene-2- carbaldehyde and l-Benzenesulfonyl-3-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)-lH- pyrrolo[2,3-b]pyridine.
- Step 1 Synthesis of tert-butyl thiazol-2-ylmethylcarbamate: To a solution of thiazol-2-ylmethanamine (1.14 g, 10 mmol) in THF (10 mL), was added NaHC0 3 (920 mg, 11 mmol, 1.1 equiv) and (Boc) 2 0 (2.18 g, 10 mmol, 1.05 equiv) slowly. The resulted mixture was stirred at rt for 2 h. The reaction was filtrated through a short path of silica gel and concentrated to give tert-butyl thiazol-2-ylmethylcarbamate (2.05g, 96%).
- Step 2 Synthesis of tert-butyl (5-bromothiazol-2-yl)methylcarbamate: The mixture of tert-butyl thiazol-2-ylmethylcarbamate (2 g, 9.5 mmol), NBS (1.78 g, 10 mmol, 1.1 equiv) in DMF (20 mL) was stirred at rt for 2 h. The reaction was diluted with ethyl acetate and washed with water for three times. The organic layer was dried over MgS0 4 and concentrated in vacuum. The residue was purified by chromatography with silica gel to give the desired product (2.24 g, 80%).
- Step 3 Synthesis of tert-butyl (5-(4-(di-Boc-amino)quinazolin-6-yl)thiazol-2- yl)methylcarbamate: A flask charged with compound di-Boc-6-(4,4,5,5-tetramethyl-l,3,2- dioxaborolan-2-yl)quinazolin-4-amine (2.35 g, 5 mmol), tert-butyl (5-bromothiazol-2- yl)methylcarbamate (1.46 g, 5 mmol, 1.0 equiv), 2M K 2 C0 3 (5.0 mL, 2.0 equiv) and [1,1 -bis
- Step 4 Synthesis of 6-(2-(aminomethyl)thiazol-5-yl)quinazolin-4-amine (7.1a): A solution of tert-butyl (5-(4-(di-Boc-amino)quinazolin-6-yl)thiazol-2-yl)methylcarbamate: (1.5 g, 2.7 mmol) in DCM/TFA (30 mL, 1 : 1) was stirred at rt for 30 min, then the solvent was removed and the residue was dissolved in water. Sat aqueous NaHC0 3 was added, white solid was formed, filtered to give the desired product (690 mg, 100%).
- Ex. 7.2 was prepared following the procedure for Ex. 7.1 from l-(thiophen-2- yl)ethanamine.
- Ex. 7.3.1 was prepared following the procedure for Ex. 7.1 from 6-(5- (aminomethyl)thiophen-2-yl)quinazolin-4-amine (7.1b) and 2-chloro-N-(3,4-difluorobenzyl)-5- fluoronicotinamide .
- Ex. 7.3.2 was prepared by an analogous procedure to Ex. 7.3.1.
- Ex. 7.4 was prepared following the procedure for Ex. 7.1 from 6-(5- (aminomethyl)thiophen-2-yl)quinazolin-4-amine (7.1b) and 2-chloro-N-(3,4-difluorobenzyl)-4- methoxynicotinamide .
- Ex. 7.5 was prepared following the procedure for Ex. 7.1 from 6-(5- (aminomethyl)thiophen-2-yl)quinazolin-4-amine (7.1b) and 2-chloro-N-(3,4-difluorobenzyl)-4- ethoxynicotinamide .
- Ex. 7.6 was prepared following the procedure for Ex. 7.1 from 6-(5- (aminomethyl)thiophen-2-yl)quinazolin-4-amine (7.1b) and (S)-2-chloro-N-(l-(4- fluorophenyl)ethyl)-4-methoxynicotinamide.
- Ex. 7.7 was prepared following the procedure for Ex. 7.1 from 6-(5- (aminomethyl)thiophen-2-yl)quinazolin-4-amine (7.1b) and (S)-2-chloro-N-(l-(4- fluorophenyl)ethyl)-4-ethoxynicotinamide.
- Ex. 7.8 was prepared following the procedure for Ex. 7.1 from 6-(5- (aminomethyl)thiophen-2-yl)quinazolin-4-amine (7.1b) and 5-chloro-3-(3,4- difluorobenzy l)pyrido [4 , 3 -d]pyrimidin-4(3 H)-one .
- Ex. 7.9 was prepared following the procedure for Ex. 7.1 from 6-(5- (aminomethyl)thiophen-2-yl)quinazolin-4-amine (7.1b) and (S)-5-chloro-3-(l-(4- fluorophenyl)ethyl)pyrido[4,3-d]pyrimidin-4(3H)-one.
- Examples 7.10-7.16 were prepared in a manner analogous to Ex. 7.1.
- Ex. 7.17 was prepared following the procedure for Ex. 7.1 from 6-(5- (aminomethyl)thiophen-2-yl)quinazolin-4-amine (7.1b) and 5,7-dichloro-3-(3,4- difluorobenzy l)pyrido [4 , 3 -d]pyrimidin-4(3 H)-one .
- Ex. 7.18 was prepared following the procedure for Ex. 7.1 from 6-(5- (aminomethyl)thiophen-2-yl)quinazolin-4-amine (7.1b) and 8-chloro-2-(3,4-difiuorobenzyl)-3,4- dihydro-2,7-naphthyridin- 1 (2H)-one.
- Methyl 2-chloro-4-cyanonicotinate (392 mg, 2mmol) was hydrogenated in the presence of 10% Pt/C (150 mg) catalyst at atmospheric pressure in abs methanol (25 mL) for 36h. The catalyst was filtered off and the solvent was evaporated off to give methyl 4- (aminomethyl)-2-chloronicotinate as a light yellow solid, (0.472 g, 100%).
- ESI-MS (M-35) + 201.0.
- Ex. 7.19 was prepared following the procedure for Ex. 7.1 from 6-(5- (aminomethyl)thiophen-2-yl)quinazolin-4-amine (7.1b) and 4-chloro-2-(3,4-difluorobenzyl)-lH- pyrrolo[3,4-c]pyridin-3(2H)-one.
- Ex. 7.21.1 was prepared following the procedure for Ex. 7.1 from 6-(5- (aminomethyl)thiophen-2-yl)quinazolin-4-amine (7.1b) and (S)-2-chloro-N-(l-(3,4- difluorophenyl)ethyl)-5-iodonicotinamide.
- LCMS RT 1.60 min.
- Ex. 7.21.2 was prepared in a manner analogous to Ex. 7.21.1.
- Ex. 7.22.2 was prepared in a manner analogous to Ex. 7.22.1.
- Ex. 7.23.2 was prepared in a manner analogous to Ex. 7.23.1.
- Ex. 7.24.2-7.24.6 were prepared in a manner analogous to Ex. 7.24.1.
- Ex. 8.1.1 was prepared following the procedure for Ex. 6.1 from 2-(((5- bromothiophen-2-yl)methyl)amino)-N-(3,4-difiuorobenzyl)-5-iodonicotinamide and N-(2,4- dimethoxybenzyl)-6-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)quinazolin-4-amine.
- LC-MS Alent 460, acidic method
- RT 1.4 min.
- Ex. 8.2 was prepared following the procedure for Ex. 6.1 from 2-(((5-bromothiophen- 2-yl)methyl)amino)-N-(3,4-difiuorobenzyl)-5-nitronicotinamide and N-(2,4-dimethoxybenzyl)- 6-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)quinazolin-4-amine.
- LC-MS Alent 460, acidic method
- Ex. 8.3 was prepared following the procedure for Ex. 6.1 from 2-(((5-bromothiophen- 2-yl)methyl)amino)-N-(3,4-difiuorobenzyl)-5-iodonicotinamide and N-(2,4-dimethoxybenzyl)-6- (4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)quinazolin-4-amine.
- LC-MS Alent 460, acidic method
- the crude reaction mixture was purged under an atmosphere of Nitrogen.
- the reaction was microwaved on 300 watts, 140°C for 30 minutes.
- the crude reaction mixture was diluted EtOAc and was filtered. The filtrate was washed (brine), was extracted EtOAc, dried over sodium sulfate and solvent removed in vacuo. Purification was done by HPLC to yield desired product as a TFA salt.
- Ex. 8.9 was prepared following the procedure for Ex. 6.1 from 2-(((5-bromothiophen- 2-yl)methyl)amino)-N-(3,4-difluorobenzyl)-5-bromonicotinamide and N-(2,4-dimethoxybenzyl)- -(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)quinazolin-4-amine.
- Examples 8.12.2-8.12.8 were prepared in a manner analogous to Ex. 8.12.1.
- Ex. 8.14.1 was prepared following the procedure for Ex. 6.1 from 2-(((5- bromothiophen-2-yl)methyl)amino)-N-(3 ,4-difluorobenzyl)quinoline-3 -carboxamide and 6-
- Examples 8.14.2-8.14.4 were prepared in a manner analogous to Ex. 8.14.1.
- reaction mix was then concentrated and purified on a short silica gel column with DCM to give the desired product as a white solid, which was then dissolved back in Methylene chloride (20mL) and added 3,4- Difluoro-benzylamine (1200 ⁇ , 0.010 mol), followed with addition of a solution of Zirconium tetrachloride (0.5 g, 0.002 mol) in Acetonitrile (5 mL, 0.1 mol) and stirred for lh. LC-MS showed clean conversion to the desired product (1.58min, ES+/323.25). The mix was then diluted with EtOAc and filtered thru a silica gel cake and washed with EtOAc.
- Ex. 8.15.1 was prepared following the procedure for Ex. 6.1 from 2-(((5- bromothiophen-2-yl)methyl)amino)-N-(3,4-difluorobenzyl)-6,7-dihydro-5H- cyclopenta[b]pyridine-3-carboxamide and 6-(4,4,5,5-Tetramethyl-l,3,2-dioxaborolan-2-yl)- quinazolin-4-ylamine .
- Ex. 8.15.2 was prepared in a manner analogous to Ex. 8.15.1.
- N 4 -(2,4-dimethoxybenzyl)quinazoline-4,6-diamine N-(2,4- dimethoxybenzyl)-6-nitroquinazolin-4-amine (102.3 mg, 0.3006 mmol), tin dichloride (285 mg,
- the reaction was stirred at room temperature for 2 hours before being diluted by 4mL of 1 : 1 water:tert-butanol and heating at 60 °C for 1 hour.
- the reaction was cooled to room temperature, diluted with 175 mL ethyl acetate and washed with 75 mL of 1 :1 ammonium chloride (saturated, aqueous)/NaOH(lN, aqueous), 75 mL aqueous sodium bicarbonate, and 75 mL brine.
- the organic phase was dried over magnesium sulfate, evaporated to yield a powder.
- the powder was triturated with methylene chloride followed by ethyl acetate to yield an off-white powder (67.2 mg).
- Example 9.2 was synthesized in a manner analogous to Ex. 9.1.
- N-(3,4-difluorobenzyl)-3-((5-(4-(2,4-dimethoxybenzylamino)quinazolin-6- yl)thiophen-2-yl)methyl)amino)pyrazine-2-carboxamide (120.9 mg, 0.1849 mmol) was stirred in trifluoroacetic acid (2.0 mL) at 40 °C for 1.5 hours. The reaction was diluted with 2 mL dichloromethane, and slowly quenched with saturated aqueous sodium carbonate. Added 75 mL ethyl acetate and washed twice with 50 mL aqueous sodium bicarbonate, then 50 mL brine. The organic phase was dried over magnesium sulfate, evaporated, and purified by flash chromatography (0-8% methanol: dichloromethane). Collected 41.2mg of a yellow powder
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Pyridine Compounds (AREA)
- Enzymes And Modification Thereof (AREA)
- Peptides Or Proteins (AREA)
- Treating Waste Gases (AREA)
Abstract
Description
Claims
Priority Applications (35)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP18207990.5A EP3466929B1 (en) | 2009-10-06 | 2010-10-05 | Heterocyclic compounds useful as pdk1 inhibitors |
ES10822550.9T ES2586856T3 (en) | 2009-10-06 | 2010-10-05 | Heterocyclic compounds useful as PDK1 inhibitors |
JP2012533248A JP6016635B2 (en) | 2009-10-06 | 2010-10-05 | Heterocyclic compounds useful as PDK1 inhibitors |
SI201031251A SI2485731T1 (en) | 2009-10-06 | 2010-10-05 | Heterocyclic compounds useful as pdk1 inhibitors |
US13/499,835 US9546165B2 (en) | 2009-10-06 | 2010-10-05 | Heterocyclic compounds useful as PDK1 inhibitors |
EP16167938.6A EP3070077B1 (en) | 2009-10-06 | 2010-10-05 | Heterocyclic compounds useful as pdk1 inhibitors |
LTEP10822550.9T LT2485731T (en) | 2009-10-06 | 2010-10-05 | Heterocyclic compounds useful as pdk1 inhibitors |
IL295518A IL295518B2 (en) | 2009-10-06 | 2010-10-05 | Heterocyclic compounds useful as pdk1 inhibitors |
CA2776690A CA2776690C (en) | 2009-10-06 | 2010-10-05 | Heterocyclic compounds useful as pdk1 inhibitors |
KR1020197003115A KR102097664B1 (en) | 2009-10-06 | 2010-10-05 | Heterocyclic Compounds Useful as PDK1 Inhibitors |
KR1020177034734A KR101947307B1 (en) | 2009-10-06 | 2010-10-05 | Heterocyclic Compounds Useful as PDK1 Inhibitors |
EP10822550.9A EP2485731B1 (en) | 2009-10-06 | 2010-10-05 | Heterocyclic compounds useful as pdk1 inhibitors |
IL302896A IL302896A (en) | 2009-10-06 | 2010-10-05 | Heterocyclic compounds useful as pdk1 inhibitors |
CN201080055337.2A CN102665718B (en) | 2009-10-06 | 2010-10-05 | Can be used as the heterocyclic compound of PDK1 inhibitor |
AU2010303567A AU2010303567B2 (en) | 2009-10-06 | 2010-10-05 | Heterocyclic compounds useful as PDK1 inhibitors |
RS20160640A RS55101B1 (en) | 2009-10-06 | 2010-10-05 | Heterocyclic compounds useful as pdk1 inhibitors |
IL266563A IL266563B (en) | 2009-10-06 | 2010-10-05 | Heterocyclic compounds useful as pdk1 inhibitors |
KR1020127011581A KR20120087936A (en) | 2009-10-06 | 2010-10-05 | Heterocyclic compounds useful as pdk1 inhibitors |
RU2012118667A RU2615130C2 (en) | 2009-10-06 | 2010-10-05 | Heterocyclic compounds useful as pdk1 inhibitors |
IN3883DEN2012 IN2012DN03883A (en) | 2009-10-06 | 2010-10-05 | |
MX2012004114A MX353257B (en) | 2009-10-06 | 2010-10-05 | Heterocyclic compounds useful as pdk1 inhibitors. |
DK10822550.9T DK2485731T3 (en) | 2009-10-06 | 2010-10-05 | Heterocyclic compounds that are useful as PDK1 INHIBITORS |
BR112012007747A BR112012007747B8 (en) | 2009-10-06 | 2010-10-05 | heterocyclic compounds useful as pdk1 inhibitors, their pharmaceutical composition and their uses |
IL218915A IL218915B (en) | 2009-10-06 | 2012-03-28 | Heterocyclic compounds useful as pdk1 inhibitors |
HK12108807.2A HK1168044A1 (en) | 2009-10-06 | 2012-09-10 | Heterocyclic compounds useful as pdk1 inhibitors pdk1 |
US14/966,821 US10030016B2 (en) | 2009-10-06 | 2015-12-11 | Heterocyclic compounds useful as PDK1 inhibitors |
HRP20160967TT HRP20160967T1 (en) | 2009-10-06 | 2016-07-29 | Heterocyclic compounds useful as pdk1 inhibitors |
CY20161100796T CY1118143T1 (en) | 2009-10-06 | 2016-08-10 | Heterocyclic compounds useful as PDK1 inhibitors |
SM201600275T SMT201600275B (en) | 2009-10-06 | 2016-08-12 | USEFUL HETEROCYCLIC COMPOUNDS AS INHIBITORS OF PDK1 |
AU2016225896A AU2016225896C1 (en) | 2009-10-06 | 2016-09-09 | Heterocyclic compounds useful as PDK1 inhibitors |
US15/987,523 US20190119268A1 (en) | 2009-10-06 | 2018-05-23 | Heterocyclic compounds useful as pdk1 inhibitors |
AU2018222943A AU2018222943B2 (en) | 2009-10-06 | 2018-08-29 | Heterocyclic compounds useful as PDK1 inhibitors |
US16/904,890 US20210070752A1 (en) | 2009-10-06 | 2020-06-18 | Heterocyclic compounds useful as pdk1 inhibitors |
US17/814,224 US20230113598A1 (en) | 2009-10-06 | 2022-07-21 | Heterocyclic compounds useful as pdk1 inhibitors |
US18/632,638 US20240294524A1 (en) | 2009-10-06 | 2024-04-11 | Heterocyclic compounds useful as pdk1 inhibitors |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US24909509P | 2009-10-06 | 2009-10-06 | |
US61/249,095 | 2009-10-06 |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/499,835 A-371-Of-International US9546165B2 (en) | 2009-10-06 | 2010-10-05 | Heterocyclic compounds useful as PDK1 inhibitors |
US14/966,821 Division US10030016B2 (en) | 2009-10-06 | 2015-12-11 | Heterocyclic compounds useful as PDK1 inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2011044157A1 true WO2011044157A1 (en) | 2011-04-14 |
Family
ID=43857093
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2010/051517 WO2011044157A1 (en) | 2009-10-06 | 2010-10-05 | Heterocyclic compounds useful as pdk1 inhibitors |
Country Status (27)
Country | Link |
---|---|
US (6) | US9546165B2 (en) |
EP (3) | EP2485731B1 (en) |
JP (5) | JP6016635B2 (en) |
KR (3) | KR20120087936A (en) |
CN (1) | CN102665718B (en) |
AR (2) | AR078540A1 (en) |
AU (3) | AU2010303567B2 (en) |
BR (1) | BR112012007747B8 (en) |
CA (1) | CA2776690C (en) |
CY (1) | CY1118143T1 (en) |
DK (2) | DK2485731T3 (en) |
ES (2) | ES2712875T3 (en) |
HK (1) | HK1168044A1 (en) |
HR (1) | HRP20160967T1 (en) |
HU (2) | HUE043536T2 (en) |
IL (4) | IL266563B (en) |
IN (1) | IN2012DN03883A (en) |
LT (1) | LT2485731T (en) |
MX (1) | MX353257B (en) |
PL (1) | PL2485731T4 (en) |
PT (1) | PT2485731T (en) |
RS (1) | RS55101B1 (en) |
RU (2) | RU2017109664A (en) |
SI (1) | SI2485731T1 (en) |
SM (1) | SMT201600275B (en) |
TW (1) | TWI525093B (en) |
WO (1) | WO2011044157A1 (en) |
Cited By (40)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2012034526A1 (en) * | 2010-09-16 | 2012-03-22 | Hutchison Medipharma Limited | Fused heteroaryls and their uses |
CN102627632A (en) * | 2012-04-16 | 2012-08-08 | 中国科学院广州生物医药与健康研究院 | Amino quinazoline derivative and preparation method as well as application thereof |
US8389718B2 (en) | 2010-07-20 | 2013-03-05 | Vestaron Corporation | Insecticidal triazines and pyrimidines |
CN103159741A (en) * | 2011-12-19 | 2013-06-19 | 天津市国际生物医药联合研究院 | Preparation and application of novel tyrosine kinase inhibitor |
US20140309211A1 (en) * | 2011-03-30 | 2014-10-16 | Arrien Pharmaceuticals Llc | Substituted 5-(pyrazin-2-yl)-1h-pyrazolo [3, 4-b] pyridine and pyrazolo [3, 4-b] pyridine derivatives as protein kinase inhibitors |
WO2015012328A1 (en) | 2013-07-24 | 2015-01-29 | 武田薬品工業株式会社 | Heterocyclic compound |
US9034900B2 (en) | 2013-10-18 | 2015-05-19 | Quanticel Pharmaceuticals, Inc. | Bromodomain inhibitors |
JP2015516429A (en) * | 2012-05-08 | 2015-06-11 | アンヴィル エルエルシー | Alpha 7 nicotinic acetylcholine receptor allosteric modulators, derivatives thereof and uses thereof |
US20160107996A1 (en) * | 2013-03-14 | 2016-04-21 | The Board Of Trustees Of The Le-Land Stanford Junior University | Mitochondrial Aldehyde Dehyrogenase-2 Modulators and Methods of Use Thereof |
US9334244B2 (en) | 2010-05-12 | 2016-05-10 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of ATR kinase |
WO2016075224A1 (en) | 2014-11-14 | 2016-05-19 | Nerviano Medical Sciences S.R.L. | 6-amino-7-bicyclo-7-deaza-purine derivatives as protein kinase inhibitors |
US9365557B2 (en) | 2008-12-19 | 2016-06-14 | Vertex Pharmaceuticals Incorporated | Substituted pyrazin-2-amines as inhibitors of ATR kinase |
US9469637B2 (en) | 2012-04-25 | 2016-10-18 | Takeda Pharmaceutical Company Limited | Nitrogenated heterocyclic compound |
US9527841B2 (en) | 2012-07-13 | 2016-12-27 | Takeda Pharmaceutical Company Limited | Substituted pyrido[2,3-b]pyrazines as phosphodiesterase 2A inhibitors |
WO2017015152A1 (en) | 2015-07-17 | 2017-01-26 | Memorial Sloan-Kettering Cancer Center | Combination therapy using pdk1 and pi3k inhibitors |
US9630968B1 (en) | 2015-12-23 | 2017-04-25 | Arqule, Inc. | Tetrahydropyranyl amino-pyrrolopyrimidinone and methods of use thereof |
US9630956B2 (en) | 2010-05-12 | 2017-04-25 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of ATR kinase |
WO2017070565A1 (en) | 2015-10-23 | 2017-04-27 | Sunesis Pharmaceuticals, Inc. | Heterocyclic pdk1 inhibitors for use to treat cancer |
KR101753652B1 (en) * | 2015-10-21 | 2017-07-05 | 한국화학연구원 | Novel N-aryl-1H-pyrazolopyridin-3-amine derivatives or pharmaceutically acceptable salts thereof, preparation method therof and pharmaceutical composition for use in preventing or treating MELK(maternal embryonic leucine zipper kinase) activity related diseases containing the same as an active ingredient |
KR101753654B1 (en) | 2015-10-21 | 2017-07-05 | 한국화학연구원 | Novel 3-(4-(piperazin-1-yl)benzamido)-1H-pyrazolopyridine derivatives or pharmaceutically acceptable salts thereof, preparation method thereof and pharmaceutical composition for use in preventing or treating MELK(maternal embryonic leucine zipper kinase) activity related diseases containing the same as an active ingredient |
US9791456B2 (en) | 2012-10-04 | 2017-10-17 | Vertex Pharmaceuticals Incorporated | Method for measuring ATR inhibition mediated increases in DNA damage |
WO2017184491A1 (en) | 2016-04-19 | 2017-10-26 | Celgene Quanticel Research, Inc. | Histone demethylase inhibitors |
WO2017184462A1 (en) | 2016-04-18 | 2017-10-26 | Celgene Quanticel Research, Inc. | Therapeutic compounds |
US9834520B2 (en) | 2013-03-14 | 2017-12-05 | Takeda Pharmaceutical Company Limited | Heterocyclic compound |
US9862709B2 (en) | 2011-09-30 | 2018-01-09 | Vertex Pharmaceuticals Incorporated | Processes for making compounds useful as inhibitors of ATR kinase |
US10053468B2 (en) | 2013-07-03 | 2018-08-21 | Takeda Pharmaceutical Company Limited | Heterocyclic compound |
US10131668B2 (en) | 2012-09-26 | 2018-11-20 | The Regents Of The University Of California | Substituted imidazo[1,5-a]pYRAZINES for modulation of IRE1 |
CN109087534A (en) * | 2018-10-09 | 2018-12-25 | 王业宝 | A kind of traffic conflict detection method based on vehicle driving trace |
US10457659B2 (en) | 2011-04-29 | 2019-10-29 | The Board Of Trustees Of The Leland Stanford Junior University | Compositions and methods for increasing proliferation of adult salivary stem cells |
US10472376B2 (en) | 2013-07-03 | 2019-11-12 | Takeda Pharmaceutical Company Limited | Amide compound |
US10478430B2 (en) | 2012-04-05 | 2019-11-19 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of ATR kinase and combination therapies thereof |
US10813929B2 (en) | 2011-09-30 | 2020-10-27 | Vertex Pharmaceuticals Incorporated | Treating cancer with ATR inhibitors |
WO2021064141A1 (en) * | 2019-10-02 | 2021-04-08 | Tolremo Therapeutics Ag | Inhibitors of dual specificity tyrosine phosphorylation regulated kinase 1b |
US11020398B2 (en) | 2016-08-24 | 2021-06-01 | Arqule, Inc. | Amino-pyrrolopyrimidinone compounds and methods of use thereof |
EP3831383A1 (en) | 2015-04-15 | 2021-06-09 | Celgene Quanticel Research, Inc. | Bromodomain inhibitors |
US11464774B2 (en) | 2015-09-30 | 2022-10-11 | Vertex Pharmaceuticals Incorporated | Method for treating cancer using a combination of DNA damaging agents and ATR inhibitors |
US11618753B2 (en) | 2018-01-26 | 2023-04-04 | Bristol-Myers Squibb Company | Aminopyrrolotriazines as kinase inhibitors |
WO2023112056A1 (en) * | 2021-12-17 | 2023-06-22 | Pi Industries Ltd. | Novel substituted fused bicyclic pyridine carboxamide compounds for combating phytopathogenic fungi |
WO2024040241A1 (en) | 2022-08-19 | 2024-02-22 | Viracta Therapeutics, Inc. | Pharmaceutical formulations, processes for preparation, and methods of use |
WO2024040242A1 (en) | 2022-08-19 | 2024-02-22 | Viracta Therapeutics, Inc. | Combinations of pdk1 inhibitors and kinase inhibitors |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
HUE043536T2 (en) | 2009-10-06 | 2019-08-28 | Millennium Pharm Inc | Heterocyclic compounds useful as pdk1 inhibitors |
JP2013529200A (en) * | 2010-05-12 | 2013-07-18 | バーテックス ファーマシューティカルズ インコーポレイテッド | Compounds useful as ATR kinase inhibitors |
WO2014192936A1 (en) * | 2013-05-31 | 2014-12-04 | 日産化学工業株式会社 | Heterocyclic amide compound |
WO2015073804A2 (en) * | 2013-11-15 | 2015-05-21 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Method of blocking transmission of malarial parasite |
CA2929858C (en) | 2013-11-22 | 2022-03-29 | CL BioSciences LLC | Gastrin antagonists (eg yf476, netazepide) for treatment and prevention of osteoporosis |
CN104130256B (en) * | 2014-08-01 | 2016-08-24 | 上海毕得医药科技有限公司 | A kind of pyrido [3,4-d] pyrimidine-4(3H) preparation method of-one derivative |
US10214537B2 (en) * | 2014-10-22 | 2019-02-26 | Bristol-Myers Squibb Company | Bicyclic heteroaryl amine compounds |
CN105130980B (en) * | 2015-09-09 | 2018-05-22 | 沈阳药科大学 | N-3- benzimidazole thiazole amines derivatives and preparation method and application |
RU2722149C1 (en) * | 2015-09-14 | 2020-05-27 | Пфайзер Инк. | New derivatives of imidazo [4,5-c] quinolines and imidazo [4,5-c] [1,5] naphthyridines as lrrk2 inhibitors |
SG11201808582RA (en) | 2016-03-28 | 2018-10-30 | Incyte Corp | Pyrrolotriazine compounds as tam inhibitors |
WO2018119208A1 (en) | 2016-12-22 | 2018-06-28 | Global Blood Therapeutics, Inc. | Histone methyltransferase inhibitors |
CN110382554B (en) * | 2017-03-10 | 2022-03-22 | 大塚化学株式会社 | Reaction product and rubber composition |
WO2018226998A1 (en) * | 2017-06-09 | 2018-12-13 | Global Blood Therapeutics, Inc. | Azaindole compounds as histone methyltransferase inhibitors |
WO2019094779A1 (en) * | 2017-11-09 | 2019-05-16 | Sunesis Pharmaceuticals, Inc. | Pharmaceutical formulations, processes for preparation, and methods of use |
US11780857B2 (en) * | 2019-04-17 | 2023-10-10 | EWHA University—Industry Collaboration Foundation | Probe compounds for amino alcohols, and simultaneous fluorescence and circular dichroism analysis method |
CN110066221B (en) * | 2019-05-16 | 2022-03-08 | 海门瑞一医药科技有限公司 | Preparation method of cyclopropylmethylamine |
WO2021107590A1 (en) * | 2019-11-25 | 2021-06-03 | 주식회사 대웅제약 | Novel triazolopyridine derivative and pharmaceutical composition comprising same |
Citations (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4861760A (en) | 1985-10-03 | 1989-08-29 | Merck & Co., Inc. | Ophthalmological composition of the type which undergoes liquid-gel phase transition |
US4911920A (en) | 1986-07-30 | 1990-03-27 | Alcon Laboratories, Inc. | Sustained release, comfort formulation for glaucoma therapy |
US5212162A (en) | 1991-03-27 | 1993-05-18 | Alcon Laboratories, Inc. | Use of combinations gelling polysaccharides and finely divided drug carrier substrates in topical ophthalmic compositions |
US5403841A (en) | 1991-01-15 | 1995-04-04 | Alcon Laboratories, Inc. | Use of carrageenans in topical ophthalmic compositions |
WO1996005309A2 (en) | 1994-08-17 | 1996-02-22 | The Rockefeller University | Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof |
WO2000039111A1 (en) | 1998-12-23 | 2000-07-06 | Eli Lilly And Company | Antithrombotic amides |
WO2000039117A1 (en) | 1998-12-23 | 2000-07-06 | Eli Lilly And Company | HETEROROAROMATIC AMIDES AS INHIBITOR OF FACTOR Xa |
WO2001055114A1 (en) | 2000-01-27 | 2001-08-02 | Novartis Ag | 2-amino-nicotinamide derivatives and their use as vegf-receptor tyrosine kinase inhibitors |
WO2004007458A1 (en) | 2002-07-17 | 2004-01-22 | Amgen Inc. | Substituted 2-alkylamine nicotinic amide derivatives and use there of |
WO2004072033A2 (en) | 2003-02-12 | 2004-08-26 | Biogen Idec Ma Inc. | Pyrazoles and methods of making and using the same |
US20050182061A1 (en) * | 2003-10-02 | 2005-08-18 | Jeremy Green | Phthalimide compounds useful as protein kinase inhibitors |
US7105563B2 (en) * | 2003-10-24 | 2006-09-12 | Schering Aktiengesellschaft | Indolinone derivatives and their use in treating disease-states such as cancer |
WO2006138695A1 (en) | 2005-06-17 | 2006-12-28 | Bristol-Myers Squibb Company | Triazolopyridine derivatives as cannabinoid receptor 1 antagonists |
WO2007056170A2 (en) | 2005-11-02 | 2007-05-18 | Bayer Healthcare Ag | Pyrrolo[2,1-f] [1,2,4] triazin-4-ylamines igf-1r kinase inhibitors for the treatment of cancer and other hyperproliferative diseases |
WO2008001115A2 (en) * | 2006-06-29 | 2008-01-03 | Astex Therapeutics Limited | Pharmaceutical combinations of 1-cyclopropyl-3- [3- (5-m0rphoolin-4-ylmethyl-1h-benzoimidazol-2-yl) -lh-1-pyrazol- 4-yl] -urea |
WO2008005457A2 (en) | 2006-06-30 | 2008-01-10 | Sunesis Pharmaceuticals | Pyridinonyl pdk1 inhibitors |
WO2008156726A1 (en) * | 2007-06-20 | 2008-12-24 | Merck & Co., Inc. | Inhibitors of janus kinases |
US20090023761A1 (en) * | 2007-03-23 | 2009-01-22 | Yi Chen | Heterocyclic compounds and their uses |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3175980A (en) * | 1958-05-23 | 1965-03-30 | Geigy Ag J R | Compositions of matter of improved appearance in daylight, containing a 3.5-diaminopyrazine-2.6-dicarboxylic acid derivative |
PL114780B1 (en) * | 1978-03-10 | 1981-02-28 | Inst Przemyslu Farmaceutic | Process for preparing novel alkylamides of 2-anilinonicotinic acids |
JP4901102B2 (en) * | 2002-05-03 | 2012-03-21 | エクセリクシス, インク. | Protein kinase modulator and method of use thereof |
JP2009513523A (en) * | 2003-07-08 | 2009-04-02 | ノバルティス アクチエンゲゼルシャフト | Benzenesulfonylamino compounds and pharmaceutical compositions containing them |
US7320992B2 (en) * | 2003-08-25 | 2008-01-22 | Amgen Inc. | Substituted 2,3-dihydro-1h-isoindol-1-one derivatives and methods of use |
AR049418A1 (en) * | 2004-02-27 | 2006-08-02 | Bayer Pharmaceuticals Corp | DERIVATIVES OF HETEROARILAMINOPIRAZOL AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF DIABETES. |
SE0401345D0 (en) * | 2004-05-25 | 2004-05-25 | Astrazeneca Ab | Therapeutic compounds: Pyridine as scaffold |
EP1655297A1 (en) | 2004-11-03 | 2006-05-10 | Schering Aktiengesellschaft | Nicotinamide pyridinureas as vascular endothelial growth factor (VEGF) receptor kinase inhibitors |
WO2006133006A2 (en) | 2005-06-03 | 2006-12-14 | Bayer Healthcare Ag | 1-methyl-1h-pyrazole-4-carboxamides useful as cancer chemotherapeutic agents |
US7547782B2 (en) * | 2005-09-30 | 2009-06-16 | Bristol-Myers Squibb Company | Met kinase inhibitors |
WO2007084667A2 (en) | 2006-01-19 | 2007-07-26 | Osi Pharmaceutical, Inc. | Fused heterobicyclic kinase inhibitors |
WO2008016643A2 (en) | 2006-08-01 | 2008-02-07 | Cytokinetics, Incorporated | Certain chemical entities, compositions, and methods |
AU2007338795B2 (en) * | 2006-12-20 | 2012-07-19 | Amgen Inc. | Substituted heterocycles and methods of use |
US7868001B2 (en) | 2007-11-02 | 2011-01-11 | Hutchison Medipharma Enterprises Limited | Cytokine inhibitors |
EP2440051A4 (en) * | 2009-06-08 | 2012-12-19 | California Capital Equity Llc | Triazine derivatives and their therapeutical applications |
HUE043536T2 (en) | 2009-10-06 | 2019-08-28 | Millennium Pharm Inc | Heterocyclic compounds useful as pdk1 inhibitors |
-
2010
- 2010-10-05 HU HUE16167938A patent/HUE043536T2/en unknown
- 2010-10-05 US US13/499,835 patent/US9546165B2/en active Active
- 2010-10-05 EP EP10822550.9A patent/EP2485731B1/en active Active
- 2010-10-05 KR KR1020127011581A patent/KR20120087936A/en active Search and Examination
- 2010-10-05 CN CN201080055337.2A patent/CN102665718B/en active Active
- 2010-10-05 DK DK10822550.9T patent/DK2485731T3/en active
- 2010-10-05 MX MX2012004114A patent/MX353257B/en active IP Right Grant
- 2010-10-05 KR KR1020177034734A patent/KR101947307B1/en active IP Right Grant
- 2010-10-05 RU RU2017109664A patent/RU2017109664A/en unknown
- 2010-10-05 IL IL266563A patent/IL266563B/en unknown
- 2010-10-05 RU RU2012118667A patent/RU2615130C2/en active
- 2010-10-05 BR BR112012007747A patent/BR112012007747B8/en not_active IP Right Cessation
- 2010-10-05 LT LTEP10822550.9T patent/LT2485731T/en unknown
- 2010-10-05 SI SI201031251A patent/SI2485731T1/en unknown
- 2010-10-05 PL PL10822550T patent/PL2485731T4/en unknown
- 2010-10-05 JP JP2012533248A patent/JP6016635B2/en active Active
- 2010-10-05 DK DK16167938.6T patent/DK3070077T3/en active
- 2010-10-05 WO PCT/US2010/051517 patent/WO2011044157A1/en active Application Filing
- 2010-10-05 ES ES16167938T patent/ES2712875T3/en active Active
- 2010-10-05 IL IL295518A patent/IL295518B2/en unknown
- 2010-10-05 EP EP18207990.5A patent/EP3466929B1/en active Active
- 2010-10-05 ES ES10822550.9T patent/ES2586856T3/en active Active
- 2010-10-05 IN IN3883DEN2012 patent/IN2012DN03883A/en unknown
- 2010-10-05 RS RS20160640A patent/RS55101B1/en unknown
- 2010-10-05 CA CA2776690A patent/CA2776690C/en active Active
- 2010-10-05 PT PT108225509T patent/PT2485731T/en unknown
- 2010-10-05 IL IL302896A patent/IL302896A/en unknown
- 2010-10-05 HU HUE10822550A patent/HUE028082T2/en unknown
- 2010-10-05 KR KR1020197003115A patent/KR102097664B1/en active IP Right Grant
- 2010-10-05 AU AU2010303567A patent/AU2010303567B2/en not_active Ceased
- 2010-10-05 EP EP16167938.6A patent/EP3070077B1/en active Active
- 2010-10-06 AR ARP100103633A patent/AR078540A1/en active IP Right Grant
- 2010-10-06 TW TW099134073A patent/TWI525093B/en active
-
2012
- 2012-03-28 IL IL218915A patent/IL218915B/en active IP Right Grant
- 2012-09-10 HK HK12108807.2A patent/HK1168044A1/en not_active IP Right Cessation
-
2015
- 2015-12-11 US US14/966,821 patent/US10030016B2/en active Active
-
2016
- 2016-07-29 HR HRP20160967TT patent/HRP20160967T1/en unknown
- 2016-08-08 JP JP2016155272A patent/JP2016188253A/en not_active Withdrawn
- 2016-08-10 CY CY20161100796T patent/CY1118143T1/en unknown
- 2016-08-12 SM SM201600275T patent/SMT201600275B/en unknown
- 2016-09-09 AU AU2016225896A patent/AU2016225896C1/en not_active Ceased
-
2018
- 2018-05-23 US US15/987,523 patent/US20190119268A1/en not_active Abandoned
- 2018-06-01 JP JP2018106041A patent/JP2018145196A/en active Pending
- 2018-08-29 AU AU2018222943A patent/AU2018222943B2/en not_active Ceased
-
2020
- 2020-06-18 US US16/904,890 patent/US20210070752A1/en not_active Abandoned
- 2020-09-07 JP JP2020149736A patent/JP2020203925A/en not_active Withdrawn
-
2021
- 2021-12-22 AR ARP210103639A patent/AR124483A2/en unknown
-
2022
- 2022-07-21 US US17/814,224 patent/US20230113598A1/en not_active Abandoned
- 2022-11-04 JP JP2022177407A patent/JP2023002840A/en active Pending
-
2024
- 2024-04-11 US US18/632,638 patent/US20240294524A1/en active Pending
Patent Citations (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4861760A (en) | 1985-10-03 | 1989-08-29 | Merck & Co., Inc. | Ophthalmological composition of the type which undergoes liquid-gel phase transition |
US4911920A (en) | 1986-07-30 | 1990-03-27 | Alcon Laboratories, Inc. | Sustained release, comfort formulation for glaucoma therapy |
US5403841A (en) | 1991-01-15 | 1995-04-04 | Alcon Laboratories, Inc. | Use of carrageenans in topical ophthalmic compositions |
US5212162A (en) | 1991-03-27 | 1993-05-18 | Alcon Laboratories, Inc. | Use of combinations gelling polysaccharides and finely divided drug carrier substrates in topical ophthalmic compositions |
WO1996005309A2 (en) | 1994-08-17 | 1996-02-22 | The Rockefeller University | Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof |
WO2000039111A1 (en) | 1998-12-23 | 2000-07-06 | Eli Lilly And Company | Antithrombotic amides |
WO2000039117A1 (en) | 1998-12-23 | 2000-07-06 | Eli Lilly And Company | HETEROROAROMATIC AMIDES AS INHIBITOR OF FACTOR Xa |
WO2001055114A1 (en) | 2000-01-27 | 2001-08-02 | Novartis Ag | 2-amino-nicotinamide derivatives and their use as vegf-receptor tyrosine kinase inhibitors |
WO2004007458A1 (en) | 2002-07-17 | 2004-01-22 | Amgen Inc. | Substituted 2-alkylamine nicotinic amide derivatives and use there of |
WO2004072033A2 (en) | 2003-02-12 | 2004-08-26 | Biogen Idec Ma Inc. | Pyrazoles and methods of making and using the same |
US20050182061A1 (en) * | 2003-10-02 | 2005-08-18 | Jeremy Green | Phthalimide compounds useful as protein kinase inhibitors |
US7105563B2 (en) * | 2003-10-24 | 2006-09-12 | Schering Aktiengesellschaft | Indolinone derivatives and their use in treating disease-states such as cancer |
WO2006138695A1 (en) | 2005-06-17 | 2006-12-28 | Bristol-Myers Squibb Company | Triazolopyridine derivatives as cannabinoid receptor 1 antagonists |
WO2007056170A2 (en) | 2005-11-02 | 2007-05-18 | Bayer Healthcare Ag | Pyrrolo[2,1-f] [1,2,4] triazin-4-ylamines igf-1r kinase inhibitors for the treatment of cancer and other hyperproliferative diseases |
WO2008001115A2 (en) * | 2006-06-29 | 2008-01-03 | Astex Therapeutics Limited | Pharmaceutical combinations of 1-cyclopropyl-3- [3- (5-m0rphoolin-4-ylmethyl-1h-benzoimidazol-2-yl) -lh-1-pyrazol- 4-yl] -urea |
WO2008005457A2 (en) | 2006-06-30 | 2008-01-10 | Sunesis Pharmaceuticals | Pyridinonyl pdk1 inhibitors |
US20090023761A1 (en) * | 2007-03-23 | 2009-01-22 | Yi Chen | Heterocyclic compounds and their uses |
WO2008156726A1 (en) * | 2007-06-20 | 2008-12-24 | Merck & Co., Inc. | Inhibitors of janus kinases |
Non-Patent Citations (26)
Title |
---|
"Handbook of Chemistry and Physics" |
"Pharmaceutical Sciences", MACK PUB. CO. |
ALESSI, D. ET AL., BIOCHEM. SOC. TRANS, vol. 29, 2001, pages 1 |
AVRUCH, J. ET AL., PROG. MOL. SUBCELL. BIOL., vol. 26, 2001, pages 115 |
BELHAM, C. ET AL., CURR. BIOL., vol. 9, 1999, pages R93 - R96 |
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, vol. 18, no. 3, 2008, pages 1027 - 1030 |
BROGNARD, J. ET AL., CANCER RES., vol. 61, 2001, pages 3986 - 3997 |
CARRUTHERS: "Some Modern Methods of Organic Synthesis", 1987, CAMBRIDGE UNIVERSITY PRESS |
CULLY ET AL., NATURE REVIEWS CANCER, vol. 6, 2006, pages 184 - 192 |
ELIEL, E.L.: "Stereochemistry of Carbon Compounds", 1962, MCGRAW-HILL |
FELDMAN ET AL., J. BIOL. CHEM., vol. 280, 2005, pages 19867 - 19874 |
FLYNN, P. ET AL., CURR. BIOL., vol. 10, 2000, pages 1439 - 1442 |
FRODIN, M. ET AL., EMBO J., vol. 19, 2000, pages 2924 - 2934 |
GRAFF, J. R., EXPERT OPIN. THER. TARGETS, vol. 6, 2002, pages 103 - 113 |
JACQUES ET AL.: "Enantiomers, Racemates and Resolutions", 1981, WILEY INTERSCIENCE |
JMC, vol. 50, 2007, pages 1584 - 97 |
LAROCK: "Comprehensive Organic Transformations", 1989, VCH PUBLISHERS, INC. |
LAWLOR, M. A. ET AL., EMBO J., vol. 21, 2002, pages 3728 - 3738 |
LAWLOR, M. A. ET AL., J. CELL SCI., vol. 114, 2001, pages 2903 - 2910 |
LE GOOD ET AL., SCIENCE, vol. 281, 1998, pages 2042 - 2045 |
SMITH; MARCH: "March's Advanced Organic Chemistry", 2001, JOHN WILEY & SONS, INC. |
THOMAS SORRELL: "Organic Chemistry", 1999, UNIVERSITY SCIENCE BOOKS |
W. ZHU, J. ORG. CHEM., vol. 70, no. 7, 2005, pages 2696 - 2700 |
WILEN ET AL., TETRAHEDRON, vol. 33, 1977, pages 2725 |
WILEN, S.H.: "Tables of Resolving Agents and Optical Resolutions", 1972, UNIV. OF NOTRE DAME PRESS, pages: 268 |
YOUNG ET AL., JMC, vol. 51, no. 13, 2008, pages 3934 - 3945 |
Cited By (78)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9701674B2 (en) | 2008-12-19 | 2017-07-11 | Vertex Pharmaceuticals Incorporated | Substituted pyrazines as ATR kinase inhibitors |
US9365557B2 (en) | 2008-12-19 | 2016-06-14 | Vertex Pharmaceuticals Incorporated | Substituted pyrazin-2-amines as inhibitors of ATR kinase |
US10961232B2 (en) | 2008-12-19 | 2021-03-30 | Vertex Pharmaceuticals Incorporated | Substituted pyrazines as ATR kinase inhibitors |
US10479784B2 (en) | 2008-12-19 | 2019-11-19 | Vertex Pharmaceuticals Incorporated | Substituted pyrazin-2-amines as inhibitors of ATR kinase |
US9630956B2 (en) | 2010-05-12 | 2017-04-25 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of ATR kinase |
US9334244B2 (en) | 2010-05-12 | 2016-05-10 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of ATR kinase |
US8389718B2 (en) | 2010-07-20 | 2013-03-05 | Vestaron Corporation | Insecticidal triazines and pyrimidines |
US8785630B2 (en) | 2010-07-20 | 2014-07-22 | Vestaron Corporation | Insecticidal triazines and pyrimidines |
US9181264B2 (en) | 2010-09-16 | 2015-11-10 | Hutchison Medipharma Limited | Fused heteroaryls and their uses |
AU2011301518B2 (en) * | 2010-09-16 | 2014-07-03 | Hutchison Medipharma Limited | Fused heteroaryls and their uses |
WO2012034526A1 (en) * | 2010-09-16 | 2012-03-22 | Hutchison Medipharma Limited | Fused heteroaryls and their uses |
US9187473B2 (en) * | 2011-03-30 | 2015-11-17 | Arrien Pharmaceuticals Llc | Substituted 5-(pyrazin-2-yl)-1H-pyrazolo [3, 4-b] pyridine and pyrazolo [3, 4-b] pyridine derivatives as protein kinase inhibitors |
US20140309211A1 (en) * | 2011-03-30 | 2014-10-16 | Arrien Pharmaceuticals Llc | Substituted 5-(pyrazin-2-yl)-1h-pyrazolo [3, 4-b] pyridine and pyrazolo [3, 4-b] pyridine derivatives as protein kinase inhibitors |
US9962382B2 (en) | 2011-03-30 | 2018-05-08 | Arrien Pharmaceuticals Llc | Substituted 5-(pyrazin-2-yl)-1H-pyrazolo [3, 4-b] pyridine and pyrazolo [3, 4-b] pyridine derivatives as protein kinase inhibitors |
US9669028B2 (en) | 2011-03-30 | 2017-06-06 | Arrien Pharmaceuticals Llc | Substituted 5-(pyrazin-2-yl)-1H-pyrazolo [3, 4-B] pyridine and pyrazolo [3, 4-B] pyridine derivatives as protein kinase inhibitors |
US10457659B2 (en) | 2011-04-29 | 2019-10-29 | The Board Of Trustees Of The Leland Stanford Junior University | Compositions and methods for increasing proliferation of adult salivary stem cells |
US10813929B2 (en) | 2011-09-30 | 2020-10-27 | Vertex Pharmaceuticals Incorporated | Treating cancer with ATR inhibitors |
US10822331B2 (en) | 2011-09-30 | 2020-11-03 | Vertex Pharmaceuticals Incorporated | Processes for preparing ATR inhibitors |
US9862709B2 (en) | 2011-09-30 | 2018-01-09 | Vertex Pharmaceuticals Incorporated | Processes for making compounds useful as inhibitors of ATR kinase |
US10208027B2 (en) | 2011-09-30 | 2019-02-19 | Vertex Pharmaceuticals Incorporated | Processes for preparing ATR inhibitors |
CN103159741B (en) * | 2011-12-19 | 2016-08-24 | 天津市国际生物医药联合研究院 | The preparation of one class tyrosine kinase inhibitor and purposes |
CN103159741A (en) * | 2011-12-19 | 2013-06-19 | 天津市国际生物医药联合研究院 | Preparation and application of novel tyrosine kinase inhibitor |
US11110086B2 (en) | 2012-04-05 | 2021-09-07 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of ATR kinase and combination therapies thereof |
US10478430B2 (en) | 2012-04-05 | 2019-11-19 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of ATR kinase and combination therapies thereof |
CN102627632A (en) * | 2012-04-16 | 2012-08-08 | 中国科学院广州生物医药与健康研究院 | Amino quinazoline derivative and preparation method as well as application thereof |
US10017508B2 (en) | 2012-04-25 | 2018-07-10 | Takeda Pharmaceutical Company Limited | Nitrogenated heterocyclic compound |
US9469637B2 (en) | 2012-04-25 | 2016-10-18 | Takeda Pharmaceutical Company Limited | Nitrogenated heterocyclic compound |
JP2015516429A (en) * | 2012-05-08 | 2015-06-11 | アンヴィル エルエルシー | Alpha 7 nicotinic acetylcholine receptor allosteric modulators, derivatives thereof and uses thereof |
US9527841B2 (en) | 2012-07-13 | 2016-12-27 | Takeda Pharmaceutical Company Limited | Substituted pyrido[2,3-b]pyrazines as phosphodiesterase 2A inhibitors |
US10131668B2 (en) | 2012-09-26 | 2018-11-20 | The Regents Of The University Of California | Substituted imidazo[1,5-a]pYRAZINES for modulation of IRE1 |
US11613544B2 (en) | 2012-09-26 | 2023-03-28 | The Regents Of The University Of California | Substituted imidazo[1,5-a]pyrazines for modulation of IRE1 |
US10822340B2 (en) | 2012-09-26 | 2020-11-03 | The Regents Of The University Of California | Substituted imidazolopyrazine compounds and methods of using same |
US9791456B2 (en) | 2012-10-04 | 2017-10-17 | Vertex Pharmaceuticals Incorporated | Method for measuring ATR inhibition mediated increases in DNA damage |
US9834520B2 (en) | 2013-03-14 | 2017-12-05 | Takeda Pharmaceutical Company Limited | Heterocyclic compound |
US20160107996A1 (en) * | 2013-03-14 | 2016-04-21 | The Board Of Trustees Of The Le-Land Stanford Junior University | Mitochondrial Aldehyde Dehyrogenase-2 Modulators and Methods of Use Thereof |
JP2016514154A (en) * | 2013-03-14 | 2016-05-19 | ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー | Mitochondrial aldehyde dehydrogenase-2 modulator and method of use thereof |
US9670162B2 (en) * | 2013-03-14 | 2017-06-06 | The Board Of Trustees Of The Leland Stanford Junio | Mitochondrial aldehyde dehyrogenase-2 modulators and methods of use thereof |
US10227304B2 (en) | 2013-03-14 | 2019-03-12 | The Board Of Trustees Of The Leland Stanford Junior University | Mitochondrial aldehyde dehydrogenase-2 modulators and methods of use thereof |
US11053262B2 (en) | 2013-07-03 | 2021-07-06 | Takeda Pharmaceutical Company Limited | Heterocyclic amide compounds having RORyT inhibitory action |
US10472376B2 (en) | 2013-07-03 | 2019-11-12 | Takeda Pharmaceutical Company Limited | Amide compound |
US11851449B2 (en) | 2013-07-03 | 2023-12-26 | Takeda Pharmaceutical Company Limited | Heterocyclic amide compounds having an RORvt inhibitory action |
US10053468B2 (en) | 2013-07-03 | 2018-08-21 | Takeda Pharmaceutical Company Limited | Heterocyclic compound |
WO2015012328A1 (en) | 2013-07-24 | 2015-01-29 | 武田薬品工業株式会社 | Heterocyclic compound |
EP3640241A1 (en) | 2013-10-18 | 2020-04-22 | Celgene Quanticel Research, Inc. | Bromodomain inhibitors |
EP4134364A2 (en) | 2013-10-18 | 2023-02-15 | Celgene Quanticel Research, Inc. | Bromodomain inhibitors |
US11884680B2 (en) | 2013-10-18 | 2024-01-30 | Celgene Quanticel Research, Inc. | Bromodomain inhibitors |
US10023592B2 (en) | 2013-10-18 | 2018-07-17 | Celgene Quanticel Research, Inc. | Bromodomain inhibitors |
US9034900B2 (en) | 2013-10-18 | 2015-05-19 | Quanticel Pharmaceuticals, Inc. | Bromodomain inhibitors |
US10941160B2 (en) | 2013-10-18 | 2021-03-09 | Celgene Quanticel Research, Inc. | Bromodomain inhibitors |
EP3290407A1 (en) | 2013-10-18 | 2018-03-07 | Celgene Quanticel Research, Inc | Bromodomain inhibitors |
US10562915B2 (en) | 2013-10-18 | 2020-02-18 | Celgene Quanticel Research, Inc. | Bromodomain inhibitors |
US9598372B2 (en) | 2013-10-18 | 2017-03-21 | Celgene Quanticel Research, Inc. | Bromodomain inhibitors |
US9115114B2 (en) | 2013-10-18 | 2015-08-25 | Quanticel Pharmaceuticals, Inc. | Bromodomain inhibitors |
WO2016075224A1 (en) | 2014-11-14 | 2016-05-19 | Nerviano Medical Sciences S.R.L. | 6-amino-7-bicyclo-7-deaza-purine derivatives as protein kinase inhibitors |
EP3831383A1 (en) | 2015-04-15 | 2021-06-09 | Celgene Quanticel Research, Inc. | Bromodomain inhibitors |
WO2017015152A1 (en) | 2015-07-17 | 2017-01-26 | Memorial Sloan-Kettering Cancer Center | Combination therapy using pdk1 and pi3k inhibitors |
US11696924B2 (en) | 2015-07-17 | 2023-07-11 | Memorial Sloan-Kettering Cancer Center | Combination therapy using PDK1 and PI3K inhibitors |
US11464774B2 (en) | 2015-09-30 | 2022-10-11 | Vertex Pharmaceuticals Incorporated | Method for treating cancer using a combination of DNA damaging agents and ATR inhibitors |
KR101753654B1 (en) | 2015-10-21 | 2017-07-05 | 한국화학연구원 | Novel 3-(4-(piperazin-1-yl)benzamido)-1H-pyrazolopyridine derivatives or pharmaceutically acceptable salts thereof, preparation method thereof and pharmaceutical composition for use in preventing or treating MELK(maternal embryonic leucine zipper kinase) activity related diseases containing the same as an active ingredient |
KR101753652B1 (en) * | 2015-10-21 | 2017-07-05 | 한국화학연구원 | Novel N-aryl-1H-pyrazolopyridin-3-amine derivatives or pharmaceutically acceptable salts thereof, preparation method therof and pharmaceutical composition for use in preventing or treating MELK(maternal embryonic leucine zipper kinase) activity related diseases containing the same as an active ingredient |
AU2016342352B2 (en) * | 2015-10-23 | 2022-06-02 | Sunesis Pharmaceuticals, Inc. | Heterocyclic PDK1 inhibitors for use to treat cancer |
EP3763368A1 (en) | 2015-10-23 | 2021-01-13 | Sunesis Pharmaceuticals, Inc. | Heterocyclic pdk1 inhibitors for use to treat cancer |
US20230099829A1 (en) * | 2015-10-23 | 2023-03-30 | Viracta Therapeutics, Inc. | Heterocyclic pdk1 inhibitors for use to treat cancer |
WO2017070565A1 (en) | 2015-10-23 | 2017-04-27 | Sunesis Pharmaceuticals, Inc. | Heterocyclic pdk1 inhibitors for use to treat cancer |
US11020400B2 (en) | 2015-12-23 | 2021-06-01 | Arqule, Inc. | Tetrahydropyranyl amino-pyrrolopyrimidinone and methods of use thereof |
US9630968B1 (en) | 2015-12-23 | 2017-04-25 | Arqule, Inc. | Tetrahydropyranyl amino-pyrrolopyrimidinone and methods of use thereof |
US10245263B2 (en) | 2015-12-23 | 2019-04-02 | Arqule, Inc. | Tetrahydropyranyl amino-pyrrolopyrimidinone and methods of use thereof |
US10933065B2 (en) | 2015-12-23 | 2021-03-02 | Arqule Inc. | Tetrahydropyranyl amino-pyrrolopyrimidinone and methods of use thereof |
WO2017184462A1 (en) | 2016-04-18 | 2017-10-26 | Celgene Quanticel Research, Inc. | Therapeutic compounds |
WO2017184491A1 (en) | 2016-04-19 | 2017-10-26 | Celgene Quanticel Research, Inc. | Histone demethylase inhibitors |
EP4011876A1 (en) | 2016-04-19 | 2022-06-15 | Celgene Quanticel Research, Inc. | Histone demethylase inhibitors |
US11020398B2 (en) | 2016-08-24 | 2021-06-01 | Arqule, Inc. | Amino-pyrrolopyrimidinone compounds and methods of use thereof |
US11618753B2 (en) | 2018-01-26 | 2023-04-04 | Bristol-Myers Squibb Company | Aminopyrrolotriazines as kinase inhibitors |
CN109087534A (en) * | 2018-10-09 | 2018-12-25 | 王业宝 | A kind of traffic conflict detection method based on vehicle driving trace |
WO2021064141A1 (en) * | 2019-10-02 | 2021-04-08 | Tolremo Therapeutics Ag | Inhibitors of dual specificity tyrosine phosphorylation regulated kinase 1b |
WO2023112056A1 (en) * | 2021-12-17 | 2023-06-22 | Pi Industries Ltd. | Novel substituted fused bicyclic pyridine carboxamide compounds for combating phytopathogenic fungi |
WO2024040241A1 (en) | 2022-08-19 | 2024-02-22 | Viracta Therapeutics, Inc. | Pharmaceutical formulations, processes for preparation, and methods of use |
WO2024040242A1 (en) | 2022-08-19 | 2024-02-22 | Viracta Therapeutics, Inc. | Combinations of pdk1 inhibitors and kinase inhibitors |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2016225896C1 (en) | Heterocyclic compounds useful as PDK1 inhibitors | |
JP5989805B2 (en) | Methyl group-modifying enzyme regulator, composition and use thereof | |
KR20110039383A (en) | Cmet inhibitors | |
CN110041316B (en) | TAM family kinase/CSF 1R kinase inhibitors and uses thereof | |
JP2024056742A (en) | Novel quinoline derivative inhibitor | |
EP4267137A1 (en) | Lactam (hetero)arylfusedpyrimidine derivatives as inhibitors of erbb2 | |
TW202412773A (en) | Heteroaryl derivative compounds, and uses thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 201080055337.2 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 10822550 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 218915 Country of ref document: IL |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2010822550 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 13499835 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2776690 Country of ref document: CA Ref document number: 12012500674 Country of ref document: PH |
|
WWE | Wipo information: entry into national phase |
Ref document number: MX/A/2012/004114 Country of ref document: MX |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2010303567 Country of ref document: AU Ref document number: 2012533248 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1201001614 Country of ref document: TH |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 3883/DELNP/2012 Country of ref document: IN |
|
ENP | Entry into the national phase |
Ref document number: 2010303567 Country of ref document: AU Date of ref document: 20101005 Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 20127011581 Country of ref document: KR Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2012118667 Country of ref document: RU |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112012007747 Country of ref document: BR |
|
WWE | Wipo information: entry into national phase |
Ref document number: P-2016/0640 Country of ref document: RS |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01E Ref document number: 112012007747 Country of ref document: BR |
|
ENP | Entry into the national phase |
Ref document number: 112012007747 Country of ref document: BR Kind code of ref document: A2 Effective date: 20120404 |